



Rak
v Sloveniji

2009

Cancer
in Slovenia

Naslov / Title

Rak v Sloveniji 2009 / Cancer in Slovenia 2009

Uredniški odbor / Editorial Board

Maja Primic Žakelj, glavna urednica / editor-in-chief
Matej Bračko, Marko Hočevar, Katja Jarm,
Vera Pompe-Kirn, Primož Strojani, Vesna Zadnik,
Branko Zakotnik in Tina Žagar

Računalniška obdelava / EDP analysis

Katja Jarm, Cveto Šval, Vesna Zadnik in Tina Žagar

Oblikovanje in priprava za tisk / Design & Typesetting

Studio N, studio za oblikovanje in grafično pripravo

Tisk / Printing

Littera Picta d.o.o.

Izdajatelj / Published by

Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana, Slovenia
Epidemiologija in register raka / Epidemiology and Cancer Registry
Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia

Naklada / Published in

600 izvodov / 600 copies

Nasvet za citiranje / Recommended reference

Rak v Sloveniji 2009. Ljubljana: Onkološki inštitut Ljubljana, Epidemiologija in register raka, Register raka Republike Slovenije, 2013.

Cancer in Slovenia 2009. Ljubljana: Institute of Oncology Ljubljana, Epidemiology and Cancer Registry, Cancer Registry of Republic of Slovenia, 2013.

Osebe Registra raka Republike Slovenije / Staff of the Cancer Registry of Republic of Slovenia

Maja Primic Žakelj, vodja / head
Barbara Babuder, Andrej Kirn, Andrej Krašovec, Polona Škulj, Darja Strle, Fani Škrlec,
Nataša Šturm in Tina Žagar

Naslov / Correspondence to

Register raka Republike Slovenije / Cancer Registry of Republic of Slovenia
Onkološki inštitut Ljubljana / Institute of Oncology Ljubljana
Zaloška c. 2, 1001 Ljubljana, p.p. 2217, Slovenija
Telefon / Phone: + 386 1 5879 450
E-pošta / E-mail: register@onko-i.si
Spletna stran / Web site:

<http://www.onko-i.si/rrs/>
<http://www.onko-i.si/crs/>

<http://www.slora.si/>
<http://www.slora.si/en/>

Uvod	6
Viri podatkov in metode registracije	8
Viri in nabor podatkov	8
Priprava podatkov za računalniško obdelavo	9
Kakovost podatkov RRRS in popolnost registracije	10
Statistične metode	11
Incidenca in umrljivost	11
Grobe in starostno specifične stopnje	11
Starostno standardizirane stopnje	11
Kumulativne incidenčne stopnje in kumulativno tveganje	12
Prevalenca	12
Relativno preživetje	13
Prebivalstvo Slovenije	14
Rak v Sloveniji 2009	15
Zahvala	18
Introduction	19
Data sources and methods of registration	21
Data sources and the list of data collected	21
Preparation of data for computer processing	22
Data quality and completeness of registration	23
Statistical methods	24
Incidence and mortality	24
Crude and age-specific rates	24
Age-standardised rates	24
Cumulative incidence rate and cumulative risk	25
Prevalence	25
Relative survival	26
Population of Slovenia	27
Cancer in Slovenia 2009	28
Acknowledgment	31
Reference / References	32

Slike / Figures

Slika 1:	Breme raka, Slovenija 2009.	34
Figure 1:	Cancer burden, Slovenia 2009.	
Slika 2:	Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2009.	34
Figure 2:	Percentage distribution of all cancer sites by age group and by sex, Slovenia 2009.	
Slika 3:	Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2009.	35
Figure 3:	The leading cancer sites with percentage distribution by sex and in for both sexes together, Slovenia 2009.	
Slika 4:	Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2009.	36
Figure 4:	Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2009.	
Slika 5:	Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2009.	37
Figure 5:	Crude annual incidence rates of selected primary cancer sites by sex, Slovenia 1950–2009.	
Slika 6:	Pet-letno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2000–2004 in 2005–2009 po spolu.	38
Figure 6:	Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2000–2004 and 2005–2009 by sex.	
Slika 7:	Odstotni deleži napogostejših rakov po starostnih skupinah in spolu, Slovenija 2005–2009.	40
Figure 7:	Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2005–2009.	
Slika 8:	Rak pri starejših, C00–C96 brez nemelanomskega kožnega raka (C44), Slovenija 2005–2009.	42
Figure 8:	Cancer in the elderly, C00–C96 except non-melanoma skin cancer (C44), Slovenia 2005–2009.	

Podatki v tabelah / Data in tables

Tabela 1:	Opazovana in ocenjena incidenca raka, Slovenija 2000–2009 in 2012.	44
Table 1:	Observed and estimated cancer incidence, Slovenia 2000–2009 and 2012.	
Tabela 2:	Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2009.	45
Table 2:	Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2009.	
Tabela 3:	Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2009.	46
Table 3:	Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2009.	
Tabela 4:	Incidenca raka po lokaciji, spolu in starosti, Slovenija 2009.	50
Table 4:	Cancer incidence by site, by sex and by age, Slovenia 2009.	
Tabela 5:	Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter komulativna stopnja (KS) po lokaciji in spolu, Slovenija 2009.	54
Table 5:	Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2009.	

Tabela 6a:	Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2009.	60
Table 6a:	Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2009.	
Tabela 6b:	Starostno standardizirana incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2009.	61
Table 6b:	Age standardised incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2009.	
Tabela 7:	Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2009.	62
Table 7:	Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2009.	
Tabela 8:	Incidenca ne-Hodgkinovih limfomov po lokaciji, spolu in starosti, Slovenija 2009.	71
Table 8:	Incidence of non-Hodgkin's malignant lymphomas by site, by sex and by age, Slovenia 2009.	
Tabela 9:	Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2009.	72
Table 9:	Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2009.	
Tabela 10a:	Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.	75
Table 10a:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.	
Tabela 10b:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so bilo v okviru prvega zdravljenja operirani, po lokaciji raka in bolnici posega.	76
Table 10b:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by surgery during their first treatment by primary sites and treatment institution.	
Tabela 10c:	Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so v okviru prvega zdravljenja prejeli sistemsko terapijo, po lokacijah raka in bolnici posega.	77
Table 10c:	Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by systemic therapy during their first treatment by primary sites and treatment institution.	
Tabela 11:	Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2009.	78
Table 11:	Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2009.	
Tabela 12:	Umrljivost za rakom po lokaciji, spolu in starosti, Slovenija 2009.	79
Table 12:	Cancer mortality by site, by sex and by age, Slovenia 2009.	
Izbor publikacij / Selected publications		82


Register raka Republike Slovenije (RRRS) je eden najstarejših populacijskih registrov raka v Evropi. Leta 1950 ga je na Onkološkem inštitutu Ljubljana (OI) ustanovila in do leta 1975 vodila pokojna profesorica dr. Božena Ravnihar. Njeno delo je prevzela profesorica dr. Vera Pompe Kirn, ki je do upokojitve leta 2003 skrbela za nadaljnje uveljavljanje RRRS v domačem in mednarodnem merilu. Od leta 2003 je RRRS z Enoto za epidemiologijo posebna služba OI, ki se imenuje Epidemiologija in register raka. V njej delujejo še *bolnišnični register OI*, ki omogoča podrobnejši pregled nad bolniki, zdravljenimi na OI (ne glede na to, kje imajo stalno prebivališče), in RRRS oskrbuje z velikim delom podatkov, *državni register za vodenje in spremljanje organiziranega presejalnega programa za raka materničnega vratu* (Register ZORA) in od leta 2007 *informacijski sistem za vabljenje žensk in epidemiološko spremljanje organiziranega presejalnega programa za raka dojk* (Register DORA).

Podatki o novih primerih raka, incidenci, preživetju in prevalenci, ki se zbirajo v RRRS, so skupaj s podatki o umrljivosti, ki jih zbira in obdeluje Inštitut za varovanje zdravja RS, osnova za ocenjevanje bremena rakavih bolezni v državi. Pomembni so za načrtovanje in ocenjevanje onkološkega varstva na področju primarne in sekundarne preventive, diagnostike, zdravljenja in rehabilitacije, za načrtovanje zmogljivosti in sredstev, ki so potrebni za obvladovanje rakavih bolezni (osebje, medicinska oprema, posteljne zmogljivosti); dragoceni so tudi za klinične in epidemiološke raziskave v Sloveniji in v širših mednarodnih raziskavah ter za vrednotenje učinkovitosti presejalnih programov.

Redna letna poročila RRRS so namenjena neposrednemu seznanjanju strokovne javnosti in drugih zainteresiranih z obdelanimi podatki RRRS. Ker nas omejuje tehnologija zbiranja podatkov, saj je njihovih virov več, je za dokončanje letne zbirke podatkov, njihovo analizo in objavo rezultatov potreben čas, ki je pri nas in v drugih državah podoben, običajno 2 leti do 3. V poročilih pa zadnja leta objavimo še, kakšna je pričakovana incidenca raka v letu, ko je poročilo izdano (v tokratnem poročilu za leto 2012); izračunana je s posebno statistično metodo za napovedovanje incidence raka.

RRRS je prva letna poročila izdal v letih 1953–1957 za leta 1951–1955. Prva analiza podatkov za leto 1950 je bila objavljena v *Zdravstvenem vestniku leta 1951*. Podatki za leta 1957–1971 so bili objavljeni v periodičnih publikacijah Svetovne zdravstvene organizacije *Epidemiological and Vital Statistics* in v *World Health Statistics Report*. Od leta 1965 so bili podatki spet redno objavljani v posebnih letnih poročilih z naslovom *Rak v Sloveniji* (1965–1977) in *Incidenca raka v Sloveniji* (1978–2006), in sicer v slovenskem in angleškem jeziku. Poleg letnih poročil so objavljene tudi 4 monografije: *Zemljevidi incidence raka v Sloveniji 1978–1987*, *Preživetje bolnikov z rakom v Sloveniji 1963–1990*, *Preživetje bolnikov z rakom v Sloveniji 1983–1997* in *Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji*. Seznam drugih pomembnejših del, objavljenih v zadnjih pet letih, je v dodatku na koncu poročila.

Podatki RRRS so vključeni v številne mednarodne podatkovne zbirke in projekte. Objavljeni so v vseh devet zvezkih knjige *Rak na petih kontinentih* (*Cancer Incidence in Five Continents*), ki jo izdaja Mednarodna agencija za raziskovanje raka, in v podatkovnih zbirkah *EUROCIM*, *GLOBOCAN* in *ACCIS*. Preživetje slovenskih bolnikov pa je obdelano v mednarodnih raziskavah *EUROCARE II*, *EUROCARE III*, *EUROCARE IV*, *EUROCARE V* in *EUNICE*.



Leta 2010 smo v celoti prenovili računalniško bazo in posodobili obdelavo podatkov v RRRS. Zaradi številnih tehničnih težav ob prenovi in po njej zamujamo tudi s tem letnim poročilom. Od leta 2010 deluje tudi *interaktivni spletni portal*, ki smo ga poimenovali *SLORA* po začetnih črkah besed »Slovenija in rak«. Dostopen je na elektronskem naslovu www.slora.si. Omogoča preprost in hiter dostop do večine podatkov o raku v Sloveniji, ki jih zbirata RRRS do zaključenega leta obdelave, trenutno 2009 (incidenca, prevalenca in preživetje) in Inštitut za varovanje zdravja (umrljivost) ter do evropskih in svetovnih podatkovnih zbirk o raku. S hitrim dostopom do tujih baz tako omogoča tudi primerjavo bremena raka z drugimi državami v Evropski uniji in svetu. Dodane so tudi obširna strokovne razlage, ki pojasnjujejo podatke in seznanjajo uporabnike z nevarnostnimi dejavniki raka, možnostmi zgodnjega odkrivanja in uspešnostjo zdravljenja raka.

Viri in nabor podatkov

Prijavljanje raka je v Republiki Sloveniji obvezno in zakonsko predpisano že od ustanovitve RRRS (Ur. l. SRS št. 10/50, št. 29/50, št. 14/65, št. 1/80, št. 45/82, št. 42/85; Ur. l. RS št. 9/92 in št. 65/00). Osnovni vir podatkov so *prijavnice rakave bolezni*. Registru jih pošiljajo iz vseh bolnišnic in diagnostičnih centrov v Sloveniji, iz ordinacij osnovnega zdravstvenega varstva pa le izjemoma, če bolnik ni napoten na nadaljnje preiskave in/ali zdravljenje.

S prijavicami zbiramo osebne podatke, podatke o vrsti bolezni (anatomsko mesto raka, histološka oz. citološka diagnoza, stadij po TNM ali drugi klinični klasifikaciji) in o vrsti zdravljenja. Dodatni vir podatkov so zdravniška poročila o vzroku smrti, ki nam jih pošilja Inštitut za varovanje zdravja RS. Veliko časa porabimo za poizvedbe o bolnikih, za katere nimamo popolnih podatkov ali pa dobimo o njih prvo informacijo šele ob smrti.

Za izračun preživetja bolnikov potrebujemo podatek, ki se imenuje *vitalno stanje* (ali je oseba živa, mrtva ali izgubljena iz registra prebivalstva). Podatek dobimo iz Centralnega registra prebivalstva (CRP), in sicer za vse osebe iz RRRS, ki so po naših podatkih še žive. Od leta 2010 smo po prenovi računalniške baze s posebej varovano spletno tehnologijo neposredno povezani s CRP, zato ta podatek dobimo sproti dnevno. Pri izgubljenih osebah upoštevamo kot datum izgube datum zadnje prijave oz. datum izgube, kot velja v CRP, odvisno od tega, kateri datum je kasnejši. Od leta 1985, odkar RRRS prejema od CRP enotno matično številko občana (EMŠO), je v RRRS odstotni delež izgubljenih manjši od 1 %; pri bolnikih, registriranih v zadnjem desetletju, je znašal le 0,1 %.

Pri analizi prostorske razporeditve raka upoštevamo Uredbo o standardni klasifikaciji teritorialnih enot – SKTE (2000), ki predpisuje delitev slovenskega ozemlja na 11 ravneh. Točno opredeljevanje stalnih naslovov bolnikov z rakom nam omogoča redna povezava z Registrom prostorskih enot Geodetske uprave RS. V Tabeli 6 smo do Letnega poročila 2002 prikazovali podatke po 9 zdravstvenih regijah, v skladu z omenjeno uredbo pa smo potem prešli na raven SKTE-3, na 12 statističnih regij.

Slovenske statistične regije



Priprava podatkov za računalniško obdelavo

Podatke, prispel v RRRS na prijavnica, posebej usposobljene medicinske sestre najprej kodirajo v skladu z mednarodnimi in v RRRS dogovorjenimi pravili.

Za razvrščanje neoplazem po primarni lokaciji je od leta 1997 v veljavi deseta revizija Mednarodne klasifikacije bolezni in sorodnih zdravstvenih problemov za statistične namene (MKB-10), do takrat pa smo uporabljali osmo.

Pri uvrščanju med maligne bolezni je treba opozoriti še na klasifikacijo morfologije neoplazem, za katero uporabljamo morfološki del Mednarodne klasifikacije bolezni za onkologijo, od poročila za leto 2001 njeno tretjo izdajo. V tej izdaji je nekaj novosti, med drugimi navedba, katere histološke vrste sodijo med maligne in nekaj novih histoloških vrst, ki do tedaj niso bile obravnavane posebej. Tako npr. gastrointestinalne stromalne tumorje (GIST) uvrščamo med posebne histološke vrste šele od leta 2001. Po tretji reviziji so med maligne uvrščene kronične mieloproliferativne bolezni in mielodisplastični sindromi (sedaj v topografski šifri C96.7) in policitemije, ki jih od 2001 uvrščamo v skupino C94. V skladu z novimi pravili mejno malignih tumorjev jajčnikov ne uvrščamo več v kategorijo C56, pač pa v D39.1.

Od leta 1993 je obvezno prijavljanje sprememb materničnega vratu, označenih kot CIN III (šifra 219 po 8. reviziji MKB), dotlej pa so se registrirale le spremembe, označene s šifro 234.0 (carcinoma in situ). Primerjava s podatki za obdobje 1961–1992 tako ni možna. Po 10. reviziji MKB so vse intraepiteljske spremembe materničnega vratu uvrščene v šifro D06. Od leta 1987 registriramo tudi prijavljene intraepiteljske karcinome dojke (šifra D05), od leta 1995 pa intraepiteljske karcinome mehurja (šifra D09.0) in kožne melanome Clark I (šifra D03).

Ker so podatki o stadiju bolezni po klasifikaciji TNM na prijavnica pogosto pomanjkljivi, za opredelitev stadija bolezni večinoma uporabljamo poenostavljeno razvrščanje v eno od treh skupin: omejena bolezen, regionalno razširjena bolezen in oddaljeno razširjena bolezen. Primer opredelimo na osnovi ugotovitev katere koli zapisane preiskave – od popisa operacije do obdukcije, če bolnik poprej ni bil zdravljen. Poenostavljena opredelitev stadijev pri solidnih tumorjih praviloma sledi klasifikaciji TNM. V omejeni stadij je tako praviloma uvrščen primer bolezni, pri katerem je tumor označen s T1 ali T2. Pri dojki, kožnem melanomu in ščitnici so v omejeni stadij vključeni tudi tumorji T3; pri materničnem vratu, telesu in sarkomih, ter pri jajčniku, jajcevodu in trofoblastnih tumorjih v omejeni stadij sodijo le tumorji T1. Pri omejeni bolezni seveda niso prizadete področne bezgavke in ni zasevkov v oddaljenih organih (N0, M0). V stadiju regionalne razširitve je primer, pri katerem je tumor opredeljen kot T3 in T4 (razen v omenjenih izjemah) in/ali so prizadete tudi področne bezgavke (N1), zasevkov v oddaljenih bezgavkah in organih pa ni (M0). V skupino oddaljeno razširjene bolezni pa uvrščamo primere, pri katerih je zapisano, da so bili zasevki že v oddaljenih bezgavkah ali organih (M1). Maligni limfomi so opredeljeni po klasifikaciji Ann-Arbor.

Kakovost podatkov RRRS in popolnost registracije

Kakovost podatkov registrov raka osvetljujejo naslednji kazalci: odstotni delež mikroskopsko (histološko ali citološko) potrjenih primerov in odstotni delež primerov, registriranih samo iz zdravniških poročil o vzroku smrti. Vrednosti teh kazalcev so prikazane v Tabeli 3.

Popolnost registracije kaže delež vseh novih primerov raka na področju, ki ga pokriva register in ki so vključeni v podatkovno zbirko registra. Neposredno jo je mogoče meriti samo s posebnimi raziskavami, namenjenimi oceni popolnosti, npr. s ponovnim pregledom odpustnih diagnoz in popisov bolezni v bolnišnicah ali ambulantah na določenem območju. V Sloveniji takih raziskav zaenkrat še nismo delali, veliko pa nam k popolnosti zajema pomagajo kolegi kliniki, ki jih zanima, kakšno je preživetje bolnikov, zdravljenih pri njih; ko nam pošljejo podatke o svojih skupinah bolnikov, v njih velikokrat najdemo take, ki jih v podatkovni zbirki RRRS še ni.

Na splošno velja, da je popolnost podatkov večja tam, kjer ima register dostop do zdravniških poročil o vzroku smrti. Za tiste, ki so umrli za rakom, pa (še) niso zapisani v registru, RRRS tako išče dodatne podatke. Na ta način se izboljša popolnost registracije rakov s slabo napovedjo izida, ne pa manj usodnih. Domnevamo, da je v Sloveniji – in tudi v drugih evropskih populacijskih registrih raka – manj popolna registracija nemelanomskega kožnega raka in tistih malignomov, ki se zdravijo samo ambulantno.

Incidenca in umrljivost

Incidenca in *umrljivost* pomenita absolutno število vseh na novo ugotovljenih primerov kake bolezni oz. število vseh umrlih za to boleznijo v točno določeni populaciji v enem koledarskem letu. V incidenco raka ne štejemo novih primarnih rakov parnega organa iste lokacije, če je bila histološka vrsta obeh rakov, npr. leve in desne dojke, enaka. Prav tako v incidenco ne štejemo novega pojava raka iste histološke vrste na istem organu, npr. multiple lezije v debelem črevesu. V incidenco so vključeni primeri bolezni bolnikov s stalnim bivališčem na območju Republike Slovenije ne glede na to, kje so bili bolniki zdravljeni.

Za *oceno incidence* v letošnjem letu (prikazano v Tabeli 1) je uporabljena metoda po Dybi in Hakulinenu, ki je primerna za napoved incidence v krajšem časovnem obdobju, saj upošteva samo obdobje diagnoze in starost; pri dolgoročnejših napovedih je treba upoštevati tudi vpliv rojstne kohorte.

Grobe in starostno specifične stopnje

Groba incidenčna stopnja je število novih primerov bolezni, preračunana na 100.000 oseb opazovane populacije, *groba umrljivostna stopnja* pa število vseh umrlih na 100.000 oseb opazovane populacije. Natančneje sta stopnji definirani kot število novih primerov bolezni (oz. število umrlih) v določenem časovnem obdobju, praviloma enem letu (= incidenca oz. umrljivost), deljeno s številom oseb, ki so na začetku tega obdobja izpostavljene tveganju, da zbolijo oz. umrejo zaradi določene bolezni; izražamo jo na 100.000 oseb-let. *Starostno specifična stopnja* pove to relativno število (incidenčno oz. umrljivostno stopnjo) v posamezni petletni starostni skupini.

Starostno standardizirane stopnje

Če analiziramo incidenco (ali umrljivost) v daljšem časovnem obdobju, v katerem se lahko starostna struktura prebivalstva v času spreminja, ali če primerjamo incidenco (ali umrljivost) med populacijami z različno starostno strukturo, je treba uporabiti eno od metod starostne standardizacije. Starostno standardizirana stopnja je teoretična incidenčna (oz. umrljivostna) stopnja, pri kateri predpostavimo, da je starostna struktura opazovane populacije taka kot v standardni populaciji. V Tabeli 2 prikazujemo poleg grobe incidenčne stopnje rakavih bolezni v Sloveniji še starostno standardizirane stopnje na svetovno, evropsko in slovensko standardno populacijo z metodo *neposredne standardizacije*. Starostno standardizirane umrljivostne stopnje so dostopne na spletišču SLORA. V Tabeli 6b je za primerjavo incidenčnih stopenj med slovenskimi statističnimi regijami uporabljen slovenski standard, starostna struktura prebivalcev Slovenije ob popisu leta 2002. Uporabljena standardna populacija je vedno enaka za oba spola, kar v posameznih primerih lahko privede do nepričakovanih rezultatov, ko so standardizirane stopnje pri enem spolu (ponavadi pri moških, ki so v povprečju mlajši) večje od grobih stopenj, pri drugem spolu pa manjše.

Kumulativne stopnje in kumulativno tveganje

Kumulativna incidenčna (ali umrljivostna) stopnja (KS) (prikazana v zadnjem stolpiču Tabele 5) je petkratna vsota starostno specifičnih incidenčnih (ali umrljivostnih) stopenj po petletnih starostnih skupinah do 74. leta starosti, preračunana na 100 prebivalcev. Je poseben primer neposredne starostne standardizacije, kjer je standardna populacija v vseh starostnih skupinah enaka in zato vrednost ni odvisna od izbora standarda. Kumulativno stopnjo smo uporabili za prikaz časovnega trenda incidence in umrljivosti v spodnjem delu Slike 4.

Kumulativno tveganje (KT) je verjetnost posameznika, da zbolje za rakom v izbranem starostnem obdobju, npr. do 74. leta starosti, če ne umre prej zaradi drugih vzrokov. Kumulativno tveganje izražamo v odstotkih. Če je KS manjša kot 10/100, jo lahko uporabimo za približek kumulativnemu tveganju. Pri večjih kumulativnih stopnjah pa kumulativno tveganje izračunamo iz kumulativne stopnje po obrazcu: $KT = 100 (1 - e^{-KS/100})$.

Kumulativno incidenčno stopnjo raka dojk pri ženskah 6,8/100 tako lahko uporabimo za oceno kumulativnega tveganja raka dojk, ki je v tem primeru 6,8-odstotno. To pomeni, da bo 6,8 % deklic, rojenih leta 2009 (ali približno ena od 15), do 74. leta starosti verjetno zbolelo za rakom dojk.

Prevalenca

Prevalenca je število vseh bolnikov z rakom, ki so bili živi na izbrani datum, ne glede na to, kdaj so zboleli. Celotna prevalenca obsega vse bolnike, ne glede na to, kako dolgo pred datumom izračuna so zboleli, medtem ko delna prevalenca šteje samo bolnike, ki so zboleli v določenem obdobju, npr. 1, 5 ali 10 let pred datumom, na katerega to mero računamo. Pri raku so ta obdobja še zlasti pomembna, saj odsevajo število bolnikov v različnih fazah poteka bolezni, npr. enoletna vključuje bolnike v času prvega zdravljenja, triletna bolnike v obdobju rednih kontrolnih kliničnih pregledov, petletna in zlasti še desetletna pa vključuje bolnike, za katere vsaj pri večini rakavih bolezni menimo, da so ozdravljeni.

Nekateri bolniki zbolijo za več kot eno rakavo boleznijo, zato je vsota prevalenc bolnikov po posameznih vrstah raka večja kot skupna prevalenca, pri kateri štejemo samo bolnike ne glede na število posameznih rakavih bolezni.

Relativno preživetje

Relativno preživetje je približek preživetja bolnikov kot v primeru, da bi upoštevali kot vzrok smrti samo izbranega raka. Izračuna se kot razmerje med opazovanim preživetjem proučevane skupine bolnikov in preživetjem, ki ga glede na spol in starost v določenem obdobju pričakujemo v celotni populaciji, iz katere prihajajo bolniki. Pričakovano preživetje se izračuna na podlagi podatkov o splošni umrljivosti, ki se v obliki tablic umrljivosti za posamezno državo rutinsko objavljajo v okviru demografske statistike; za naše izračune so uporabljene slovenske letne popolne momentne tablice umrljivosti. Izračunano je s knjižnjico *relsurv* v programskem paketu R.

Opozarjamo še, da metoda, uporabljena za izračun relativnega preživetja, prikazanega v tem poročilu, ni enaka tisti, s katero je mogoče prikazati relativno preživetje na spletnem portalu SLORA. Za izračun relativnega preživetja na spletišču SLORA je uporabljena t.i. Hakulinenova ali popolna metoda izračuna relativnega preživetja. Po tej metodi prispevajo bolniki, ki jim zaradi predhodnega zaključka opazovanja ne sledimo polni čas, k relativnemu preživetju samo leta, za katera so dejanski podatki na voljo. Tako skupina zbolelih tri leta pred zaključkom opazovanja prispeva k eno- in triletnemu relativnemu preživetju, k petletnemu pa ne.

Podatki o številu prebivalcev in o starostni strukturi so pomembni pri izračunavanju in interpretiranju večine kazalnikov bremena raka. Za Slovenijo je točno število in starostna struktura prebivalcev na voljo za popisna leta že ves čas registracije raka. Nacionalni popis prebivalstva je bil napravljen približno na vsakih deset let. Podatkov za vmesna obdobja do leta 1985 ni, zato smo pri izračunu kazalnikov predpostavili, da je bila med dvema popisnima letoma struktura enaka. Od sredine osemdesetih let, odkar število prebivalstva v Sloveniji spremlja Centralni register prebivalstva, je mogoče dobiti ažuren podatek o številu in starostni strukturi prebivalcev. V letnih poročilih uporabljamo podatek o prebivalcih na datum 30. junij posameznega leta, kot ga dobimo na podatkovnem portalu SI-STAT Statističnega urada RS. Podatki za leto 2009 o prebivalstvu po spolu in petletnih starostnih skupinah za celotno Slovenijo so v spodnji tabeli.

Starostna skupina	Skupaj	Moški	Ženske
0–4	99.666	51.086	48.580
5–9	90.088	46.390	43.698
10–14	94.263	48.566	45.697
15–19	106.795	54.861	51.934
20–24	127.403	64.989	62.414
25–29	144.341	73.699	70.642
30–34	152.921	78.477	74.444
35–39	144.917	73.949	70.968
40–44	153.012	76.529	76.483
45–49	153.939	77.508	76.431
50–54	156.317	79.296	77.021
55–59	151.723	76.780	74.943
60–64	111.376	54.705	56.671
65–69	103.919	48.531	55.388
70–74	87.166	37.851	49.315
75–79	73.028	27.624	45.404
80+	78.648	21.690	56.958
Skupaj	2.029.522	992.531	1.036.991

Prebivalci Slovenije po starosti in spolu na dan 30. 6. 2009.

Pri razporeditvi prebivalcev v posamezne statistične regije (spodnja tabela) je uporabljen le podatek o stalnem naslovu oseb in ne tudi začasnem, kot je upoštevan v pripravi števila prebivalcev po klasični »statistični« definiciji.

Statistična regija	Skupaj	Moški	Ženske
Pomurska	123.489	60.003	63.486
Podravska	322.954	157.649	165.305
Koroška	73.659	36.645	37.014
Savinjska	261.825	128.683	133.142
Zasavska	45.222	21.989	23.233
Spodnjeposavska	71.318	35.217	36.101
JV Slovenija	140.763	69.681	71.082
Osrednjeslovenska	511.459	247.536	263.923
Gorenjska	202.596	99.200	103.396
Notranjsko-Kraška	51.443	25.495	25.948
Goriška	118.511	58.302	60.209
Obalno-Kraška	106.283	52.131	54.152
Slovenija	2.029.522	992.531	1.036.991

Prebivalci Slovenije po statističnih regijah in spolu na dan 30. 6. 2009.

Leta 2009 je za rakom zbolelo 12.226 ljudi, 6.602 moških in 5.624 žensk, umrlo pa 5.787 ljudi, 3.260 moških in 2.527 žensk (*Slika 1*). Od rojenih leta 2009 bosta do 75. leta starosti predvidoma za rakom zbolela eden od dveh moških in ena od treh žensk (*Tabela 5*).

Konec decembra 2009 je živel 76.968 ljudi (32.325 moških in 44.643 žensk), ki so kdaj koli od ustanovitve RRRS zboleli za rakom (*Slika 1*). Ocenjujemo, da bo leta 2012 za rakom zbolelo približno 13.800 prebivalcev Slovenije, približno 7.500 moških in 6.300 žensk. Ocene incidence za posamezne lokacije raka so prikazane v *Tabeli 1* skupaj s povprečnimi petletnimi vrednostmi za zadnje 10-letno obdobje.

Kljub temu, da se ogroženost z rakom zmerno večja, je največja v starejših letih; od vseh bolnikov z rakom je leta 2009 kar 60 % moških in 59 % žensk zbolelo po 65. letu starosti. Pri otrocih in mladostnikih (do 20. leta) obsegajo rakave bolezni manj kot 1 % vseh primerov raka (*Slika 2*). Ker se slovensko prebivalstvo stara, je samo zaradi vedno večjega deleža starejših pričakovati, da se bo število novih primerov raka še večalo.

Ker na incidenco raka najbolj vpliva starostna struktura prebivalstva, so za verodostojnejšo primerjavo z drugimi državami z različno starostno strukturo v *Tabeli 2* poleg grobih stopenj izračunane tudi starostno standardizirane. Glede na to, da so v uporabi različni standardi, smo uporabili tri standardne populacije, svetovno, evropsko in slovensko.

Pet najpogostejših vrst raka pri nas – kožni (razen melanoma), raki debelega črevesa in danke, prostate, pljuč in dojke – obsegajo 59 % vseh novih primerov rakavih bolezni (*Slika 3*). Raki teh organov so sicer povezani z nezdravim življenjskim slogom, čezmernim sončenjem, nepravilno prehrano, kajenjem in čezmernim pitjem alkoholnih pijač; ogroženost z njimi je treba zmanjšati z ukrepi primarne preventive. Pri moških je bil s skoraj 20 % vseh rakov na prvem mestu rak prostate, sledili so mu rak debelega črevesa in danke, nemelanomski kožni rak in pljučni rak. Pri ženskah je bil na prvem mestu rak dojke, dobra petina primerov vseh rakov (20,1 %), sledili so mu nemelanomski kožni rak, rak debelega črevesa in danke ter pljučni rak (*Slika 3*).

Od leta 1950 se je groba incidenčna stopnja raka v Sloveniji zvečala za 546 % pri moških in za 326 % pri ženskah; v zadnjih 10 letih se je pri moških večala za 3,5 % povprečno letno, pri ženskah pa za 2,6 %. Groba umrljivostna stopnja se je v zadnjih 10 letih večala pri moških za 1,8 % povprečno letno, pri ženskah pa za 2,2 % (*Slika 4*). Več kot polovica zvečanja incidence gre na račun staranja prebivalstva. Kumulativna, starostno standardizirana incidenčna stopnja se je v zadnjih 10 letih pri moških večala v povprečju letno le za 1,6 %, pri ženskah pa za 1,0 %. Kumulativna, starostno standardizirana umrljivostna stopnja se od leta 1985 pri obeh spolih manjša (*Slika 4*), pri moških za 1,1 % letno, pri ženskah pa za 0,7 %. Manjšanje verjetnosti smrti za rakom ob večanju incidence kaže, da je zdravljenje uspešnejše in da vse več bolnikov ozdravi ali živi z rakom, medtem ko jih je poprej več umrlo.

Časovni trend pogostejših rakov pri moških kaže, da se je incidenčna stopnja pljučnega raka večala vse do začetka devetdesetih let prejšnjega stoletja, ko se je ustalila pri vrednosti okoli 85/100.000, v zadnjih letih se postopno manjša, strmo pa pljučnega raka prehitevata rak prostate in rak debelega črevesa in danke. Izjemno

povečanje incidence raka prostate v zadnjem desetletju ni posledica kakega novega nevarnostnega dejavnika, pač pa predvsem vse širše rabe testa PSA pri zdravih moških in odkrivanja velikega števila primerov, ki bi drugače ostali vse življenje prikriti. V zadnjem desetletju se počasi manjša incidenčna stopnja raka glave in vratu. Pri ženskah se večja incidenčna stopnja raka dojk, čeprav v zadnjih letih manj, kot v devetdesetih. Več je tudi pljučnega raka in raka materničnega telesa, medtem ko se incidenčna stopnja raka materničnega vratu od leta 2003 počasi manjša. Pri obeh spolih se večja pogostost raka debelega črevesa in danke, malignega melanoma in drugih kožnih rakov, podobno kot drugod v svetu pa je želodčnega raka pri obeh spolih počasi vse manj (*Slika 5*).

Slika 6 prikazuje pet-letno relativno preživetje bolnikov z vsemi (razen kožnega) in izbranimi raki, zbolelih v letih 2005–2009. Za primerjavo je prikazano tudi relativno preživetje bolnikov, zbolelih v predhodnem petletnem obdobju (2000–2004). Pri moških se je skupno preživetje povečalo za 8,6 odstotnih točk, predvsem zaradi večjega odkrivanja in boljšega prijavljanja raka prostate nižjih stadijev, ki so povezani z boljšo prognozo, saj je pri tej bolezni preživetje večje kar za 15,0 odstotnih točk. Ker se 95 % intervala zaupanja ne prekrivata, lahko zaključimo, da je razlika statistično značilna. Večje preživetje bolnikov s kožnim melanomom, rakom ledvic in ledvičnega meha, debelega črevesa in danke ter sečnega mehurja je gotovo realno in je posledica odkrivanja bolezni v nižjem stadiju in večje kakovosti zdravljenja. Pri ženskah je skupno preživetje večje za 3,6 odstotnih točk. Preživetje bolnic z rakom dojk se je izboljšalo za 6,3 odstotnih točk, večje preživetje pa so imele tudi bolnice z rakom ščitnice, kožnim melanomom, z rakom debelega črevesa in danke ter pljuč.

Najpogostejši raki so v raznih življenjskih obdobjih različni. Pri otrocih in mladostnikih do 20. leta je rak zelo redka bolezen, v zadnjih letih (2005–2009) je v povprečju letno zbolelo 34 dečkov in 31 deklic. Najpogostejše pri dečkih so bile levkemije (24,0 %), sledili so jim tumorji centralnega in avtonomnega živčnega sistema (18,7 %) in Hodgkinova bolezen (11,7 %), pri deklicah pa so bili na prvih dveh mestih tudi levkemije (30,1 %) in tumorji centralnega in avtonomnega živčnega sistema (16,3 %), na tretjem pa kostni tumorji (8,5 %). Mlajših odraslih moških (starih 20–34 let) je zbolelo v povprečju 129 letno; med njimi je skoraj polovica primerov raka mod (42,4 %), sledi kožni melanom (9,6 %), za nemelanomskim kožnim rakom (7,1 %) pa tumorji centralnega in avtonomnega živčnega sistema (6,1 %). Pri mlajših ženskah (v povprečju je letno 152 novih primerov) pa je bil na prvem mestu rak dojk (15,2 %), sledili so kožni melanom (14,9 %) in rak materničnega vratu (14,8 %) (*Slika 7*).

Kot že omenjeno pri komentarkju k *Sliki 2*, je ogroženost z rakom povezana s staranjem in več kot polovico vseh ljudi pri nas zboli po 64. letu starosti. Zdravljenje teh bolnikov je poseben izziv, saj zaradi pridruženih bolezni ni vedno optimalno. Nekateri značilnosti bolezni in izida zdravljenja pri starejših nasploh in po 10-letnih starostnih skupinah so prikazane v *Sliki 8*.

Pri večini bolnikov je diagnoza bolezni potrjena mikroskopsko. Iz *Tabele 3* je razvidno, da je bila leta 2009 pri 94,1 % od 12.226 na novo registriranih primerov raka diagnoza potrjena mikroskopsko (histološko ali citološko), pri 5,6 % z drugimi

preiskavami, le 0,4 % primerov pa je bilo v RRRS vpisanih samo na osnovi zdravniškega poročila o vzroku smrti. Ta, zadnja odstotna vrednost, ki je že več let podobna, odseva število bolnikov, ki verjetno zaradi starosti ali napredovale bolezni niso bili zdravljeni v bolnišnici. Iz *Tabele 3* je poleg načina postavitve diagnoze razvidno tudi število vseh novih primerov po posameznih lokacijah raka, kako se primeri razporejajo po 5-letnih starostnih skupinah, pa prikazuje *Tabela 4*, v *Tabeli 5* pa so te vrednosti preračunane v starostno specifične stopnje na 100.000 prebivalcev.

V *Tabeli 6a* je število novih primerov vseh in izbranih rakov prikazano po statističnih regijah. Ta števila so pomembne za načrtovanje zdravstvenih zmogljivosti, starostno standardizirane vrednosti v *Tabeli 6b* pa kažejo razlike v ogroženosti z rakom v posameznih regijah, saj te niso posledica razlik v starostni strukturi prebivalcev.

Kakšna je bila morfološka slika malignomov pri 11.482 primerih, pri katerih je bila diagnoza potrjena mikroskopsko, kaže *Tabela 7*. V njej so posebej primeri, ki so potrjeni histološko (94 %), in tisti, ki so bili potrjeni samo citološko (6 %).

Tabela 8 kaže starostno porazdelitev ekстранodalnih in nodalnih lokacij ne-Hodgkinovih malignih limfomov. Ker je število ekстранodalnih lokacij majhno, so prikazane le absolutne številke.

Tabela 9 prikazuje porazdelitev bolnikov po stadiju, v katerem je bila bolezen odkrita. Uporabljena je poenostavljena opredelitev stadijev, ki upošteva vse preiskovalne metode, vključno operacijo in tudi obdukcijo, če bolnik ni bil poprej zdravljen.

Tabela 10 prikazuje osnovne podatke o zdravljenju bolnikov. Ker je veliko bolnikov zdravljenih na več načinov, je vsota bolnikov po vrsti zdravljenja večja od števila novih primerov. Iz *Tabele 10a* je razvidno, kako so bili bolniki zdravljeni, v *Tabelah 10b* in *10c* pa, v katerih zdravstvenih ustanovah so bili bolniki v okviru prvega zdravljenja operirani in/ali zdravljeni s sistemskimi zdravili; z obsevanjem se z redkimi izjemami (tujina) zdravijo samo na Onkološkem inštitutu Ljubljana.

Tabela 11 prikazuje prevalenco vseh in pogostejših rakov na dan 31. 12. 2009. Poleg celotne prikazujemo tudi delno, to je 1-, 3-, 5- in 10-letno prevalenco.

V *Tabeli 12* so uradni podatki o umrljivosti za rakom v letu 2009; zbira jih Inštitut za varovanje zdravja RS.

Zdravniki, medicinske sestre in administrativno osebje iz slovenskih bolnišnic in drugih zdravstvenih ustanov so Registru raka RS dokaj vestno pošiljali prijavnice s podatki o novih primerih raka, o poteku bolezni in usodi bolnikov. Dopolnili so nam tudi morebitne pomanjkljive prijave. Podatke, ki so za Register raka nujni, a jih ni bilo mogoče najti v bolnišnicah, so nam z zavzetim delom priskrbeli družinski in splošni zdravniki.

Vsaj polovico podatkov, obdelanih v tem poročilu, sta prispevali sodelavki Bolnišničnega registra Onkološkega inštituta v Ljubljani Ana Dotzauer in Maruška Ferjančič.

Poročila bi skorajda ne mogli napraviti, njegovi podatki pa bi bili bistveno manj verodostojni, ko bi ne imeli naklonjenega sodelovanja Centralnega registra prebivalstva RS, Inštituta za varovanje zdravja RS in Statističnega urada RS.

Vsem imenovanim in tudi drugim, ki so kakorkoli prispevali k temu poročilu, se najlepše zahvaljujemo.

Uredniški odbor

Cancer Registry of the Republic of Slovenia (CRRS) is one of the oldest population based cancer registries in Europe. It was founded at the Institute of Oncology Ljubljana (IO) in 1950 by the late Professor Božena Ravnihar, who headed it till 1975. She was succeeded by Professor Vera Pompe-Kirn, who contributed a lot to the further development of the CRRS as well as its recognition at the national and international level all until her retirement in 2003. Since 2003, the CRRS together with the Unit of Epidemiology is merged in a single Epidemiology and Cancer Registry service. Besides the CRRS, the new service also comprises the *hospital-based Cancer Registry* of the IO, which contributes a considerable part of information to the CRRS and facilitates a more detailed overview of patients treated at the IO, irrespective of their permanent residence. In the last decade, a new *national registry in charge of coordinating and monitoring the organised cervical cancer screening programme* (Registry ZORA) has been established, while an *information system to support organized breast screening program* has been underway since 2007 (Registry DORA).

The data on cancer, that are collected by the CRRS, incidence, survival and prevalence, serve together with mortality data, collected by the Institute of Public Health as the basis for assessing the cancer burden in the country. They are important for planning and evaluation of all levels of cancer control, primary prevention, diagnosis, treatment and rehabilitation, for planning facilities and funding needed for cancer control (personnel, equipment and hospital capacities) as well as for clinical and epidemiological research in Slovenia and in international multicentre studies and for evaluation of effectiveness of cancer screening programs.

The Annual Reports of CRRS are one of the regular ways of disseminating information on cancer among professionals and all other groups. As we are limited by the technology of data collection because of a variety of data sources, data collection, their linking and publication is rather time consuming (with us and elsewhere) and usually takes two to three years. As preliminary information on expected incidence in the year when the Annual Report is published (in this report for the year 2012), estimated numbers and rates are presented; they are calculated by a special statistical method.

The first annual reports of the CRRS for the period 1951–1955 were issued during the years 1953–1957. The first data analysis for the year 1950 was published in *Zdravstveni vestnik* in 1951. The data for the period 1957–1971 were appearing in the periodicals *Epidemiological and Vital Statistics Report* and *World Health Statistics Report*, both edited by World Health Organization. From 1965 onwards, the data have been appearing regularly in special bi-lingual (Slovene-English) annual reports, first entitled *Cancer in Slovenia* (1965–1977), and then *Cancer Incidence in Slovenia* (1978–2006). Besides Annual Reports, four special publications have been published: *Atlas of Cancer Incidence in Slovenia 1978–1987*, *Cancer Patients' Survival in Slovenia 1963–1990*, *Cancer Patients' Survival in Slovenia 1983–1997* and *Survival of Cancer Patients, diagnosed in 1991–2005 in Slovenia*. The list of other relevant publications in last five years is at the end of this report.

Data of the CRRS are included in several international databases and projects. They have been published in all nine volumes of the *Cancer Incidence in Five Continents* issued by International Agency for Research on Cancer. The data are included in international databases *EUROCIM*, *GLOBOCAN* and *ACCIS*. The survival of Slovenian cancer patients is analysed in the international studies EUROCORE II, EUROCORE III, EUROCORE IV, EUROCORE V and EUNICE.

In 2010, the Registry's database has been upgraded and data processing modernized. This is also the reason for a delay in publishing this report, as several technical problems have been encountered. But we managed to launch in 2010 an interactive web portal with the name SLORA, according to the first letters in Slovenian language: "SLOvenia and RAK/cancer". It is available at www.slora.si. It enables a simple access to data on cancer in Slovenia, registered in CRRS, currently till 2009 (incidence, prevalence and survival) or Institute of Public health (mortality) and comparison with other countries in the European Union and in the world. It describes the data and informs users with professional explanations about cancer risk factors, about screening and early detection and treatment outcome.

Data sources and the list of data collected

Notification of cancer has been compulsory in Slovenia since the foundation of the CRRS and prescribed by law (Official Gazette of SRS, No 10/50, 29/50, 14/65, 1/80, 45/82 and 42/85; Official Gazette of RS, No 9/92 and 65/00). The main sources of data are *notifications of cancer*, gathered from all hospitals and diagnostic centres in Slovenia, exceptionally also from primary health care centres in case the patient has not been referred for further diagnostic investigations and/or treatment.

The data, gathered with notifications are identification data, data on the cancer disease (anatomic cancer site, histological or cytological diagnosis and stage by TNM or other clinical classification) and basic data on treatment. Additional sources of information are death certificates that we get from Institute of Public health of RS. A lot of time of CRRS's staff is needed for queries about patients, from who we do not have all data or we get their data at death only.

Calculation of patient survival requires the patient's *vital status* (a person may be alive, dead or lost to follow-up). This data is obtained from the Central Population Registry for all persons registered in the CRRS data base as alive. Since 2010, together with the upgrade of CRRS's database, an on-line connection with the Central Population Registry has been established through a specially secured web technology. This enables an on-line connection and up-to-date vital status of all registered patients. In persons lost to follow-up, the date of last notification or the date of loss obtained from the Central Population Registry, whichever first, is considered as date of loss. From 1985, since the uniform personal ID number has been used in Slovenia, in CRRS the percentage of the lost to follow-up is below 1%, in patients registered in the last decade being 0.1%.

When analysing the spatial distribution of cancer, the new law on regional division of Slovenia is followed, that in the year 2000 introduced the system of division of Slovenian territory at eleven levels. The exact mapping of patients' permanent address is also possible, as we maintain the regular connection with the Registry of spatial units of the Surveying and Mapping Authority. Till the Annual Report 2002, the data have been presented by 9 health regions in Table 6, since then, 12 statistical regions are used to present the data.

Statistical regions of Slovenia



Preparation of data for computer processing

In CRS specially trained nurses code the data retrieved from notifications in accordance with the internationally and in CRRS agreed rules.

Since 1997, cancer sites are coded according to the 10th revision of the International Statistical Classification of Diseases and Related health Problems (ICD-10); before, the 8th revision was used (ICD-8). When classifying tumours as malignant, the behaviour digit of the morphology code of the third edition of International Classification of Diseases for Oncology has been used since the report for 2001 on. In this edition, some changes were introduced in terms of morphology and behaviour code and some new morphology codes were added for tumours that till 2001 have not been coded separately. Gastrointestinal stromal tumours (GIST) are a distinct entity since 2001. According to this classification, chronic myeloproliferative disorders and myelodysplastic syndromes are classified as malignant (currently C96.7 topography code) as well as polycythaemia, assigned the code C94. According to the new rules, ovarian tumours of borderline malignancy are currently coded as D39.1 (and not C56).

In 1993, compulsory registration of all cervical intraepithelial dysplasia classified as CIN III was introduced (code 219 according to ICD-8). Till then, only carcinoma in situ (code 234.0) was registered. Thus, the comparison with the data for the period 1961–1992 is not possible. According to ICD-10, all cervical intraepithelial neoplasm (in situ and CIN III) are coded as D06. Since 1987, the number of all reported intraepithelial carcinomas of breast (D05) and since 1995, all reported intraepithelial carcinomas of the bladder (D09.0) and all malignant melanomas Clark I (D03) have been registered.

As data on the stage of disease by TNM Classification System in cancer notification forms are often lacking, a simplified definition of stages at diagnosis is used, classifying them in localised, regional and remote stage of disease. The simplified definition is based on all investigation methods, including surgery. In case the patient was not treated before death, the autopsy record is considered as well. In solid tumours, the simplified stage definition generally follows the TNM classification. Localised stage includes all cancers where the tumour has been classified as T1 and T2. In breast cancer, skin melanoma and thyroid cancer, T3 tumour is also included in localised stage. In uterine cervix, corpus and sarcomas, ovarian cancer, tube and trophoblast tumours only T1 tumour is included in localised stage. In all of these cases neither regional node involvement nor distant metastases are found (N0, M0). The regional stage includes tumours classified as T3 and T4 (exceptions already mentioned) and/or regional node metastases (N1), without presence of metastases in distant lymph nodes or organs (M0). The disease with metastases in distant lymph nodes or organs is classified as the remote stage (M1). Malignant lymphomas are classified according to Ann-Arbor System.

Data quality and completeness of registration

The quality of information can be assessed by the following parameters: the percentage of microscopically (histologically or cytologically) confirmed cases and the percentage of cancer cases registered on the basis of death certificates only. The values of these parameters are presented in Table 3.

The completeness of registration shows the proportion of all new cancer cases in the region covered by the registry, which are included in the registry's data base. It can be measured directly only by means of special surveys for the evaluation of completeness, e.g. by reviewing patient record in the hospitals or outpatient clinics in a particular region. In Slovenia, no such surveys have been carried out so far. However, a considerable contribution towards the completeness of registration is made by our colleagues – clinicians, who send us the data on their groups of patients in order to get information about their vital status and among them we often find cases that have not been entered in the CRS database yet.

The registration is more complete where the registries have access to death certificates, and can send out additional inquiries about disease for the deceased that have not been entered into the database yet. This improves the completeness of registration of cancers with poor prognosis, but not also of less fatal ones. It is presumed that in Slovenia – as well in other European population based cancer registries – registration is less complete in non-melanoma skin cancer and in malignomas that are treated on the out-patient basis only.

Incidence and mortality

Incidence and mortality are absolute numbers of all newly diagnosed cases of any disease or number of deceased from this disease in a defined population in one calendar year. New primary cancers of the same histology in paired organs, e. g. on the left and right breast, are not comprised in the incidence figures, neither are any new cancers of the same histology appearing in the same organ, e.g. multiple lesions of the colon. The incidence registered by CRRS includes only the data on patients with permanent residence in Slovenia, regardless of the country, where they have been treated.

The method by Dyba and Hakulinen was used for estimation of incidence in 2010 (presented in Table 1). This method is suitable for predictions in shorter time period, taking into account the period of diagnosis and age structure of population. For long-term predictions the cohort effect should be included also.

Crude and age specific rates

Crude incidence rate is the number of new cases per 100,000 population, while crude mortality rate is the number of deaths per 100,000 population. More precisely it is defined as number of new cases (or number of deaths) in a specified time interval, usually one calendar year (=incidence or mortality), divided by the number of persons at risk of disease (or death) at the beginning of time interval; it is expressed per 100,000 person-years. The *age specific rate* expresses incidence or mortality rate in an individual five-year age group.

Age standardized rates

When analysing the incidence (or mortality) rate within longer time period (if the age structure of population changes) or comparing the incidence (or mortality) between populations with different age structure, age standardisation is needed to adjust the rate for the effect of age. The age-standardised rate is a theoretical incidence (or mortality) rate assuming that the age structure in the observed population is the same as in the standard population. In Table 2, besides crude cancer incidence rates, age standardised rates by direct method are presented, using World, European and Slovenian standard population. Age standardised mortality rates are also available at SLORA web-portal. In Table 6b the standard is the age structure of Slovenian 2002 census population. The standard population is always the same for both sexes that may in some situations result in standardized rate being bigger than crude rate in one sex, usually in males, who are on average younger, and smaller in females.

Cumulative incidence rate and cumulative risk

The cumulative incidence (or mortality) rate (cumulative incidence rate is presented in the last column of Table 5) is five times the sum of the age-specific incidence (or mortality) rates over five-year age groups up to the age of 74 years, calculated per 100 population. The cumulative rate can be interpreted as a form of direct age-standardization with the same standard population size in each age group. Thus, it avoids the arbitrary choice of standard population. The cumulative incidence rate was also used to present the incidence time trend in the lower part of the Figure 4.

The cumulative risk (CR) is the risk an individual would have of developing the disease in question during a certain age period, e.g. up to the age of 74, if no other causes of death were in operation. The cumulative risk is expressed per 100 (per cent). If cumulative rate is lower than 10/100, its value is practically equal to that of the cumulative risk. When cumulative rate is greater than 10/100, it should be calculated from cumulative risk according to the following formula: $CR = 100 (1 - e^{-CR/100})$.

Cumulative incidence rate of breast cancer in females 6.8/100 can be used to estimate cumulative risk of breast cancer that is in this case 6.8%. This means that 6.8% of women born in 2008 (approximately each 15th woman) are expected to develop breast cancer by their age of 75 in the absence of any other cause of death.

Prevalence

Prevalence is the number of all cancer patients that are alive on a given date, regardless of time, when they were diagnosed with cancer. Lifetime cancer prevalence is defined as all persons living and ever diagnosed with cancer, while partial prevalence counts only those patients, diagnosed with cancer within a defined period of time e. g. 1, 5 or 10 years before the date on which prevalence is calculated. In cancer these periods are important, as they reflect the number of cancer cases in different course of disease, e. g. the one-year prevalence includes patients during their primary treatment, 1–4 years prevalence those requiring regular follow-up, while 5–9 and especially 10 and more years prevalence includes predominantly those considered cured from cancer.

Some patients have more than one cancer, hence the sum of prevalence of cancer patients by individual cancer site is bigger than the prevalence of all cancer patients, as patients are counted only once regardless of the number of cancer diseases.

Relative survival

Relative survival is an approximation of patients' survival in the case where the observed cancer would be considered as the only cause of death. Relative survival is a ratio between the observed and the expected survival, i.e. the survival expected with respect to gender and age in certain time period in the whole population the patients come from. The expected survival is calculated from general mortality data, published routinely in the form of mortality tables for an individual country within the framework of its vital statistics. The relative survival for the needs of this report was calculated using the Slovenian annual complete yearly life tables, using package *relsurv* in statistical software R.

It should be noted that the method, used for survival calculation in this report is different from the one used to present survival at web-portal SLORA, where the relative survival is computed by complete or Hakulinen's method. In this method the patients followed up for a shorter period of time are considered in the calculation only for the time when they were actually followed. Thus, a group diagnosed three years before the completion of study, contributes to one- and three-year complete relative survival but not also to five-year survival.

Population of Slovenia

Population data, especially the number and age structure, are important for calculation and interpretation of most indicators of cancer burden. Census population data are available for the whole time period since the beginning of cancer registration. Census has been performed nearly every 10 years, but till 1985 no data were available for intermediate years, so for this time period it was assumed that the population structure between two censuses was the same. Since the middle of the eighties, the population data are available for any particular date from the Central Population Registry. In CRRS Annual Reports, the number of population on June 30 of a particular year is used, that is obtained from Statistical Office of Republic of Slovenia. In the following table, numbers of inhabitants of Slovenia in 2009 by age and by sex are presented.

Age	Total	Males	Females
0–4	99.666	51.086	48.580
5–9	90.088	46.390	43.698
10–14	94.263	48.566	45.697
15–19	106.795	54.861	51.934
20–24	127.403	64.989	62.414
25–29	144.341	73.699	70.642
30–34	152.921	78.477	74.444
35–39	144.917	73.949	70.968
40–44	153.012	76.529	76.483
45–49	153.939	77.508	76.431
50–54	156.317	79.296	77.021
55–59	151.723	76.780	74.943
60–64	111.376	54.705	56.671
65–69	103.919	48.531	55.388
70–74	87.166	37.851	49.315
75–79	73.028	27.624	45.404
80+	78.648	21.690	56.958
Total	2.029.522	992.531	1.036.991

Population of Slovenia by age and by sex, June 30, 2009.

In the number of population by statistical regions (following table) the permanent, but not the temporary residence of the Slovenian citizens is used, contrary to the standard "statistical" definition.

Statistical region	Total	Males	Females
Pomurska	123.489	60.003	63.486
Podravska	322.954	157.649	165.305
Koroška	73.659	36.645	37.014
Savinjska	261.825	128.683	133.142
Zasavska	45.222	21.989	23.233
Spodnjeposavska	71.318	35.217	36.101
JV Slovenija	140.763	69.681	71.082
Osrednjeslovenska	511.459	247.536	263.923
Gorenjska	202.596	99.200	103.396
Notranjsko-Kraška	51.443	25.495	25.948
Goriška	118.511	58.302	60.209
Obalno-Kraška	106.283	52.131	54.152
Slovenia	2.029.522	992.531	1.036.991

Population by Slovenian statistical regions and by sex, June 30, 2009.

In 2009, 12,226 patients were diagnosed with cancer, 6,602 males and 5,624 females, and 5,787 patients died from cancer, 3,260 males and 2,527 females (*Figure 1*). From those born in 2009, one in two males and one in three females are expected to develop cancer by their age of 75 (*Table 5*).

At the end of December 2009, there were 76,968 people (32,325 males and 44,643 females) alive who were diagnosed with cancer at any time since the foundation of the CRRS (*Figure 1*). It is estimated, that in 2012, there will be about 13,800 Slovenian inhabitants newly diagnosed with cancer, approximately 7,500 males and 6,300 females. The estimated incidence of different cancer sites together with 5-year average values in the last 10-year period are presented in *Table 1*.

Though the risk of cancer is slowly increasing, the risk is the highest in older age groups; from all cancer patients, diagnosed in 2009, 60% of males and 59% females were aged 65 or more at diagnosis. Less than 1% of all cancer is among children and young adults (till the age of 20) (*Figure 2*). As Slovenian population is ageing, it is expected that the cancer burden will increase because of longer life expectancy.

As cancer incidence depends on the age structure of a population, in *Table 2* besides crude also age standardised rates are presented. For better comparison with other countries and as different standard populations are used worldwide, three standard populations, World, European and Slovenian were applied.

First five most frequent cancers (skin – except melanoma, colorectal, prostate, lung and breast) comprise 59% of all new cancer cases (*Figure 3*). Cancer of these sites is associated with unhealthy lifestyle, such as excessive sunbathing, unhealthy diet, smoking and excessive alcohol consumption; the aim of primary prevention is to lower the risk associated with these factors. In males, the most frequent cancer site in 2009 was prostate (*Figure 3*), followed by colorectal, skin (non-melanoma) and lung cancer. In females, breast is in the first place with 20% of all new cases, followed by skin (non-melanoma), colorectal and lung cancer (*Figure 3*).

Since 1950, the crude cancer incidence rate in Slovenia increased for 546% in males and for 326% in females. In the last 10 years, the average annual increase in males was 3.5% and 2.6% in females. The crude mortality rate in the last 10 years increased on average by 1.8% per year in males and by 2.2% in females (*Figure 4*). More than half of the crude incidence rate increase is a consequence of ageing of the population. Since 1999, the average annual increase in cumulative, age standardised incidence rate in males was 1.6% and 1.0% in females. Cumulative, age standardised mortality rate is decreasing in both sexes in the last 10 years, in males on average by 1.1% and in females on average by 0.7% annually. The decreasing mortality, despite increasing incidence, indicates improvement of treatment of cancer patients and is a proof that they are cured of, not dying from cancer.

The time trend of common cancers in males shows that lung cancer incidence was increasing since the beginning of the nineties, while it became stable onwards (85/100.000) and is slowly decreasing; it was overcome by prostate and colorectal cancer. The huge increase in prostate cancer incidence rate in the last years is not due to some new risk factor, but more frequent use of PSA test as an opportunistic

screening method, resulting in detection of many cancers that would never progress or even not be detected during lifetime without screening. In the last 10 years the incidence rate of head and neck cancer is slowly decreasing. In females, the incidence rate of cancers of breast, lung and uterine corpus is increasing, while the incidence of cervical cancer is slowly decreasing since 2003. In both sexes, the incidence of cancers of colon and rectum, melanoma and other skin is increasing as in other countries, while the incidence of stomach cancer is decreasing (Figure 5).

In Figure 6, 5-year relative survival of all cancer patients (without patients with non-melanoma skin cancer) and patients with cancer of selected sites is presented of those, diagnosed in 2005–2009 and for comparison of those diagnosed in 2000–2004. In males the overall survival increased for 8.6 percentage points, especially because of better detection and reporting of earlier stage prostate cancer with better prognosis, as for these patients the survival increased for 15.0 percentage points. As 95% confidence intervals are not overlapping, it can be concluded that the difference is statistically significant. Better relative survival of patients with skin melanoma, cancers of kidney with pelvis, colon, rectum and urinary bladder is real and is probably due to earlier stage at diagnosis and better treatment. In females, the overall survival increased for 3.6 percentage points. In breast cancer patients it increased for 6.3 percentage points, while it increased also for patients with skin melanoma and cancers of thyroid, colon, rectum and lung.

The most frequent cancers vary by age. In children and adolescents till the age of 20, cancer is a very rare disease; in the last 5 years (2005–2009) it was diagnosed in 34 boys and 31 girls on average per year. In boys, the most frequent were leukaemias (24.0%), followed by tumours of central and autonomous nervous system (18.7%) and Hodgkin's lymphoma (11.7%), while in girls the most frequent were leukaemias (30.1%), followed by tumours of central and autonomous nervous system (16.3%) as well and bone cancer on the third place (8.5%). In young adult males (aged 20–34) there were on average 129 new cases per year; the most frequent cancer sites were testis (42.4%), followed by skin cancer (melanoma –9.6%) and non-melanoma–7.1%) and tumours of central and autonomous nervous system (6.1%). In younger females (152 new cases on average per year) the first was breast cancer (15.2%), followed by melanoma (14.9%), and cervical cancer (14.8%) (Figure 7).

As already mentioned with Figure 2, cancer risk is increasing with increasing age and half of cancer patients are aged 65 or older at diagnosis. This group of cancer patients represents a special challenge for treatment, as due to comorbidity it is always not optimal. Some characteristics of cancer in the elderly and the outcome of their disease in general and by 10-year age groups are presented in Figure 8.

In the majority of new cases, the diagnosis was confirmed microscopically. Table 3 shows that in 2009, in 94.1 % from 12,226 newly diagnosed cancer cases, the diagnosis was confirmed by histology or by cytology, in 5.6% with other investigations and only 0.4% of cases were registered from death certificate only. This latter percentage has been similar for several years and represents those patients that, due to advanced age or disease have not been treated in the hospital. Table 3 presents the number of new cases by cancer site, while in Table 4 their distribution by 5-year age group is presented. In Table 5, there are age specific incidence rates for all and specific cancer sites.

In *Table 6a*, the number of new cases of all and selected cancer sites by different statistical regions is presented. While these data are important for planning health care facilities, the age standardised rates in *Table 6b* indicate the differences in the risk of cancer, as these differences are not due to different age structure of population in these regions.

The morphology of tumours in 11,482 cases, diagnosed microscopically, is presented in *Table 7*. In this table, cases confirmed by histology (94%) and by cytology only (6%) are presented separately.

Age distribution of extranodal and nodal sites of non-Hodgkin's malignant lymphomas is presented in *Table 8*. Owing to a small number of extranodal sites, only the absolute numbers are given.

Table 9 shows the distribution of cancer patients by stage at diagnosis. A simplified definition of stages at diagnosis is used, that takes into account all investigation methods, including surgery or autopsy in case the patient has not been treated before death.

Table 10 presents basic data on cancer patients treatment. As in many cases combined treatment is applied, the sum of patients treated by different modalities is bigger than the number of new cases. *Table 10a* presents the mode of treatment of all cancer patients. *Tables 10b and 10c* show the hospital where patients had surgery and/or systemic treatment as primary treatment; radiotherapy is performed at IO only (with few exceptions, that have been irradiated abroad).

In *Table 12*, there are official data on cancer mortality in 2009. The table has been prepared at the Institute of Public Health of the Republic of Slovenia.

Acknowledgement

Physicians, nurses, and the administrative staff from the Slovenian hospitals and other health institutions have been conscientiously providing data on new cancer cases, on the course of each individual disease as well as of its eventual outcome. If data on new cases had been incomplete, they effectively sought for the additional necessary information. If the data necessary for the Registry had not been available in hospitals, they were kindly provided by the family and general physicians.

At least half of data presented in the current report have been contributed by Mrs. Ana Dotzauer in Mrs. Maruška Ferjančič from the Ljubljana Institute of Oncology Hospital Registry.

The Report could not be published – at least with the currently assured high credibility of data – without the traditional good cooperation of the Republic of Slovenia Population Registry, Institute of Public Health, and Statistical Office with the Cancer Registry.

The Registry is grateful to the above mentioned as well as to all others who have contributed to the current Report.


Editors

- Ravnihar B, Gruden I. Statističen pregled in kratka analiza prijavljenih rakovnih obolenj iz področja LRS za leto 1950. *Zdrav Vestn* 1951; 20: 264–77.
- Epidemiological and vital statistics report. Geneva: World Health Organization, 1961–1966.
- World health statistics report. Geneva: World Health Organization, 1970–1974.
- Rak v Sloveniji (1965–77). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1967–1980.
- Incidenca raka v Sloveniji (1978–2001). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1981–2004.
- Doll R, Payne P, Waterhouse J, eds. Cancer incidence in five continents. Vol 1. Berlin: Springer, 1966.
- Doll R, Muir C, Waterhouse J, eds. Cancer incidence in five continents. Vol 2. Lyon: International Agency for Research on Cancer, 1970.
- Waterhouse J, Muir C, Correa C, Powell J, eds. Cancer incidence in five continents. Vol 3. Lyon: International Agency for Research on Cancer, 1976 (IARC Sci Publ 15).
- Waterhouse J, Muir C, Shanmugaratnam K, Powell J, eds. Cancer incidence in five continents. Vol 4. Lyon: International Agency for Research on Cancer, 1982 (IARC Sci Publ 42).
- Muir C, Waterhouse J, Mack T, Powell J, Whelan S, eds. Cancer incidence in five continents. Vol 5. Lyon: International Agency for Research on Cancer, 1987 (IARC Sci Publ 88).
- Parkin DM, Muir C, Whelan S, Gao Y, Ferlay J, Powell J, eds. Cancer incidence in five continents. Lyon. Vol 6. International Agency for Research on Cancer, 1992 (IARC Sci Publ 120).
- Parkin DM, Whelan S, Ferlay J, Raymond L, Young J, eds. Cancer incidence in five continents. Vol 7. Lyon: International Agency for Research on Cancer, 1997 (IARC Sci Publ 143).
- Parkin DM, Whelan S, Ferlay J, Teppo L, Thomas DB, eds. Cancer incidence in five continents. Vol 8. Lyon: International Agency for Research on Cancer, 2002 (IARC Sci Publ 155).
- Curado MP, Edwards B, Shin HR, Storm H, Ferlay J, Heanue M, Boyle P, eds. Cancer incidence in five continents. Vol 9. Lyon: International Agency for Research on Cancer, 2007 (IARC Sci Publ 160).
- European Network of Cancer Registries. EUROCIM version 4.0. European incidence database V2.4, ICD-10 dictionary (2003), Lyon 2001.
- Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. URL: <http://globocan.iarc.fr>.
- Steliarova-Foucher E, O'Callaghan M, Ferlay J, Masuyer E, Forman D, Comber H, Bray F: European Cancer Observatory: Cancer Incidence, Mortality, Prevalence and Survival in Europe. Version 1.0 (September 2012) European Network of Cancer Registries, International Agency for Research on Cancer. URL: <http://eco.iarc.fr>.
- Berrino F, Capocaccia R, Esteve J et al, eds. Survival of cancer patients in Europe: the EUROCORE-2 study. Lyon: International Agency for Research on Cancer, 1999.
- Berrino F, Capocaccia R, Gatta G et al, eds. Survival of cancer patients in Europe: the EUROCORE-3 study. *Ann Oncol* 2003; 14 (Suppl 5).
- Berrino F, DeAngelis R, Sant M et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–1999: Results of the EUROCORE-4 study. *Lancet Oncol* 2007; 8: 773–83.
- Pompe-Kirn V, Primic Žakelj M, Ferligoj A, Škrk J. Zemljevidi incidence raka v Sloveniji 1978–1987 (Atlas of cancer incidence in Slovenia 1978–1987). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1992.
- Pompe-Kirn V, Zakotnik B, Benulič T, Volk N, Škrk J. Preživetje bolnikov z rakom v Sloveniji 1963–1990 (Cancer patients' survival in Slovenia 1963–1990). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 1995.

- Pompe-Kirn V, Zakotnik B, Zadnik V. Preživetje bolnikov z rakom v Sloveniji 1983–1997 (Cancer patients' survival in Slovenia 1983–1997). Ljubljana: Onkološki inštitut, Register raka za Slovenijo, 2003.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut, 2009.
- Uredba o standardni klasifikaciji teritorialnih enot – SKTE. Ur. l. RS št. 28/2000.
- Savezni zavod za zdravstveno zaščito. Mednarodna klasifikacija bolezni, povreda i uzroka smrti. 8. revizija. Novi sad: Savezni zavod za zdravstveno zaščito, 1970.
- Inštitut za varovanje zdravja RS. Mednarodna klasifikacija bolezni in sorodnih zdravstvenih problemov za statistične namene. 10. revizija (International statistical classification of diseases and related health problems). Ljubljana: Inštitut za varovanje zdravja, 1995.
- World Health Organisation. International classification of diseases for Oncology. Geneva: World Health Organisation, 2000.
- Jensen OM, Parkin M et al, eds. Cancer registration: principles and methods. Lyon: International Agency for Research on Cancer, 1991. (IARC Sci Publ 95).
- Dos Santos Silva I. Cancer epidemiology: principles and methods. Lyon: International Agency for Research on Cancer, 1999.
- Moller B, Fekjaer H, Hakulinen T et al. Prediction of cancer incidence in the Nordic countries: empirical comparison of different approaches. *Stat Med* 2003; 15: 2751–66.
- SI-STAT podatkovni portal. Ljubljana, Statistični urad Republike Slovenije, 2013. URL: <http://pxweb.stat.si/>.
- Pohar M, Stare J. Relative survival analysis in R. *Computer Methods and Programs in Biomedicine* 2006; 81: 272–8.
- Žagar T. Lifetables for Slovenia 1982–2007. Rostock: Max Planck, 2008. URL: <http://www.lifetable.de/cgi-bin/Country.plx?Country=Slovenia>.


Slika 1: Breme raka, Slovenija 2009.

Figure 1: Cancer burden, Slovenia 2009.




Slika 2: Odstotni delež vseh rakov po starostnih skupinah in spolu, Slovenija 2009.


Figure 2: Percentage distribution of all cancer sites by age group and by sex, Slovenia 2009.



Slika 3: Najpogostejše lokacije raka in njihov odstotni delež po spolu in pri obeh spolih skupaj, Slovenija 2009.
Figure 3: The leading cancer sites with percentage distribution by sex and in for both sexes together, Slovenia 2009.



MOŠKI IN ŽENSKE / MALES AND FEMALES



* Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)



Debelo črevo in danka / Colorectum (C18–C20)

Ledvica z ledvičnim mehonom / Kidney with renal pelvis (C64–C65)

NHL: ne-Hodgkinovi limfomi / NHL: non-Hodgkin's lymphoma (C82–C85)


Slika 4: Groba in kumulativna letna incidenčna in umrljivostna stopnja vseh rakov po spolu s povprečno letno spremembo za zadnjih 10 let, Slovenija 1950–2009.

Figure 4: Crude and cumulative annual incidence and mortality rates for all cancer sites by sex with average annual change in last 10 years, Slovenia 1950–2009.




Slika 5: Groba letna incidenčna stopnja izbranih rakov po spolu, Slovenija 1950–2009.

Figure 5: Crude annual incidence rates of selected primary cancer sites by sex, Slovenia 1950–2009.




Slika 6: Pet-letno relativno preživetje (s 95 % intervalom zaupanja) bolnikov, zbolelih za izbranimi raki v letih 2000–2004 in 2005–2009 po spolu.

Figure 6: Five-year relative survival (with 95% confidence interval) of patients diagnosed with selected cancers in periods 2000–2004 and 2005–2009 by sex.




Slika 6: Nadaljevanje.
Figure 6: Continued.

ŽENSKE / FEMALES



Slika 7: Odstotni deleži napogostejših rakov po starostnih skupinah in spolu, Slovenija 2005–2009.
Figure 7: Percentage distribution of leading cancer sites by age group and by sex, Slovenia 2005–2009.

MOŠKI / MALES



Pojasnilo / Explanation:

Glava in vrat / Head and neck (C00–C14, C30–C32)

Želodec / Stomach (C16)

Debelo črevo in danka / Colorectum (C18–C20)

Pljuča / Lung (C33–C34)

Koža, melanom / Skin, melanoma (C43)

Koža, razen melanoma / Skin, non-melanoma (C44)

Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)

Prostata / Prostate (C61)

Modo / Testis (C62)

Ledvica z ledvičnim mehkom / Kidney with renal pelvis (C64–C65)

Sečni mehur / Bladder (C67)

Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)

Hodgkinova bolezen / Hodgkin's disease (C81)

NHL: ne-Hodgkinovi limfomi / NHL: non-Hodgkin's lymphoma (C82–C85)

Levkemije / Leukaemias (C91–C95)

Slika 7: Nadaljevanje.
Figure 7: Continued.

ŽENSKE / FEMALES

Starost / Age						
0–19	20–34	35–49	50–64	65–74	75+	Vse starosti / All
Ostalo 25,5 %	Ostalo 26,9 %	Ostalo 28,8 %	Ostalo 31,2 %	Ostalo 34,3 %	Ostalo 35,7 %	Ostalo 36,2 %
NHL (ne-Hodgkinovi limfomi) 4,6 %	Hodgkinova bolezen 4,9 %	Jajčnik 4,6 %	Jajčnik 4,5 %	Želodec 3,5 %	Trebušna slinavka 4,2 %	Koža, melanom 4,1 %
Hodgkinova bolezen 7,2 %	Koža, razen melanoma 9,1 %	Ščitnica 5,2 %	Pljuča 7,0 %	Pljuča 6,2 %	Želodec 4,7 %	Maternično telo 5,3 %
Ščitnica 7,8 %	14,2 %	Koža, melanom 9,0 %	Maternično telo 7,4 %	Maternično telo 6,5 %	Pljuča 5,4 %	Pljuča 5,8 %
Kosti 8,5 %	Ščitnica 14,2 %	Maternični vrat 9,3 %	Debelo črevo in danka 9,3 %	Debelo črevo in danka 13,1 %	Pljuča 5,4 %	Pljuča 5,8 %
Centralni in avtonomni živčni sistem 16,3 %	Maternični vrat 14,8 %	Koža, razen melanoma 10,6 %	Debelo črevo in danka 13,0 %	Debelo črevo in danka 13,1 %	Dojka 13,0 %	Debelo črevo in danka 10,7 %
Levkemije 30,1 %	Koža, melanom 14,9 %	Dojka 32,5 %	Koža, razen melanoma 27,7 %	Koža, razen melanoma 17,9 %	Dojka 13,3 %	Koža, razen melanoma 17,3 %
	Dojka 15,2 %		Dojka 27,7 %	Dojka 18,4 %	Koža, razen melanoma 23,7 %	Dojka 20,6 %
31	152	664	1525	1339	1866	5576
Povprečna letna incidenca / Average annual incidence						

Pojasnilo / Explanation:

- Želodec / Stomach (C16)
- Debelo črevo in danka / Colorectum (C18–C20)
- Trebušna slinavka / Pancreas (C25)
- Pljuča / Lung (C33–C34)
- Kosti / Bone (C40–C41)
- Koža, melanom / Skin, melanoma (C43)
- Koža, razen melanoma / Skin, non-melanoma (C44)
- Vezivno in mehko tkivo / Connective and soft tissue (C48–C49)
- Dojka / Breast (C50)
- Maternični vrat / Cervix uteri (C53)
- Maternično telo / Corpus uteri (C54)
- Jajčnik / Ovary (C56)
- Centralni in avtonomni živčni sistem / Central and autonomic nervous system (C70–C72)
- Ščitnica / Thyroid gland (C73)
- Hodgkinova bolezen / Hodgkin's disease (C81)
- Levkemije / Leukaemias (C91–C95)





Slika 8: Rak pri starejših, C00–C96 brez nemelanomskega kožnega raka (C44), Slovenija 2005–2009.

Figure 8: Cancer in the elderly, C00–C96 except non-melanoma skin cancer (C44), Slovenia 2005–2009.

MOŠKI / MALES

	65+	65–74	75–84	85+
BREME RAKA*				
Povprečno letno število primerov (N)	3.060	1.778	1.116	166
Groba incidenčna stopnja na 100.000	2.446	2.193	2.927	2.805
Celotna prevalenca (na dan 31. 12. 2009)	10.490	7.427	2.851	212
Povprečno letno število umrlih	3.058	1.981	867	210
NAČIN UGOTOVITVE (povprečno letno število (% od N))				
Mikroskopsko potrjeni	2.744 (89,7)	1.666 (93,7)	967 (86,6)	110 (66,3)
Ugotovljeni z drugimi preiskavami	294 (9,6)	106 (6,0)	139 (12,5)	49 (29,5)
Registrirani samo iz zdravniških poročil o vzroku smrti (ZPS)	22 (0,7)	6 (0,3)	10 (0,9)	7 (4,2)
STADIJ (% od N)				
Omejen	36,3	36,9	36,2	30,3
Razširjen	32,8	34,2	31,2	27,0
Razsejan	24,2	24,0	24,6	23,5
Neznan	6,7	4,9	8,0	19,2
NAČIN PRVEGA ZDRAVLJENJA (povprečno letno število (% od N brez ZPS primerov))				
Katerokoli zdravljenje	2.087 (68,7)	1.333 (75,2)	686 (62,0)	68 (43,0)
Operirani	1.292 (42,5)	864 (48,7)	391 (35,4)	37 (23,0)
Zdravljeni s sistemsko terapijo	872 (28,7)	570 (32,2)	278 (25,2)	24 (15,0)
Obsevani	531 (17,5)	371 (21,0)	147 (13,3)	13 (7,9)

* Breme nemelanomskega kožnega raka (C44) pri starejših od 65 let: povprečno letno število primerov je 596; celotna prevalenca je 4.904; povprečno letno število umrlih je 8.






Slika 8: Nadaljevanje.
Figure 8: Continued.

ŽENSKE / FEMALES

	65+	65-74	75-84	85+
CANCER BURDEN*				
Average annual number of cases (N)	2.519	1.096	1.109	314
Crude incidence rate per 100,000	1.271	1.068	1.460	1.603
Lifetime prevalence (on December 31, 2009)	11.210	7.244	3.549	417
Average annual number of deaths	2.418	1.211	854	354
BASIS OF DIAGNOSIS (average annual number (% of N))				
Microscopically confirmed	2.198 (87,3)	1.033 (94,3)	946 (85,3)	219 (69,7)
Confirmed by other investigations	289 (11,5)	59 (5,4)	151 (13,6)	79 (25,2)
Registered from death certificates only (DCO)	32 (1,3)	4 (0,4)	12 (1,1)	16 (5,1)
STAGE (% of N)				
Localized	32,4	37,1	30,1	23,8
Regional	34,5	34,9	35,3	29,9
Distant	26,5	25,2	27,7	27,2
Unknown	6,6	2,8	6,9	19,1
FIRST TREATMENT MODE (average annual number (% of N except DCO cases))				
Any treatment	1.691 (68,0)	880 (80,6)	691 (63,0)	120 (40,2)
Treated by surgery	1.300 (52,3)	706 (64,7)	519 (47,3)	74 (24,9)
Treated by systemic therapy	742 (29,8)	451 (41,3)	251 (22,9)	40 (13,3)
Treated by radiotherapy	487 (19,6)	301 (27,6)	162 (14,8)	23 (7,7)

* Burden of non-melanoma skin cancer (C44) in age 65 and above: average annual number of cases is 681; lifetime prevalence is 6,362; average annual number of deaths is 12.



Percentage distribution by age group.




Tabela 1: Opazovana in ocenjena incidenca raka, Slovenija 2000–2009 in 2012.

Table 1: Observed and estimated cancer incidence, Slovenia 2000–2009 and 2012.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Povprečne letne opazovane vrednosti 2000–2004		Povprečne letne opazovane vrednosti 2005–2009		Ocena za 2012			
			Število	Incidenčna stopnja na 100.000	Število	Incidenčna stopnja na 100.000	Število (95 % napovedni interval)		Incidenčna stopnja na 100.000 (95 % napovedni interval)	
							Estimation for 2012			
			Average annual observed values 2000–2004		Average annual observed values 2005–2009		Number (95% prediction interval)		Incidence rate per 100,000 (95% prediction interval)	
		Number	Incidence rate per 100,000	Number	Incidence rate per 100,000					
C00–C96	Vse lokacije All sites	M+Ž	10004	501,7	11746	581,8	13765	13453–14077	669	654–685
		M	5146	527,6	6203	624,0	7470	7234–7706	734	711–757
		Ž	4858	476,7	5543	540,9	6295	6091–6499	606	586–626
C00–C14	Usta in žrelo Mouth and pharynx	M	256	26,3	262	26,4	251	208–295	25	20–29
		Ž	58	5,7	67	6,5	75	51–98	7	5–9
C15	Požiralnik Oesophagus	M	76	7,8	71	7,2	65	43–86	6	4–8
		Ž	17	1,7	16	1,5	14	4–23	1	0–2
C16	Želodec Stomach	M	293	30,0	288	29,0	278	232–323	27	23–32
		Ž	185	18,2	178	17,4	169	132–205	16	13–20
C18	Debelo črevo Colon	M	355	36,4	437	44,0	515	451–580	51	44–57
		Ž	302	29,6	352	34,3	414	361–468	40	35–45
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	313	32,0	362	36,4	437	377–496	43	37–49
		Ž	223	21,9	245	23,9	264	220–307	25	21–30
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	87	8,9	112	11,3	156	117–194	15	12–19
		Ž	41	4,0	44	4,3	54	34–75	5	3–7
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	50	5,1	64	6,4	67	43–91	7	4–9
		Ž	75	7,3	105	10,3	122	93–151	12	9–15
C25	Trebušna slinavka Pancreas	M	123	12,6	153	15,4	186	148–224	18	15–22
		Ž	127	12,5	165	16,1	201	164–238	19	16–23
C32	Grlo Larynx	M	105	10,7	91	9,1	84	60–109	8	6–11
		Ž	12	1,2	11	1,1	12	3–22	1	0–2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	851	87,2	885	89,1	990	897–1082	97	88–106
		Ž	270	26,5	324	31,6	389	338–440	37	33–42
C43	Maligni melanom kože Malignant melanoma of skin	M	143	14,7	192	19,3	265	222–308	26	22–30
		Ž	155	15,2	223	21,7	290	247–333	28	24–32
C44	Druge maligne neoplazme kože Skin, other malignomas	M	655	67,1	890	89,5	1224	1128–1320	120	111–130
		Ž	741	72,7	964	94,1	1238	1147–1329	119	110–128
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	29	2,9	29	2,9	36	19–53	4	2–5
		Ž	30	3,0	38	3,7	49	37–62	5	4–6
C50	Dojka Breast	M	9	1,0	8	0,8	7	0–14	1	0–1
		Ž	1042	102,2	1136	110,9	1245	1152–1339	120	111–129
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–
		Ž	201	19,7	151	14,7	117	90–143	11	9–14
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–
		Ž	286	28,1	292	28,5	292	246–339	28	24–33
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–
		Ž	178	17,5	177	17,3	166	130–201	16	13–19
C61	Prostata Prostate	M	715	73,3	1091	109,6	1443	1341–1546	142	132–152
		Ž	–	–	–	–	–	–	–	–
C62	Modo Testis	M	95	9,7	96	9,7	108	78–139	11	8–14
		Ž	–	–	–	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	151	15,5	202	20,4	256	212–299	25	21–29
		Ž	88	8,6	107	10,4	131	102–161	13	10–16
C67	Sečni mehur Bladder	M	180	18,4	201	20,2	229	185–274	23	18–27
		Ž	64	6,3	75	7,3	94	68–119	9	7–11
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	71	7,3	79	8,0	85	66–104	8	6–10
		Ž	63	6,2	60	5,9	61	40–81	6	4–8
C73	Ščitnica Thyroid gland	M	26	2,6	30	3,1	37	20–54	4	2–5
		Ž	81	7,9	118	11,6	154	124–185	15	12–18
C81	Hodgkinova bolezen Hodgkin's disease	M	24	2,5	27	2,7	30	20–40	3	2–4
		Ž	23	2,2	21	2,0	22	10–34	2	1–3
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	113	11,6	128	12,8	139	114–163	14	11–16
		Ž	128	12,6	139	13,6	149	124–175	14	12–17
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	38	3,9	61	6,1	79	55–102	8	5–10
		Ž	49	4,8	59	5,7	61	40–82	6	4–8
C91–C95	Levkemije Leukaemias	M	115	11,8	138	13,9	149	124–175	15	12–17
		Ž	94	9,2	107	10,4	114	91–136	11	9–13

Tabela 2: Incidenca, groba incidenčna stopnja in po svetovni, evropski ter slovenski standardni populaciji standardizirane incidenčne stopnje raka, Slovenija 2009.

Table 2: Incidence, crude incidence rate and according to World, European and Slovenian standard population standardized cancer incidence rates, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število Number	Groba incidenčna stopnja na 100.000 Crude incidence rate per 100,000	SSS* – svetovni standard ASR** – World standard	SSS* – evropski standard ASR** – European standard	SSS* – slovenski standard ASR** – Slovenian standard
C00–C96	Vse lokacije All sites	M+Ž	12226	598,6	318,0	452,8	534,6
		M	6602	652,5	386,8	562,7	676,9
		Ž	5624	545,7	268,6	376,5	438,1
C00–C14	Usta in žrelo Mouth and pharynx	M	278	27,5	17,1	23,8	26,7
		Ž	75	7,3	4,2	5,6	6,2
C15	Požiralnik Oesophagus	M	74	7,3	4,4	6,3	7,3
		Ž	13	1,3	0,4	0,7	0,8
C16	Želodec Stomach	M	289	28,6	15,8	24,2	30,3
		Ž	180	17,5	7,0	10,5	13,0
C18	Debelo črevo Colon	M	520	51,4	29,1	44,1	54,5
		Ž	388	37,6	16,0	23,7	28,9
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	412	40,7	24,0	35,0	41,6
		Ž	248	24,1	10,8	15,9	18,8
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	94	9,3	5,4	7,9	9,5
		Ž	47	4,6	1,9	2,9	3,5
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	69	6,8	3,7	5,8	7,4
		Ž	111	10,8	4,1	6,2	7,7
C25	Trebušna slinavka Pancreas	M	156	15,4	8,9	13,2	16,0
		Ž	173	16,8	6,2	9,7	11,8
C32	Grlo Larynx	M	86	8,5	5,0	7,2	8,2
		Ž	16	1,6	0,9	1,3	1,4
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	839	82,9	48,6	71,1	85,1
		Ž	354	34,3	16,5	23,7	27,5
C43	Maligni melanom kože Malignant melanoma of skin	M	208	20,6	13,2	17,9	20,6
		Ž	242	23,5	14,7	18,8	21,0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	925	91,4	50,6	78,5	97,3
		Ž	1013	98,3	40,7	60,6	73,2
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	36	3,6	2,2	3,1	3,6
		Ž	32	3,1	1,7	2,3	2,6
C50	Dojka Breast	M	9	0,9	0,5	0,8	0,9
		Ž	1128	109,5	61,4	83,9	94,4
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	130	12,6	8,7	10,9	12,1
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	288	27,9	13,8	19,7	23,0
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	145	14,1	7,8	10,5	11,9
C61	Prostata Prostate	M	1313	129,8	74,7	111,1	136,5
		Ž	–	–	–	–	–
C62	Modo Testis	M	91	9,0	7,8	8,2	8,7
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	223	22,0	13,6	19,1	22,1
		Ž	104	10,1	4,9	6,9	8,1
C67	Sečni mehur Bladder	M	197	19,5	10,8	16,7	20,7
		Ž	86	8,3	3,2	4,9	6,1
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	84	8,3	6,7	7,8	8,3
		Ž	60	5,8	4,2	4,8	5,2
C73	Ščitnica Thyroid gland	M	27	2,7	1,8	2,3	2,6
		Ž	122	11,8	8,4	10,4	11,3
C81	Hodgkinova bolezen Hodgkin's disease	M	30	3,0	2,8	2,8	3,0
		Ž	32	3,1	2,3	2,6	2,8
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	147	14,5	9,5	12,9	14,9
		Ž	137	13,3	6,1	8,7	10,3
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	5,8	3,5	5,0	6,0
		Ž	64	6,2	2,3	3,6	4,6
C91–C95	Levkemije Leukaemias	M	149	14,7	10,5	13,4	15,3
		Ž	105	10,2	6,5	7,6	8,2

* SSS – starostno standardizirana incidenčna stopnja na 100.000

**ASR – age-standardised incidence rate per 100,000

Tabela 3: Incidenca raka glede na način postavitve diagnoze po lokaciji in spolu, Slovenija 2009.

Table 3: Cancer incidence according to basis of diagnosis by site and by sex, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C00–C96	Vse lokacije All sites	M+Ž	12226	11482	93,9	690	5,6	54	0,4
		M	6602	6211	94,1	369	5,6	22	0,3
		Ž	5624	5271	93,7	321	5,7	32	0,6
C00	Ustnica Lip	M	19	19	100	0	0	0	0
		Ž	12	11	—	1	—	0	—
C01	Baza jezika Base of tongue	M	16	16	100	0	0	0	0
		Ž	1	1	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	17	17	100	0	0	0	0
		Ž	7	7	—	0	—	0	—
C03	Dlesen Gum	M	6	6	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	29	29	100	0	0	0	0
		Ž	10	10	—	0	—	0	—
C05	Nebo Palate	M	17	17	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	12	—	0	—	0	—
		Ž	3	3	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	6	6	—	0	—	0	—
		Ž	9	9	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	5	5	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C09	Tonzila Tonsil	M	33	31	93,9	2	6,1	0	0
		Ž	10	10	—	0	—	0	—
C10	Orofarinks Oropharynx	M	47	47	100	0	0	0	0
		Ž	9	9	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	6	6	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	35	35	100	0	0	0	0
		Ž	4	4	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	30	30	100	0	0	0	0
		Ž	2	2	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	74	71	95,9	3	4,1	0	0
		Ž	13	11	—	2	—	0	—
C16	Želodec Stomach	M	289	282	97,6	7	2,4	0	0
		Ž	180	171	95,0	8	4,4	1	0,6
C17	Tanko črevo Small intestine	M	20	19	95,0	1	5,0	0	0
		Ž	10	9	—	1	—	0	—
C18	Debelo črevo Colon	M	520	501	96,3	18	3,5	1	0,2
		Ž	388	377	97,2	11	2,8	0	0
C19	Rektosigmoidna zveza Rectosigmoid junction	M	89	87	97,8	2	2,2	0	0
		Ž	52	50	96,2	2	3,8	0	0
C20	Rektum Rectum	M	323	317	98,1	6	1,9	0	0
		Ž	196	190	96,9	4	2,0	2	1,0
C21	Anus in analni kanal Anus and anal canal	M	4	4	—	0	—	0	—
		Ž	9	9	—	0	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	94	50	53,2	42	44,7	2	2,1
		Ž	47	24	51,1	22	46,8	1	2,1
C23	Žolčnik Gallbladder	M	15	9	60,0	6	40,0	0	0
		Ž	58	40	69,0	17	29,3	1	1,7
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	35	64,8	19	35,2	0	0
		Ž	53	27	50,9	26	49,1	0	0

Nadaljevanje —>
Continued —>

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C25	Trebušna slinavka Pancreas	M	156	93	59,6	61	39,1	2	1,3
		Ž	173	76	43,9	94	54,3	3	1,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	—	2	—	0	—
		Ž	6	5	—	1	—	0	—
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	3	3	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	4	—	0	—	0	—
		Ž	5	5	—	0	—	0	—
C32	Grlo Larynx	M	86	86	100	0	0	0	0
		Ž	16	16	100	0	0	0	0
C33	Sapnik Trachea	M	4	4	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	835	761	91,1	66	7,9	8	1,0
		Ž	354	325	91,8	26	7,3	3	0,8
C37	Timus Thymus	M	0	0	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	1	1	—	0	—	0	—
		Ž	1	0	—	1	—	0	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	4	4	—	0	—	0	—
		Ž	4	4	—	0	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	2	2	—	0	—	0	—
		Ž	2	2	—	0	—	0	—
C43	Malignni melanom kože Malignant melanoma of skin	M	208	208	100	0	0	0	0
		Ž	242	242	100	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	M	925	919	99,4	5	0,5	1	0,1
		Ž	1013	1008	99,5	4	0,4	1	0,1
C45	Mezoteliom Mesothelioma	M	23	23	100	0	0	0	0
		Ž	6	6	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	6	6	—	0	—	0	—
		Ž	18	18	100	0	0	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	30	30	100	0	0	0	0
		Ž	14	14	—	0	—	0	—
C50	Dojka Breast	M	9	9	—	0	—	0	—
		Ž	1128	1102	97,7	16	1,4	10	0,9
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—
		Ž	47	47	100	0	0	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—
		Ž	12	12	—	0	—	0	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—
		Ž	130	130	100	0	0	0	0
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—
		Ž	288	286	99,3	2	0,7	0	0
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—
		Ž	12	9	—	2	—	1	—
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—
		Ž	145	138	95,2	7	4,8	0	0

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–
		Ž	9	8	–	1	–	0	–
C58	Posteljica Placenta	M	–	–	–	–	–	–	–
		Ž	0	0	–	0	–	0	–
C60	Penis Penis	M	15	15	100	0	0	0	0
		Ž	–	–	–	–	–	–	–
C61	Prostata Prostate	M	1313	1260	96,0	48	3,7	5	0,4
		Ž	–	–	–	–	–	–	–
C62	Modo Testis	M	91	90	98,9	1	1,1	0	0
		Ž	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	2	2	–	0	–	0	–
		Ž	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	211	196	92,9	14	6,6	1	0,5
		Ž	92	75	81,5	16	17,4	1	1,1
C65	Ledvični meh Renal pelvis	M	12	12	–	0	–	0	–
		Ž	12	12	–	0	–	0	–
C66	Sečevod Ureter	M	8	8	–	0	–	0	–
		Ž	5	5	–	0	–	0	–
C67	Sečni mehur Bladder	M	197	191	97,0	5	2,5	1	0,5
		Ž	86	81	94,2	4	4,7	1	1,2
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	1	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C69	Oklo in očesni adneksi Eye and adnexa	M	16	12	75,0	4	25,0	0	0
		Ž	12	11	–	1	–	0	–
C70	Meninge Meninges	M	4	4	–	0	–	0	–
		Ž	1	1	–	0	–	0	–
C71	Možgani Brain	M	79	68	86,1	11	13,9	0	0
		Ž	59	50	84,7	9	15,3	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	1	1	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C73	Ščitnica Thyroid gland	M	27	27	100	0	0	0	0
		Ž	122	122	100	0	0	0	0
C74	Nadledvična žleza Adrenal gland	M	1	1	–	0	–	0	–
		Ž	3	3	–	0	–	0	–
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	1	–	0	–	0	–
		Ž	0	0	–	0	–	0	–
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	3	–	2	–	0	–
		Ž	27	18	66,7	7	25,9	2	7,4
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	15	14	93,3	1	6,7	0	0
		Ž	6	6	–	0	–	0	–
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	50	25	50,0	24	48,0	1	–
		Ž	42	28	66,7	14	33,3	0	–
C79	Metastaze, drugje Metastases of other sites	M	14	10	–	4	–	0	–
		Ž	16	7	43,8	8	50,0	1	6,3
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	56	41	73,2	15	26,8	0	0
		Ž	47	30	63,8	14	29,8	3	6,4
C81	Hodgkinova bolezen Hodgkin's disease	M	30	30	100	0	0	0	0
		Ž	32	32	100	0	0	0	0
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	39	39	100	0	0	0	0
		Ž	28	28	100	0	0	0	0
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	84	84	100	0	0	0	0
		Ž	91	91	100	0	0	0	0

Nadaljevanje →
Continued →

Tabela 3: Nadaljevanje.

Table 3: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	10	10	—	0	—	0	—
		Ž	7	7	—	0	—	0	—
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	14	14	—	0	—	0	—
		Ž	11	11	—	0	—	0	—
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	59	100	0	0	0	0
		Ž	64	64	100	0	0	0	0
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	18	18	100	0	0	0	0
		Ž	10	10	—	0	—	0	—
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	53	53	100	0	0	0	0
		Ž	32	31	96,9	0	0	1	3,1
C92	Mieločna levkemija Myeloid leukaemia	M	68	68	100	0	0	0	0
		Ž	45	45	100	0	0	0	0
C93	Monocitna levkemija Monocytic leukaemia	M	3	3	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	6	6	—	0	—	0	—
		Ž	11	11	—	0	—	0	—
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	1	1	—	0	—	0	—
		Ž	7	7	—	0	—	0	—
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	39	39	100	0	0	0	0
		Ž	47	47	100	0	0	0	0

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Mikroskopsko potrjeni primeri		Ugotovljeni z drugimi preiskavami		Registrirani samo iz zdravniških poročil o vzroku smrti	
				Število	%*	Število	%*	Število	%*
				Microscopically confirmed cases		Confirmed by other investigations		Registered from death certificates only	
				Number	%*	Number	%*	Number	%*
D03	Melanom, in situ Melanoma, in situ	M	83	83	100	0	0	0	0
		Ž	121	121	100	0	0	0	0
D05	Dojka, in situ Breast, in situ	M	0	0	—	0	—	0	—
		Ž	77	77	100	0	0	0	0
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	—	—	—	—	—	—	—
		Ž	944	944	100	0	0	0	0
D09.0	Sečni mehur, in situ Bladder, in situ	M	127	127	100	0	0	0	0
		Ž	44	44	100	0	0	0	0
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	26	25	96,2	1	3,8	0	0
		Ž	60	60	100	0	0	0	0
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	—	—	—	—	—	—	—
		Ž	39	39	100	0	0	0	0
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	1	0	—	1	—	0	—
		Ž	9	0	—	9	—	0	—

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 4: Incidenca raka po lokaciji, spolu in starosti, Slovenija 2009.

Table 4: Cancer incidence by site, by sex and by age, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C00–C96	Vse lokacije All sites	M+Ž	12226	24	11	13	13	37	107	141	182	336	522	925	1366	1319	1755	1721	1742	2012
		M	6602	16	7	9	6	22	46	57	80	127	220	446	805	835	1084	1112	942	788
		Ž	5624	8	4	4	7	15	61	84	102	209	302	479	561	484	671	609	800	1224
C00	Ustnica Lip	M	19	0	0	0	0	0	0	0	0	0	1	0	4	5	2	0	4	3
		Ž	12	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	4	6
C01	Baza jezika Base of tongue	M	16	0	0	0	0	0	0	0	0	1	1	0	4	3	3	1	0	3
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	17	0	0	0	0	0	0	1	0	0	1	4	4	0	4	2	1	0
		Ž	7	0	0	0	0	0	0	0	1	0	0	1	1	1	0	1	1	1
C03	Dlesen Gum	M	6	0	0	0	0	0	0	0	0	0	0	0	2	1	1	0	2	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0
C04	Ustno dno Floor of mouth	M	29	0	0	0	0	0	0	0	0	1	5	4	7	5	3	1	2	1
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	3	2	1	1	2	1
C05	Nebo Palate	M	17	0	0	0	0	0	0	1	0	0	3	3	4	2	2	1	1	0
		Ž	4	0	0	0	0	0	0	0	0	0	1	1	1	0	1	0	0	0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	0	0	0	0	0	0	0	0	2	0	1	0	2	2	2	1	2
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	1
C07	Parotidna žleza Parotid gland	M	6	0	0	0	0	0	0	0	0	1	0	0	1	0	1	2	0	1
		Ž	9	0	0	1	0	0	2	1	1	0	0	0	0	0	1	2	1	0
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	5	0	0	0	0	0	0	0	0	0	1	0	0	2	0	1	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
C09	Tonzila Tonsil	M	33	0	0	0	0	0	0	0	0	1	3	3	9	6	5	2	3	1
		Ž	10	0	0	0	0	0	0	0	0	1	0	4	1	2	1	0	1	0
C10	Orofarinks Oropharynx	M	47	0	0	0	0	0	0	0	1	2	2	5	9	10	11	6	1	0
		Ž	9	0	0	0	0	0	0	0	0	2	1	0	2	1	2	0	1	0
C11	Nazofarinks Nasopharynx	M	6	0	0	0	0	0	0	0	0	3	0	0	3	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	35	0	0	0	0	0	0	0	0	0	2	4	11	6	6	5	1	0
		Ž	4	0	0	0	0	0	0	0	0	0	2	0	0	1	1	0	0	0
C13	Hipofarinks Hypopharynx	M	30	0	0	0	0	0	0	0	0	0	1	1	4	9	6	5	2	2
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	0	0
C14	Druge in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	74	0	0	0	0	0	0	0	0	2	4	10	11	14	11	9	10	3
		Ž	13	0	0	0	0	0	0	0	0	0	0	1	1	1	1	1	1	7
C16	Želodec Stomach	M	289	0	0	0	0	0	0	3	3	5	12	20	28	22	37	60	58	41
		Ž	180	0	0	0	0	0	1	0	0	4	6	8	12	11	23	25	39	51
C17	Tanko črevo Small intestine	M	20	0	0	0	0	0	0	0	0	1	1	3	4	1	1	6	1	2
		Ž	10	0	0	0	0	0	0	1	0	0	1	2	0	2	3	0	1	0
C18	Debelo črevo Colon	M	520	0	0	0	0	0	0	3	3	4	12	25	50	58	110	88	85	82
		Ž	388	0	0	0	0	1	1	0	5	7	8	21	30	31	59	54	77	94
C19	Rektosigmoidna zveza Rectosigmoid junction	M	89	0	0	0	0	0	0	0	0	0	1	8	9	16	22	8	18	7
		Ž	52	0	0	0	0	0	1	0	0	0	1	3	8	5	5	6	11	12
C20	Rektum Rectum	M	323	0	0	0	0	0	0	3	3	6	7	21	48	53	66	46	40	30
		Ž	196	0	0	0	0	0	0	4	2	4	3	14	21	15	37	24	32	40
C21	Anus in analni kanal Anus and anal canal	M	4	0	0	0	0	0	0	0	0	0	2	0	1	0	0	0	1	0
		Ž	9	0	0	0	0	0	0	0	0	1	0	0	2	0	1	1	1	2
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	94	0	0	0	0	0	0	0	0	1	4	8	15	12	17	15	15	7
		Ž	47	0	0	0	0	0	0	0	1	0	0	6	4	3	6	8	5	14
C23	Žolčnik Gallbladder	M	15	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2	7	1
		Ž	58	0	0	0	0	0	0	0	0	1	5	4	2	1	7	9	8	21
C24	Druge in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	0	0	0	0	0	0	0	0	0	2	1	4	6	9	10	10	12
		Ž	53	0	0	0	0	0	0	0	0	0	2	2	2	4	5	7	8	23
C25	Trebšna slinavka Pancreas	M	156	0	0	0	0	0	0	0	0	2	3	11	19	20	35	28	21	17
		Ž	173	0	0	0	0	0	0	0	0	1	2	7	16	11	22	19	32	63
C26	Druge in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2
		Ž	6	0	0	0	0	0	0	0	0	0	1	1	1	0	0	0	1	2

Nadaljevanje →
Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	3	0	0	0	0	0	0	0	0	0	0	2	0	0	0	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	0	0	0	2	1	0	0	1	0
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2
C32	Grlo Larynx	M	86	0	0	0	0	0	0	0	0	2	3	12	22	12	7	14	9	5
		Ž	16	0	0	0	0	1	0	0	0	1	3	4	3	0	2	1	1	
C33	Sapnik Trachea	M	4	0	0	0	0	0	0	0	0	0	1	1	2	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C34	Sapnica in pljuča Bronchus and lung	M	835	0	0	0	0	1	2	5	10	31	67	115	121	145	150	109	79	
		Ž	354	0	0	0	0	1	0	3	4	17	37	43	39	51	42	46	71	
C37	Timus Thymus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0	
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C40	Kosti, sklepnih hrustanec udov Bone and articular cartilage of limbs	M	4	0	0	1	0	0	0	0	0	0	1	1	0	0	0	1	0	
		Ž	4	0	0	1	0	1	0	0	0	0	1	0	0	0	0	0	1	
C41	Kosti, sklepnih hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	2	0	0	0	1	0	0	0	0	1	0	0	0	0	0	0	0	
		Ž	2	0	0	0	0	0	0	0	0	0	1	1	0	0	0	0		
C43	Malignni melanom kože Malignant melanoma of skin	M	208	0	0	1	0	2	6	4	11	16	14	22	28	21	27	23	19	
		Ž	242	0	0	1	5	8	12	11	24	24	25	27	20	18	17	21	29	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	925	0	0	0	0	2	8	10	16	28	54	92	87	133	129	172	194	
		Ž	1013	0	0	0	1	6	14	6	18	40	68	73	61	113	126	168	319	
C45	Mezoteliom Mesothelioma	M	23	0	0	0	0	0	0	0	0	1	2	3	1	7	3	5	1	
		Ž	6	0	0	0	0	0	0	0	0	0	1	2	2	1	0	0		
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0		
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	6	0	0	0	0	1	1	0	0	0	1	1	0	0	1	1	0	
		Ž	18	0	0	0	0	1	0	2	2	1	1	2	1	2	2	0	4	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	30	0	0	0	0	1	0	1	5	0	4	3	2	3	2	3	6	
		Ž	14	0	0	0	0	0	1	0	1	1	1	1	2	2	0	3		
C50	Dojka Breast	M	9	0	0	0	0	0	0	1	0	0	0	2	1	0	3	1	1	
		Ž	1128	0	0	0	0	9	15	34	73	92	152	149	124	127	97	118		
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	47	0	0	0	0	0	0	0	2	1	1	2	1	2	7	4		
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	12	0	0	0	0	0	0	1	0	1	2	0	1	2	2	3		
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	130	0	0	0	1	5	12	11	16	21	14	15	6	7	10	9		
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	288	0	0	0	0	1	0	8	11	27	35	36	46	41	43	40		
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	12	0	0	0	0	1	0	1	2	1	0	0	1	0	1	5		
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	145	0	0	1	0	1	4	4	7	13	10	20	17	18	8	18		
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	9	0	0	0	0	0	0	0	0	3	1	1	2	1	0	1		
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C60	Penis Penis	M	15	0	0	0	0	0	0	0	0	1	0	1	2	4	3	2	0	
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		
C61	Prostata Prostate	M	1313	0	0	0	0	0	0	0	0	1	14	48	146	213	261	310		
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—		

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
C62	Modo Testis	M	91	1	0	1	1	8	21	19	17	7	5	4	3	1	1	0	1	1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	211	2	0	0	0	0	0	0	3	8	11	31	31	27	33	34	20	11
		Ž	92	1	0	0	0	0	0	1	0	2	4	7	12	10	12	13	13	13
C65	Ledvični meh Renal pelvis	M	12	0	0	0	0	0	0	0	0	0	0	1	1	1	3	1	4	1
		Ž	12	0	0	0	0	0	0	0	0	0	0	1	0	1	1	4	4	1
C66	Sečevod Ureter	M	8	0	0	0	0	0	0	0	0	0	0	0	0	0	3	2	3	0
		Ž	5	0	0	0	0	0	0	0	0	0	1	0	0	0	0	2	0	2
C67	Sečni mehur Bladder	M	197	0	0	0	0	0	0	0	0	2	3	13	20	22	28	39	33	37
		Ž	86	0	0	0	0	0	0	1	1	1	1	1	6	7	12	10	20	26
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Oklo in očesni adneksi Eye and adnexa	M	16	2	0	0	0	0	0	0	2	0	2	1	1	2	1	1	2	2
		Ž	12	0	0	0	0	1	0	0	0	1	2	0	1	3	1	0	2	1
C70	Meninge Meninges	M	4	0	0	0	0	0	0	0	1	0	0	0	0	1	0	1	0	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
C71	Možgani Brain	M	79	3	3	1	0	1	3	4	4	8	6	5	8	8	7	10	5	3
		Ž	59	1	2	1	1	1	2	3	1	2	5	6	5	3	9	5	5	7
C72	Hrbtni mozeg, možganski živci in drugi deli CZS Spinal cord, cranial nerves and other parts of CNS	M	1	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	27	0	0	0	0	4	1	2	0	5	2	5	2	1	2	3	0	
		Ž	122	0	0	0	2	1	7	6	11	14	13	17	15	8	13	3	5	7
C74	Nadledvična žleza Adrenal gland	M	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1	0
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	0	0	0	0	0	0	1	0	0	0	0	1	1	0	1	1	0
		Ž	27	0	0	0	0	0	0	0	0	0	0	1	0	3	1	4	6	12
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	15	0	0	0	0	0	0	0	0	1	1	2	2	3	0	2	2	2
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	50	0	0	0	0	0	0	0	0	0	2	2	4	5	7	9	7	14
		Ž	42	0	0	0	0	0	0	0	0	0	0	1	2	2	1	4	6	26
C79	Metastaze, drugje Metastases of other sites	M	14	0	0	0	0	0	0	0	0	0	0	3	2	1	2	6	0	
		Ž	16	0	0	0	0	0	0	0	0	0	1	1	1	1	2	1	2	7
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	56	0	0	0	0	1	0	0	0	0	3	4	10	6	8	7	8	9
		Ž	47	0	0	0	0	0	0	0	1	1	0	2	5	1	4	4	11	18
C81	Hodgkinova bolezen Hodgkin's disease	M	30	0	2	0	2	5	2	3	3	3	3	1	2	0	1	1	2	0
		Ž	32	0	0	1	0	0	5	6	2	2	2	0	4	0	4	0	1	5
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	39	0	0	0	0	0	0	2	1	4	3	4	4	7	5	4	3	2
		Ž	28	0	0	0	0	0	1	0	0	0	3	1	6	4	4	2	4	3
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	84	0	1	4	0	0	0	1	5	3	2	6	14	8	6	12	10	12
		Ž	91	0	0	0	0	1	1	2	2	3	2	5	6	8	9	12	19	21
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	10	0	1	0	0	0	0	0	1	1	0	2	0	0	1	2	1	1
		Ž	7	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	3	3
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	14	0	0	0	0	0	1	0	0	0	0	2	1	1	2	3	3	1
		Ž	11	0	0	0	0	0	0	0	0	0	0	1	0	2	1	0	1	6

Nadaljevanje →
Continued →

Tabela 4: Nadaljevanje.

Table 4: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	59	0	0	0	0	0	0	0	0	1	3	4	4	9	6	9	11	5	7
		Ž	64	0	0	0	0	0	0	0	0	0	0	1	4	3	6	7	7	19	17
C91.0	Limfatična levkemija, akutna Lymphoblastic leukaemia, acute	M	18	7	0	1	3	2	1	0	0	0	1	0	1	0	0	1	1	0	0
		Ž	10	5	0	0	1	1	0	0	0	0	1	0	1	1	0	0	0	0	0
C91.1–C91.9	Limfatična levkemija, druga Lymphoid leukaemia, other	M	53	0	0	0	0	0	0	0	0	0	1	4	5	9	7	13	5	9	
		Ž	32	0	0	0	0	0	0	0	0	0	0	5	3	3	6	5	3	7	
C92	Mieloična levkemija Myeloid leukaemia	M	68	0	0	0	0	1	3	0	0	3	4	10	5	3	9	8	10	12	
		Ž	45	0	1	0	0	0	1	0	0	4	2	1	4	3	6	9	5	9	
C93	Monocitna levkemija Monocytic leukaemia	M	3	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	6	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1	1	0	
		Ž	11	1	0	0	0	0	0	0	0	0	1	0	1	1	1	1	0	5	
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	
		Ž	7	0	1	0	0	0	0	0	0	0	0	0	0	1	0	1	0	1	
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	39	0	0	0	0	0	0	0	1	0	1	1	3	1	5	5	15	7	
		Ž	47	0	0	0	1	1	4	0	1	0	3	1	1	2	4	8	6	15	

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+
D03	Melanom, in situ Melanoma, in situ	M	83	0	0	1	0	1	2	1	2	6	11	7	10	12	6	11	7	6
		Ž	121	0	0	0	3	5	13	11	11	14	10	10	12	6	7	10	9	
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	77	0	0	0	0	0	0	0	2	6	6	15	13	13	9	5	6	2
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	944	0	0	0	2	71	210	215	169	123	60	42	20	16	5	7	2	2
D09.0	Sečni mehur, in situ Bladder, in situ	M	127	0	0	0	0	0	0	1	1	0	6	7	13	20	19	22	22	
		Ž	44	0	0	0	0	0	0	0	0	3	2	1	6	4	4	4	8	
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	26	0	0	0	0	1	0	1	0	1	0	3	4	4	6	2	2	
		Ž	60	0	0	0	0	0	0	1	3	4	5	9	7	6	13	4	4	
D33.0–D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
D39.1	Jajčnik, neoplazma negotovega značaja Ovary, neoplasm of uncertain behavior	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	39	0	0	0	0	0	3	2	3	3	1	6	6	5	6	2	1	
D43.0–D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	1	

Tabela 5: Groba in starostno specifična incidenčna stopnja na 100.000 prebivalcev ter kumulativna stopnja (KS) po lokaciji in spolu, Slovenija 2009.

Table 5: Crude and age specific cancer incidence rate per 100,000 and cumulative rate (CR) by site and by sex, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C00–C06	Vse lokacije All sites	M+Ž	598,6	23,9	12,1	13,7	12,1	27,7	70,8	89,8	123,2	215,9	335,0	591,2	921,7	1230,5	1739,5	2009,7	2412,9	2574,9	37,1
		M	652,5	31,1	15,0	18,5	10,8	31,4	57,7	69,1	103,5	159,5	276,0	556,7	1063,5	1593,6	2320,0	3009,2	3468,5	3671,4	46,6
		Ž	545,7	16,4	9,1	8,7	13,4	23,7	85,6	112,8	144,9	274,8	396,9	627,5	773,6	883,2	1238,8	1251,0	1776,3	2159,6	29,3
C00	Ustnica Lip	M	1,9	0	0	0	0	0	0	0	0	0	1,3	0	5,3	9,5	4,3	0	14,7	14,0	0,1
		Ž	1,2	0	0	0	0	0	0	0	0	0	0	0	0	1,8	1,8	0	8,9	10,6	0,0
C01	Baza jezika Base of tongue	M	1,6	0	0	0	0	0	0	0	0	1,3	1,3	0	5,3	5,7	6,4	2,7	0	14,0	0,1
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,8	0	0	0	0	0,0
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	1,7	0	0	0	0	0	0	1,2	0	0	1,3	5,0	5,3	0	8,6	5,4	3,7	0	0,1
		Ž	0,7	0	0	0	0	0	0	1,3	0	0	0	1,3	1,4	1,8	0	2,1	2,2	1,8	0,0
C03	Dlesen Gum	M	0,6	0	0	0	0	0	0	0	0	0	0	0	2,6	1,9	2,1	0	7,4	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	0	0	3,6	0	0	0	0	0,0
C04	Ustno dno Floor of mouth	M	2,9	0	0	0	0	0	0	0	0	1	6,3	5,0	9,2	9,5	6,4	2,7	7,4	4,7	0,2
		Ž	1,0	0	0	0	0	0	0	0	0	0	0	0	4,1	3,6	1,8	2,1	4,4	1,8	0,1
C05	Nebo Palate	M	1,7	0	0	0	0	0	0	1,2	0	0	3,8	3,7	5,3	3,8	4,3	2,7	3,7	0	0,1
		Ž	0,4	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	0	1,8	0	0	0	0,0
C06	Usta, drugi deli Mouth, other & unspecified parts	M	1,2	0	0	0	0	0	0	0	0	2,5	0	1,2	0	3,8	4,3	5,4	3,7	9,3	0,1
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	1	0	1,8	0	0	1,8	0,0
C07	Parotidna žleza Parotid gland	M	0,6	0	0	0	0	0	0	0	0	1,3	0	0	1,3	0	2,1	5,4	0	4,7	0,1
		Ž	0,9	0	0	2,2	0	0	2,8	1,3	1,4	0	0	0	0	0	1,8	4,1	2,2	0	0,1
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0,5	0	0	0	0	0	0	0	0	1,3	0	0	3,8	0	2,7	0	4,7	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	1,8	0	0	0	0	0	0,0
C09	Tonzila Tonsil	M	3,3	0	0	0	0	0	0	0	0	1,3	3,8	3,7	11,9	11,5	10,7	5,4	11,0	4,7	0,2
		Ž	1,0	0	0	0	0	0	0	0	0	1,3	0	5,2	1,4	3,6	1,8	0	2,2	0	0,1
C10	Orofarinks Oropharynx	M	4,6	0	0	0	0	0	0	0	1,3	2,5	2,5	6,2	11,9	19,1	23,5	16,2	3,7	0	0,4
		Ž	0,9	0	0	0	0	0	0	0	0	2,6	1,3	0	2,8	1,8	3,7	0	2,2	0	0,1
C11	Nazofarinks Nasopharynx	M	0,6	0	0	0	0	0	0	0	0	3,8	0	0	4,0	0	0	0	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0
C12	Piriformni sinus Pyriform sinus	M	3,5	0	0	0	0	0	0	0	0	2,5	5,0	14,5	11,5	12,8	13,5	3,7	0	0,3	
		Ž	0,4	0	0	0	0	0	0	0	0	2,6	0	0	1,8	1,8	0	0	0	0	0,0
C13	Hipofarinks Hypopharynx	M	3,0	0	0	0	0	0	0	0	0	1,3	1,2	5,3	17,2	12,8	13,5	7,4	9,3	0,3	
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,4	0	1,8	0	0	0	0	0,0
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	M	7,3	0	0	0	0	0	0	0	0	2,5	5,0	12,5	14,5	26,7	23,5	24,4	36,8	14,0	0,5
		Ž	1,3	0	0	0	0	0	0	0	0	0	0	1,3	1,4	1,8	1,8	2,1	2,2	12,4	0,0
C16	Želodec Stomach	M	28,6	0	0	0	0	0	0	3,6	3,9	6,3	15,1	25,0	37,0	42,0	79,2	162,4	213,6	191,0	1,9
		Ž	17,5	0	0	0	0	0	1,4	0	0	5,3	7,9	10,5	16,5	20,1	42,5	51,4	86,6	90,0	0,8
C17	Tanko črevo Small intestine	M	2,0	0	0	0	0	0	0	0	0	1,3	1,3	3,7	5,3	1,9	2,1	16,2	3,7	9,3	0,2
		Ž	1,0	0	0	0	0	0	0	1,3	0	0	1,3	2,6	0	3,6	5,5	0	2,2	0	0,1
C18	Debelo črevo Colon	M	51,4	0	0	0	0	0	0	3,6	3,9	5,0	15,1	31,2	66,1	110,7	235,4	238,1	313,0	382,1	3,5
		Ž	37,6	0	0	0	0	1,6	1,4	0	7,1	9,2	10,5	27,5	41,4	56,6	108,9	110,9	171,0	165,9	1,9

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C19	Rektosigmoidna zveza Rectosigmoid junction	M	8,8	0	0	0	0	0	0	0	0	0	1,3	10,0	11,9	30,5	47,1	21,6	66,3	32,6	0,6
		Ž	5,0	0	0	0	0	0	1,4	0	0	0	1,3	3,9	11,0	9,1	9,2	12,3	24,4	21,2	0,2
C20	Rektum Rectum	M	31,9	0	0	0	0	0	0	3,6	3,9	7,5	8,8	26,2	63,4	101,2	141,3	124,5	147,3	139,8	2,4
		Ž	19,0	0	0	0	0	0	0	5,4	2,8	5,3	3,9	18,3	29,0	27,4	68,3	49,3	71,1	70,6	1,0
C21	Anus in analni kanal Anus and anal canal	M	0,4	0	0	0	0	0	0	0	0	0	2,5	0	1,3	0	0	0	3,7	0	0,0
		Ž	0,9	0	0	0	0	0	0	0	1,4	0	0	2,6	0	1,8	1,8	2,1	2,2	3,5	0,0
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	9,3	0	0	0	0	0	0	0	0	1,3	5,0	10,0	19,8	22,9	36,4	40,6	55,2	32,6	0,7
		Ž	4,6	0	0	0	0	0	0	0	1,4	0	0	7,9	5,5	5,5	11,1	16,4	11,1	24,7	0,2
C23	Žolčnik Gallbladder	M	1,5	0	0	0	0	0	0	0	0	0	0	1,2	0	3,8	4,3	5,4	25,8	4,7	0,1
		Ž	5,6	0	0	0	0	0	0	0	0	1,3	6,6	5,2	2,8	1,8	12,9	18,5	17,8	37,1	0,2
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	5,3	0	0	0	0	0	0	0	0	0	2,5	1,2	5,3	11,5	19,3	27,1	36,8	55,9	0,3
		Ž	5,1	0	0	0	0	0	0	0	0	0	2,6	2,6	2,8	7,3	9,2	14,4	17,8	40,6	0,2
C25	Trebušna slinavka Pancreas	M	15,4	0	0	0	0	0	0	0	0	2,5	3,8	13,7	25,1	38,2	74,9	75,8	77,3	79,2	1,2
		Ž	16,8	0	0	0	0	0	0	0	0	1,3	2,6	9,2	22,1	20,1	40,6	39,0	71,1	111,2	0,7
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	9,3	0,0
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	0	0	0	2,2	3,5	0,0
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0,3	0	0	0	0	0	0	0	0	0	2,5	0	0	0	0	0	3,7	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C31	Obnosni sinusi Accessory sinuses	M	0,4	0	0	0	0	0	0	0	0	0	0	0	2,6	1,9	0	0	3,7	0	0,0
		Ž	0,5	0	0	0	0	0	0	0	0	0	0	0	0	1,8	1,8	2,1	0	3,5	0,0
C32	Grlo Larynx	M	8,5	0	0	0	0	0	0	0	0	2,5	3,8	15,0	29,1	22,9	15,0	37,9	33,1	23,3	0,6
		Ž	1,6	0	0	0	0	0	1,4	0	0	0	1,3	3,9	5,5	5,5	0	4,1	2,2	1,8	0,1
C33	Sapnik Trachea	M	0,4	0	0	0	0	0	0	0	0	0	1,3	1,2	2,6	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C34	Sapnica in pljuča Bronchus and lung	M	82,5	0	0	0	0	0	1,3	2,4	6,5	12,6	38,9	83,6	151,9	230,9	310,3	405,9	401,3	368,1	6,2
		Ž	34,3	0	0	0	0	0	1,4	0	4,3	5,3	22,3	48,5	59,3	71,2	94,2	86,3	102,1	125,3	2,0
C37	Timus Thymus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	1,4	0	0	0	0	0	0,0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,7	0	0	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1,8	0,0
C39	Druga in slabo opredeljena mesta v dihalih in prsni organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C40	Kosti, sklepni hrustanec udov Bone and articular cartilage of limbs	M	0,4	0	0	2,1	0	0	0	0	0	0	1,3	1,2	0	0	0	0	3,7	0	0,0
		Ž	0,4	0	0	1,9	0	1,4	0	0	0	0	1,3	0	0	0	0	0	0	1,8	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C41	Kosti, sklepni hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	0,2	0	0	0	0	1,4	0	0	0	1,3	0	0	0	0	0	0	0	0	0,0
		Ž	0,2	0	0	0	0	0	0	0	0	0	0	1,3	1,4	0	0	0	0	0	0,0
C43	Malignni melanom kože Malignant melanoma of skin	M	20,6	0	0	2,1	0	2,9	7,5	4,8	14,2	20,1	17,6	27,5	37,0	40,1	57,8	62,2	70,0	65,2	1,5
		Ž	23,5	0	0	1,9	7,9	11,2	16,1	15,6	31,6	31,5	32,7	37,2	36,5	33,2	34,9	46,6	51,2	1,5	
C44	Druge maligne neoplazme kože Skin, other malignomas	M	91,4	0	0	0	0	2,5	9,7	12,9	20,1	35,1	67,4	121,5	166,0	284,6	349,1	633,3	903,9	5,3	
		Ž	98,3	0	0	0	1,6	8,4	18,8	8,5	23,7	52,6	89,1	100,7	111,3	208,6	258,8	373,0	562,8	4,4	
C45	Mezoteliom Mesothelioma	M	2,3	0	0	0	0	0	0	0	0	1,3	2,5	4,0	1,9	15,0	8,1	18,4	4,7	0,2	
		Ž	0,6	0	0	0	0	0	0	0	0	0	1,3	2,8	3,6	1,8	0	0	0	0,0	
C46	Kaposijev sarkom Kaposi's sarcoma	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	2,1	0	0	0	0,0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	1,4	0	0	0	0	0,0	
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	0,6	0	0	0	0	1,3	1,2	0	0	0	1,2	1,3	0	0	2,7	3,7	0	0,0	
		Ž	1,7	0	0	0	0	1,4	0	2,8	2,6	1,3	1,3	2,8	1,8	3,7	4,1	0	7,1	0,1	
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	3,0	0	0	0	0	1,3	0	1,3	6,3	0	5,0	4,0	3,8	6,4	5,4	11,0	28,0	0,2	
		Ž	1,4	0	0	0	0	0	1,3	0	1,3	1,3	1,3	1,4	3,6	3,7	0	6,7	3,5	0,1	
C50	Dojka Breast	M	0,9	0	0	0	0	0	0	1,3	0	0	0	2,6	1,9	0	8,1	3,7	4,7	0,1	
		Ž	109,5	0	0	0	0	12,6	20,1	48,3	96,0	120,9	199,1	205,5	226,3	234,5	199,3	262,0	243,5	6,8	
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	4,6	0	0	0	0	0	0	0	2,6	1,3	1,3	2,8	1,8	3,7	14,4	8,9	47,6	0,1	
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	1,2	0	0	0	0	0	0	1,4	0	1,3	2,6	0	1,8	3,7	4,1	6,7	0	0,1	
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	12,6	0	0	0	1,6	7,0	16,1	15,6	21,0	27,6	18,3	20,7	10,9	12,9	20,5	20,0	5,3	0,9	
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	27,9	0	0	0	0	1,4	0	0	10,5	14,5	35,4	48,3	65,7	84,9	84,2	95,5	70,6	1,7	
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	1,2	0	0	0	0	1,4	0	1,4	2,6	1,3	0	0	0	1,8	0	2,2	8,8	0,0	
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	14,1	0	0	2,2	0	1,6	1,4	5,4	5,7	9,2	17,1	13,1	27,6	31,0	33,2	16,4	40,0	40,6	0,8
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0,9	0	0	0	0	0	0	0	0	0	3,9	1,3	1,4	3,6	1,8	0	2,2	0	0,1
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0	
C60	Penis Penis	M	1,5	0	0	0	0	0	0	0	0	1,3	0	1,2	2,6	7,6	6,4	5,4	0	9,3	0,1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje —>
Continued —>

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C61	Prostata Prostate	M	129,8	0	0	0	0	0	0	0	0	1,3	17,6	59,9	192,9	406,5	558,6	838,9	681,2	629,0	10,4
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	9,0	1,9	0	2,1	1,8	11,4	26,3	23,0	22,0	8,8	6,3	5,0	4,0	1,9	2,1	0	3,7	4,7	0,6
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0,2	0	0	0	0	0	0	0	0	0	0	0	0	0	2,1	2,7	0	0	0,0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	20,9	3,9	0	0	0	0	0	0	3,9	10,0	13,8	38,7	41,0	51,5	70,6	92,0	73,6	51,3	1,6
		Ž	8,9	2,0	0	0	0	0	0	1,3	0	2,6	5,3	9,2	16,5	18,2	22,2	26,7	28,9	30,0	0,5
C65	Ledvični meh Renal pelvis	M	1,2	0	0	0	0	0	0	0	0	0	0	1,2	1,3	1,9	6,4	2,7	14,7	4,7	0,1
		Ž	1,2	0	0	0	0	0	0	0	0	0	0	1,3	0	1,8	1,8	8,2	8,9	1,8	0,1
C66	Sečevod Ureter	M	0,8	0	0	0	0	0	0	0	0	0	0	0	0	0	6,4	5,4	11,0	0	0,1
		Ž	0,5	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	4,1	0	3,5	0,0
C67	Sečni mehur Bladder	M	19,5	0	0	0	0	0	0	0	0	2,5	3,8	16,2	26,4	42,0	59,9	105,5	121,5	172,4	1,3
		Ž	8,3	0	0	0	0	0	0	1,3	1,4	1,3	1,3	1,3	8,3	12,8	22,2	20,5	44,4	45,9	0,4
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	4,7	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	1,6	3,9	0	0	0	0	0	0	2,6	0	2,5	1,2	1,3	3,8	2,1	2,7	7,4	9,3	0,1
		Ž	1,2	0	0	0	1,6	0	0	0	0	1,3	2,6	0	1,4	5,5	1,8	0	4,4	1,8	0,1
C70	Meninge Meninges	M	0,4	0	0	0	0	0	0	0	1,3	0	0	0	0	1,9	0	2,7	0	4,7	0,0
		Ž	0,1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2,1	0	0	0,0
C71	Možgani Brain	M	7,8	5,8	6,4	2,1	0	1,4	3,8	4,8	5,2	10,0	7,5	6,2	10,6	15,3	15,0	27,1	18,4	14,0	0,6
		Ž	5,7	2,0	4,6	2,2	1,9	1,6	2,8	4,0	1,4	2,6	6,6	7,9	6,9	5,5	16,6	10,3	11,1	12,4	0,4
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	0,1	1,9	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	M	2,7	0	0	0	0	5,0	1,2	2,6	0	6,3	2,5	6,6	3,8	2,1	5,4	11,0	0	0,2	
		Ž	11,8	0	0	3,8	1,6	9,8	8,1	15,6	18,4	17,1	22,3	20,7	14,6	24,0	6,2	11,1	12,4	0,8	
C74	Nadledvična žleza Adrenal gland	M	0,1	0	0	0	0	0	0	0	1,3	0	0	0	0	0	0	0	0	0	0,0
		Ž	0,3	0	0	0	0	0	0	0	0	0	0	0	1,8	1,8	0	2,2	0	0,0	
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	0,1	0	0	0	1,4	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	0,5	0	0	0	0	0	1,2	0	0	0	0	0	1,3	1,9	0	2,7	3,7	0	0,0
		Ž	2,6	0	0	0	0	0	0	0	0	0	0	1,3	0	5,5	1,8	8,2	13,3	21,2	0,1
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	1,5	0	0	0	0	0	0	0	0	1,3	1,3	2,5	2,6	5,7	0	5,4	7,4	9,3	0,1
		Ž	0,6	0	0	0	0	0	0	0	0	0	0	0	1,4	3,6	0	2,1	2,2	1,8	0,0

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C78	Metastaze dihal in prebavil	M	4,9	0	0	0	0	0	0	0	0	0	2,5	2,5	5,3	9,5	15,0	24,4	25,8	65,2	0,3
	Metastases of respiratory and digestive organs	Ž	4,1	0	0	0	0	0	0	0	0	0	0	1,3	2,8	3,6	1,8	8,2	13,3	45,9	0,1
C79	Metastaze, drugje	M	1,4	0	0	0	0	0	0	0	0	0	0	0	4,0	3,8	2,1	5,4	22,1	0	0,1
	Metastases of other sites	Ž	1,6	0	0	0	0	0	0	0	0	0	1,3	1,3	1,4	1,8	3,7	2,1	4,4	12,4	0,1
C80	Maligna neoplazma brez opredeljenega mesta	M	5,5	0	0	0	0	1,4	0	0	0	0	3,8	5,0	13,2	11,5	17,1	18,9	29,5	41,9	0,4
	Malignant neoplasm without specification of site	Ž	4,6	0	0	0	0	0	0	0	1,4	1,3	0	2,6	6,9	1,8	7,4	8,2	24,4	31,8	0,1
C81	Hodgkinova bolezen	M	3,0	0	4,3	0	3,6	7,1	2,5	3,6	3,9	3,8	3,8	1,2	2,6	0	2,1	2,7	7,4	0	0,2
	Hodgkin's disease	Ž	3,1	0	0	2,2	0	0	7,0	8,1	2,8	2,6	2,6	0	5,5	0	7,4	0	2,2	8,8	0,2
C82	Folikularni ne-Hodgkinov limfom	M	3,9	0	0	0	0	0	0	2,4	1,3	5,0	3,8	5,0	5,3	13,4	10,7	10,8	11,0	9,3	0,3
	Follicular non-Hodgkin's lymphoma	Ž	2,7	0	0	0	0	0	1,4	0	0	0	3,9	1,3	8,3	7,3	7,4	4,1	8,9	5,3	0,2
C83	Difuzni ne-Hodgkinov limfom	M	8,3	0	2,1	8,2	0	0	0	1,2	6,5	3,8	2,5	7,5	18,5	15,3	12,8	32,5	36,8	55,9	0,6
	Diffuse non-Hodgkin's lymphoma	Ž	8,8	0	0	0	0	1,6	1,4	2,7	2,8	3,9	2,6	6,5	8,3	14,6	16,6	24,7	42,2	37,1	0,4
C84	Limfomi celic T in kožni limfom celic T	M	1,0	0	2,1	0	0	0	0	0	1,3	1,3	0	2,5	0	0	2,1	5,4	3,7	4,7	0,1
	Peripheral and cutaneous T-cell lymphomas	Ž	0,7	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	6,7	5,3	0,0	0,0
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma	M	1,4	0	0	0	0	0	1,3	0	0	0	0	2,5	1,3	1,9	4,3	8,1	11,0	4,7	0,1
	Other and unspecified types of non-Hodgkin's lymphoma	Ž	1,1	0	0	0	0	0	0	0	0	0	0	1,3	0	3,6	1,8	0	2,2	10,6	0,0
C88	Maligne imunoproliferativne bolezni	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
	Malignant immunoproliferative diseases	Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov	M	5,8	0	0	0	0	0	0	0	1,3	3,8	5,0	5,0	11,9	11,5	19,3	29,8	18,4	32,6	0,4
	Multiple myeloma and malignant plasma cell neoplasms	Ž	6,2	0	0	0	0	0	0	0	0	0	1,3	5,2	4,1	10,9	12,9	14,4	42,2	30,0	0,2
C91.0	Limfatična levkemija, akutna	M	1,8	13,6	0	2,1	5,4	2,9	1,3	0	0	0	1,3	0	1,3	0	0	2,7	3,7	0	0,2
	Lymphoblastic leukaemia, acute	Ž	1,0	10,2	0	0	1,9	1,6	0	0	0	1,3	0	1,3	1,4	0	0	0	0	0	0,1
C91.1 C91.9	Limfatična levkemija, druga	M	5,2	0	0	0	0	0	0	0	0	0	1,3	5,0	6,6	17,2	15,0	35,2	18,4	41,9	0,4
	Lymphoid leukaemia, other	Ž	3,1	0	0	0	0	0	0	0	0	0	0	6,5	4,1	5,5	11,1	10,3	6,7	12,4	0,2
C92	Mieloična levkemija	M	6,7	0	0	0	1,4	3,8	0	0	0	3,8	5,0	12,5	6,6	5,7	19,3	21,6	36,8	55,9	0,4
	Myeloid leukaemia	Ž	4,4	0	2,3	0	0	0	1,4	0	0	5,3	2,6	1,3	5,5	5,5	11,1	18,5	11,1	15,9	0,3

Nadaljevanje →
Continued →

Tabela 5: Nadaljevanje.

Table 5: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
C93	Monocitna levkemija Monocytic leukaemia	M	0,3	0	0	0	0	0	0	0	0	0	0	0	0	1,9	2,1	2,7	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	0,6	0	0	0	0	0	0	0	0	0	0	1,2	2,6	0	2,1	2,7	3,7	0	0,0
		Ž	1,1	2,0	0	0	0	0	0	0	0	0	1,3	0	1,4	1,8	1,8	2,1	0	8,8	0,1
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,3	0	0	0	0	0,0
		Ž	0,7	0	2,3	0	0	0	0	0	0	0	0	0	0	0	1,8	0	2,2	7,1	0,0
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega ali sorodnega tkiva Other and unspecified malignant neoplasms of lymphoid, haematopoietic and related tissue	M	3,9	0	0	0	0	0	0	1,3	0	1,3	1,2	4,0	1,9	10,7	13,5	55,2	32,6	0,2	
		Ž	4,6	0	0	1,9	1,6	5,6	0	1,4	0	3,9	1,3	1,4	3,6	7,4	16,4	13,3	26,5	0,2	

Zgoraj neupoštevani

Not included above

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																	KS CR
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+	
D03	Melanom, in situ Melanoma, in situ	M	8,2	0	0	2,1	0	1,4	2,5	1,2	2,6	7,5	13,8	8,7	13,2	22,9	12,8	29,8	25,8	28,0	0,6
		Ž	11,7	0	0	0	4,7	7,0	17,5	15,6	14,5	18,4	13,1	13,8	21,9	11,1	14,4	22,2	15,9	0,8	
D05	Dojka, in situ Breast, in situ	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	7,5	0	0	0	0	0	0	0	2,8	7,9	7,9	19,6	17,9	23,7	16,6	10,3	13,3	3,5	0,5
D06	Maternični vrat, CIN III Cervix uteri, in situ	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	91,6	0	0	3,8	112,2	294,6	288,8	240,0	161,7	78,8	55,0	27,6	29,2	9,2	14,4	4,4	3,5	6,6	
D09.0	Sečni mehur, in situ Bladder, in situ	M	12,6	0	0	0	0	0	1,2	1,3	0	7,5	8,7	17,2	38,2	40,7	59,5	81,0	74,5	0,9	
		Ž	4,3	0	0	0	0	0	0	0	3,9	2,6	1,3	8,3	7,3	7,4	8,2	17,8	21,2	0,2	
D32.0	Meninge, benigna neoplazma Benign neoplasm of meninges	M	2,6	0	0	0	1,4	0	1,2	0	1,3	0	3,7	5,3	7,6	12,8	5,4	7,4	9,3	0,2	
		Ž	5,8	0	0	0	0	0	1,3	4,3	5,3	6,6	11,8	9,7	10,9	24,0	8,2	8,9	7,1	0,4	
D33.0 D33.2	Možgani, benigna neoplazma Benign neoplasm of brain	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0,0
D39.1	Jajčnik, neopl. negotovega značaja Ovary, neopl. of uncertain behavior	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	3,8	0	0	0	0	4,2	2,7	4,3	3,9	1,3	7,9	8,3	9,1	11,1	4,1	2,2	1,8	0,3	
D43.0 D43.2	Možgani, neopredeljeno CNS, uncertain or unknown	M	0,1	0	0	0	0	0	0	0	0	0	0	0	0	1,9	0	0	0	0	0,0
		Ž	0,9	0	0	0	0	0	0	0	0	0	0	0	0	1,8	1,8	2,1	2,2	8,8	0,0

Tabela 6a: Incidenca najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2009.

Table 6a: Incidence of most frequent cancer sites by statistical regions and by sex, Slovenia 2009.

Statistična regija Statistical region	Spol Sex	Skupaj All sites C00–C96	Primarna lokacija (šifra MKB) Primary site (ICD code)											
			C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06*
Slovenija, skupaj Slovenia, total	M	6602	289	520	89	323	835	925	9	–	–	1313	2299	–
	Ž	5624	180	388	52	196	354	1013	1128	130	288	–	1895	944
Pomurska	M	415	18	38	8	24	53	53	0	–	–	89	132	–
	Ž	312	15	19	2	12	15	76	54	9	24	–	86	53
Podravska	M	960	50	84	10	50	130	107	1	–	–	205	323	–
	Ž	817	33	69	7	33	54	120	180	19	38	–	264	193
Koroška	M	271	8	15	4	19	45	37	0	–	–	52	91	–
	Ž	223	10	17	4	12	10	57	30	5	13	–	65	40
Savinjska	M	780	43	82	11	57	104	75	0	–	–	138	270	–
	Ž	602	20	47	11	23	35	70	128	18	31	–	219	132
Zasavska	M	141	16	11	6	7	24	13	1	–	–	15	48	–
	Ž	127	6	8	2	2	11	8	23	4	12	–	51	19
Spodnjeposavska	M	227	11	21	7	11	27	24	0	–	–	48	78	–
	Ž	191	6	18	2	6	5	24	50	3	5	–	72	39
Jugovzhodna Slovenija	M	458	22	40	8	17	52	60	1	–	–	104	154	–
	Ž	426	16	19	6	14	23	96	85	11	24	–	132	68
Osrednjeslovenska	M	1689	61	112	21	65	194	290	1	–	–	346	599	–
	Ž	1567	44	94	10	45	112	312	313	33	78	–	526	208
Gorenjska	M	715	31	40	8	26	92	142	2	–	–	131	243	–
	Ž	570	11	42	4	20	43	111	97	11	23	–	208	92
Notranjsko-kraška	M	179	3	14	0	8	16	28	0	–	–	38	72	–
	Ž	136	4	0	0	3	11	28	32	3	6	–	49	20
Goriška	M	373	11	32	4	17	45	44	2	–	–	74	144	–
	Ž	308	4	32	3	14	14	47	68	5	19	–	102	38
Obalno-kraška	M	394	15	31	2	22	53	52	1	–	–	73	145	–
	Ž	345	11	23	1	12	21	64	68	9	15	–	121	42

Opis šifer MKB/Description of the ICD code

- C16 Želodec
Stomach
- C18 Debelo črevo
Colon
- C19 Rektosigmoidna zveza
Rectosigmoid junction
- C20 Rektum
Rectum
- C34 Sapnica in pljuča
Bronchus and lung

- C44 Koža, razen melanoma
Skin, non-melanoma
- C50 Dojka
Breast
- C53 Maternični vrat
Cervix uteri
- C54 Maternično telo
Corpus uteri
- C61 Prostata
Prostate
- D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

* Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 6b: Starostno standardizirana* incidenčna stopnja najpogostejših lokacij raka po statističnih regijah in spolu, Slovenija 2009.

Table 6b: Age standardised* incidence rate of most frequent cancer sites by statistical regions and by sex, Slovenia 2009.

Statistična regija Statistical region	Spol Sex	Skupaj All sites C00–C96	Primarna lokacija (šifra MKB) Primary site (ICD code)											
			C16	C18	C19	C20	C34	C44	C50	C53	C54	C61	Drugo Other	D06**
Slovenija, skupaj Slovenia, total	M	676,9	30,3	54,5	9,1	32,5	84,8	97,3	0,9	–	–	136,5	255,8	–
	Ž	438,1	13,0	28,9	3,8	15,0	27,5	73,2	94,4	12,1	23,0	–	178,1	97,5
Pomurska	M	734,1	34,9	65,8	12,0	43,2	92,9	99,2	0	–	–	162,0	245,0	–
	Ž	385,7	16,6	23,5	2,9	16,0	17,8	89,4	72,9	13,9	30,6	–	121,6	94,5
Podravska	M	607,0	32,4	53,6	6,6	31,2	79,1	70,0	0,4	–	–	133,4	217,4	–
	Ž	392,4	14,4	31,2	3,0	15,0	27,2	52,2	93,2	11,4	18,3	–	143,4	125,2
Koroška	M	756,5	24,3	42,9	10,9	50,0	126,8	107,6	0	–	–	147,3	262,9	–
	Ž	493,6	23,5	36,5	9,2	24,1	24,4	124,4	68,8	12,2	28,1	–	161,5	117,9
Savinjska	M	648,2	37,0	71,6	9,8	46,4	86,6	63,4	0	–	–	114,9	242,3	–
	Ž	392,3	11,4	29,4	7,2	13,7	23,4	41,0	87,5	12,4	20,5	–	169,8	107,8
Zasavska	M	630,9	76,3	49,7	27,0	32,8	107,6	58,1	5,3	–	–	72,0	218,4	–
	Ž	426,2	20,9	25,1	8,3	7,0	38,7	22,0	85,2	17,0	41,3	–	179,8	92,3
Spodnjeposavska	M	652,0	32,5	62,5	20,4	33,0	74,4	70,9	0	–	–	141,2	225,0	–
	Ž	427,1	12,7	38,6	3,6	12,1	13,0	49,9	117,7	7,1	12,2	–	190,0	122,0
Jugovzhodna Slovenija	M	709,4	35,3	64,3	11,9	25,2	80,1	97,8	1,6	–	–	162,9	243,8	–
	Ž	499,0	17,5	20,0	5,9	14,9	29,6	105,4	108,9	14,3	27,9	–	181,9	104,0
Osrednjeslovenska	M	695,6	25,0	46,7	8,7	26,3	79,4	121,2	0,5	–	–	144,3	283,1	–
	Ž	483,0	13,1	27,4	2,8	13,7	33,8	91,7	102,6	12,4	25,2	–	212,8	80,2
Gorenjska	M	739,6	32,4	42,1	8,1	25,8	94,2	149,6	1,9	–	–	135,6	281,5	–
	Ž	452,0	8,4	32,4	3,0	16,3	31,3	79,7	85,4	10,7	19,1	–	195,8	96,6
Notranjsko-kraška	M	684,0	12,1	53,2	0	32,4	60,3	105,3	0	–	–	150,7	284,2	–
	Ž	404,5	9,5	0	0	6,8	36,0	76,6	104,5	12,6	17,1	–	182,3	84,5
Goriška	M	603,4	17,5	52,4	6,9	27,3	72,4	70,5	3,6	–	–	122,7	240,8	–
	Ž	395,1	3,9	36,4	3,4	19,9	16,4	55,0	89,8	8,9	24,4	–	153,7	70,0
Obalno-kraška	M	703,5	27,0	56,5	3,6	38,2	93,5	92,8	1,7	–	–	132,1	288,4	–
	Ž	476,1	12,5	31,4	0,8	17,7	26,5	80,8	102,3	14,5	22,2	–	198,4	79,8

Opis šifer MKB/Description of the ICD code

C16 Želodec
Stomach
C18 Debelo črevo
Colon
C19 Rektosigmoidna zveza
Rectosigmoid junction
C20 Rektum
Rectum
C34 Sapnica in pljuča
Bronchus and lung

C44 Koža, razen melanoma
Skin, non-melanoma
C50 Dojka
Breast
C53 Maternični vrat
Cervix uteri
C54 Maternično telo
Corpus uteri
C61 Prostata
Prostate
D06 Maternični vrat, in situ (CIN III)
Cervix uteri, in situ (CIN III)

* Standard – prebivalstvo Slovenije po popisu 2002

* Standard – population of Slovenia according to census 2002

** Neupoštevano v skupnem številu: D06 – maternični vrat, in situ (CIN III)

** Not included in All sites: D06 – Cervix uteri, in situ (CIN III)

Tabela 7: Incidenca histološko (H) in citološko (C) potrjenih primerov raka po histološki vrsti in lokaciji, Slovenija 2009.

Table 7: Incidence of histologically (H) and cytologically (C) confirmed cancer cases by histological type and by site, Slovenia 2009.

Histološka vrsta Histologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C96		C00		C01		C02		C03		C04		C05		C06		C07		C08		C09	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	30	0	17	0	24	0	8	0	38	1	19	2	15	0	15	0	6	0	41	0		
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	30	–	15	–	24	–	6	–	38	–	16	1	13	–	2	–	–	–	–	40	–	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	–	–	1	–	–	–	–	–	–	–	1	–	–	–	3	–	5	–	–	–	–	–
Other specified carcinomas	151	17	–	–	1	–	–	–	2	–	–	–	2	–	–	–	6	–	1	–	–	–	–	–
Carcinoma, unspecified	91	177	–	–	–	–	–	–	–	–	–	1	–	1	–	–	1	–	–	–	–	–	–	–
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C10		C11		C12		C13		C14		C15		C16		C17		C18	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	55	1	6	1	39	0	30	2	0	0	82	0	446	7	28	0	872	6	135	2
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	2	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	52	–	6	–	39	–	30	1	–	–	59	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	–	–	–	1	–	–	–	–	–	–	19	–	418	1	20	–	858	1	132	1
Other specified carcinomas	151	17	–	–	–	–	–	–	–	–	–	–	2	–	1	–	–	–	3	–	–	–
Carcinoma, unspecified	91	177	3	1	–	–	–	–	–	1	–	–	1	–	7	6	–	–	4	5	3	1
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	1	–	17	–	8	–	3	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																					
			C00–C06		C20		C21		C22		C23		C24		C25		C26		C30		C31		C32	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	505	2	13	0	63	11	44	5	58	4	129	40	5	0	3	0	9	0	100	2		
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	–	–	9	–	–	–	–	–	–	–	–	1	–	–	2	–	4	–	95	1		
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	495	1	2	–	60	10	38	2	54	4	121	24	5	–	1	–	2	–	–	–	–	–
Other specified carcinomas	151	17	4	–	–	–	–	–	1	–	1	–	1	1	–	–	–	–	2	–	1	–	–	–
Carcinoma, unspecified	91	177	4	1	–	–	1	–	4	3	3	–	7	12	–	–	–	–	1	–	4	1		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	1	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	1	1	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C33		C34		C37		C38		C39		C40		C41		C43		C44	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	4	0	851	235	2	0	1	0	0	0	8	0	4	0	448	2	1897	30	28	1
Small cell carcinoma	189	37	–	–	169	35	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	1	–	39	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	2	–	277	51	–	–	–	–	–	–	–	–	–	–	–	–	349	9	–	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1527	20	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	–	–	281	76	–	–	–	–	–	–	–	–	–	–	–	–	12	–	–	–
Other specified carcinomas	151	17	1	–	72	13	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	91	177	–	–	12	21	–	–	–	–	–	–	–	–	–	–	–	–	1	1	–	–
Malignant thymoma	2	0	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	448	2	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	5	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	1	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	4	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	1	–	2	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	28	1
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C46		C47		C48		C49		C50		C51		C52		C53		C54	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	1	0	1	0	24	0	42	2	1003	108	46	1	12	0	129	1	286	0	9	0
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	–	–	–	–	–	–	–	–	–	–	38	–	12	–	97	–	1	–	1	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	6	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	–	–	–	–	10	–	–	–	984	20	–	–	–	–	25	–	254	–	–	–
Other specified carcinomas	151	17	–	–	–	–	–	–	–	–	9	1	–	–	–	–	6	–	22	–	–	–
Carcinoma, unspecified	91	177	–	–	–	–	–	–	–	–	8	85	1	1	–	–	–	1	3	–	–	–
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	6	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	6	–	6	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	2	–	7	–	–	–	1	–	–	–	–	–	1	–	8	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	1	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	1	–	3	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	1	–	13	1	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	1	–	4	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	–	1	–	–	2	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																							
			C00–C96		C56		C57		C58		C60		C61		C62		C63		C64		C65		C66			
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C		
Vse vrste/All types	10803	679	132	6	7	1	0	0	15	0	1256	4	89	1	2	0	262	9	23	1	13	0				
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Squamous cell carcinoma	1296	70	1	–	–	–	–	–	14	–	1	–	–	–	–	–	–	–	–	3	–	1	–	–		
Basal cell carcinoma	1534	20	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–	–	–	–	20	–	12		
Adenocarcinoma	5633	193	120	3	6	–	–	–	–	–	1241	1	–	–	–	–	253	4	–	–	–	–	–	–		
Other specified carcinomas	151	17	4	–	–	–	–	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–		
Carcinoma, unspecified	91	177	–	2	–	1	–	–	–	–	7	3	–	–	–	–	5	5	–	1	–	–	–	–		
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–		
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	1	–	1	–	–	–	–	–	–	–		
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant complex mixed and stromal tumors	45	0	3	–	1	–	–	–	–	–	–	–	–	–	–	–	3	–	–	–	–	–	–	–		
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant gonadal stromal tumors	2	0	1	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–		
Dysgerminoma and seminoma	58	1	2	–	–	–	–	–	–	–	–	–	55	1	–	–	–	–	–	–	–	–	–	–		
Other malignant germ cell tumors	30	0	1	–	–	–	–	–	–	–	–	–	28	–	–	–	–	–	–	–	–	–	–	–		
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	5	–	–	–	–	–	–	–	–	–	–	–		
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		
Malignant tumor, unspecified	2	12	–	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–		

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C67		C68		C69		C70		C71		C72		C73		C74		C75	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	265	7	1	0	22	1	5	0	117	1	1	0	143	6	3	1	1	0	14	7
Small cell carcinoma	189	37	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	6	–	–	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	250	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	4	–	–	–	1	–	–	–	–	–	–	–	142	3	3	1	–	–	6	6
Other specified carcinomas	151	17	1	–	–	–	–	–	–	–	–	–	–	–	1	2	–	–	–	–	1	–
Carcinoma, unspecified	91	177	1	4	–	–	–	–	–	–	–	–	–	–	1	–	–	–	–	–	2	1
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–	–	–
Malignant melanoma	482	5	–	–	–	–	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	2	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	1	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	116	1	1	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	2	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Nadaljevanje →
Continued →

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)																			
			C00–C96		C77		C78		C79		C80		C81		C82		C83		C84		C85	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	12	8	24	29	16	1	45	26	58	4	64	3	153	22	16	1	18	7	0	0
Small cell carcinoma	189	37	–	–	2	–	1	–	5	2	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	8	5	–	–	1	–	1	1	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	2	3	20	16	8	–	26	15	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	151	17	–	–	–	–	2	–	2	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	91	177	–	–	1	11	–	1	7	5	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	2	–	1	–	4	–	4	2	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	64	3	153	22	16	1	18	7	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	58	4	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	2	–	–	–	1	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 7: Nadaljevanje.

Table 7: Continued.

Histološka vrsta Hystologic type	Skupaj All sites		Primarna lokacija (šifra MKB) Primary site (ICD code)													
			C00–C96		C90		C91		C92		C93		C94		C95	
	H	C	H	C	H	C	H	C	H	C	H	C	H	C	H	C
Vse vrste/All types	10803	679	103	20	90	22	98	15	3	0	16	1	5	3	80	6
Small cell carcinoma	189	37	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non-small cell carcinoma	40	36	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Squamous cell carcinoma	1296	70	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Basal cell carcinoma	1534	20	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Transitional cel carcinoma	286	3	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Adenocarcinoma	5633	193	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified carcinomas	151	17	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Carcinoma, unspecified	91	177	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant thymoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant paraganglioma/pheochromocytoma	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant melanoma	482	5	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrosarcoma	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Fibrohistiocytic sarcoma	7	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Liposarcoma	13	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Leiomyosarcoma	27	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Rhabdomyosarcoma	3	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Synovial sarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Angiosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Kaposi sarcoma	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Osteosarcoma	4	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Chondrosarcoma	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Ewing sarcoma/PNET	6	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other specified sarcomas	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Sarcoma, unspecified	17	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant complex mixed and stromal tumors	45	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignat fibroepithelial tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant mesothelioma	28	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gonadal stromal tumors	2	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Dysgerminoma and seminoma	58	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Other malignant germ cell tumors	30	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant trophoblastic tumors	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant gliomas	117	1	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant neuroepithelial tumors	3	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant meningioma	5	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant nerve sheath tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Non Hodgkin lymphoma	251	33	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Hodgkin lymphoma	58	4	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Plasma cell tumors	103	20	103	20	–	–	–	–	–	–	–	–	–	–	–	–
Chronic lymphoid leukemia	66	15	–	–	66	15	–	–	–	–	–	–	–	–	–	–
Leukemia except chronic lymphoid	133	25	–	–	24	7	98	15	3	–	3	–	5	3	–	–
Other lymphoreticular neoplasms	2	0	–	–	–	–	–	–	–	–	1	–	–	–	1	–
Chronic myeloproliferative diseases	54	1	–	–	–	–	–	–	–	–	12	1	–	–	42	–
Myelodysplastic syndromes	37	6	–	–	–	–	–	–	–	–	–	–	–	–	37	6
Other specified malignant tumors	1	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Malignant tumor, unspecified	2	12	–	–	–	–	–	–	–	–	–	–	–	–	–	–

Tabela 8: Incidenca ne-Hodgkinovih limfomov* po lokaciji, spolu in starosti, Slovenija 2009.

Table 8: Incidence of non-Hodgkin's malignant lymphomas* by site, by sex and by age, Slovenia 2009.

Šifra MKB-8 ICD-8 code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																
				0-	5-	10-	15-	20-	25-	30-	35-	40-	45-	50-	55-	60-	65-	70-	75-	80+
	Vsi NHL All NHL	M+Ž	284	0	2	4	0	1	3	5	9	11	10	22	31	30	28	35	44	49
		M	147	0	2	4	0	0	1	3	7	8	5	14	19	16	14	21	17	16
		Ž	137	0	0	0	0	1	2	2	2	3	5	8	12	14	14	14	27	33
142	Slinavke Salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
143	Dlesni Gum	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
146	Orofarinks Oropharynx	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	1
151	Želodec Stomach	M	13	0	0	0	0	0	0	0	0	1	0	1	4	2	0	1	1	3
		Ž	12	0	0	0	0	0	0	0	0	1	1	0	1	1	2	0	4	2
152	Tanko črevo Small intestine	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	1
153	Debelo črevo Colon	M	2	0	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
155	Jetra Liver	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
158	Retro- in peritonej Retro- and peritoneum	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
160	Nos, obnosne votline, drugo Nose, sinuses, etc.	M	4	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0	1	1
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
162	Sapnik, sapnica, pljuča Trachea, bronchus, lung	M	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0
163	Plevra, mediastinum, drugo Pleura, mediastinum, etc.	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	0
170	Kosti Bone	M	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
171	Mehka tkiva Soft tissues	M	2	0	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0
173	Koža, drugi malignomi Skin, other malignancies	M	3	0	0	0	0	0	0	0	1	0	0	0	1	1	0	0	0	0
		Ž	7	0	0	0	0	0	0	0	0	0	0	1	1	0	0	0	2	3
174	Dojka Breast	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	1	0
184	Nožnica, vulva, drugo Vagina, vulva, etc.	M	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
185	Prostata Prostate	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
186	Modo Testis	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
189	Ledvica, sečevod, drugo Kidney, ureter, etc.	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
190	Oko Eye	M	3	0	0	0	0	0	0	0	0	0	1	0	0	0	1	0	1	0
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1
191	Možgani Brain	M	2	0	0	0	0	0	0	0	1	0	0	0	1	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0
192	Živčevje, drugo Nervous system, other	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
193	Ščitnica Thyroid	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0	0
194	Endokrine žleze, druge Endocrine glands, other	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0
202	Bezavke Lymph nodes	M	105	0	1	4	0	0	1	2	5	5	4	9	10	13	11	18	11	11
		Ž	93	0	0	0	0	1	2	1	1	2	4	5	10	10	8	9	17	23

* Vključeni so samo citološko in histološko potrjeni primeri

* All cases included have been verified citologically and histologically

Tabela 9: Incidenca raka (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti) po stadiju, lokaciji in spolu, Slovenija 2009.

Table 9: Cancer incidence (without cases registered from death certificates only) by stage, by site and by sex, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
Localized		Regional		Distant		Unknown					
Number	%*	Number	%*	Number	%*	Number	%*				
C00 C80	Vse lokacije All sites	M+Ž	11364	5587	49,2	3305	29,1	2150	18,9	322	2,8
		M	6156	2937	47,7	1837	29,8	1179	19,2	203	3,3
		Ž	5208	2650	50,9	1468	28,2	971	18,6	119	2,3
C00	Ustnica Lip	M	19	17	89,5	2	10,5	0	0	0	0
		Ž	12	11	—	1	—	0	—	0	—
C01	Baza jezika Base of tongue	M	16	1	6,3	15	93,8	0	0	0	0
		Ž	1	0	—	1	—	0	—	0	—
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	17	6	35,3	11	64,7	0	0	0	0
		Ž	7	3	—	4	—	0	—	0	—
C03	Dlesen Gum	M	6	2	—	4	—	0	—	0	—
		Ž	2	0	—	2	—	0	—	0	—
C04	Ustno dno Floor of mouth	M	29	13	44,8	16	55,2	0	0	0	0
		Ž	10	4	—	5	—	0	—	1	—
C05	Nebo Palate	M	17	5	29,4	11	64,7	1	5,9	0	0
		Ž	4	1	—	3	—	0	—	0	—
C06	Usta, drugi deli Mouth, other & unspecified parts	M	12	2	—	9	—	1	—	0	—
		Ž	3	0	—	3	—	0	—	0	—
C07	Parotidna žleza Parotid gland	M	6	2	—	4	—	0	—	0	—
		Ž	9	7	—	2	—	0	—	0	—
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	5	1	—	4	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C09	Tonzila Tonsil	M	33	7	21,2	25	75,8	0	0	1	3,0
		Ž	10	0	—	10	—	0	—	0	—
C10	Orofarinks Oropharynx	M	47	4	8,5	42	89,4	1	2,1	0	0
		Ž	9	2	—	7	—	0	—	0	—
C11	Nazofarinks Nasopharynx	M	6	0	—	4	—	2	—	0	—
		Ž	1	0	—	1	—	0	—	0	—
C12	Piriformni sinus Pyriform sinus	M	35	3	8,6	30	85,7	2	5,7	0	0
		Ž	4	0	—	4	—	0	—	0	—
C13	Hipofarinks Hypopharynx	M	30	3	10,0	24	80,0	2	6,7	1	3,3
		Ž	2	1	—	1	—	0	—	0	—
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C15	Požiralnik Oesophagus	M	74	16	21,6	28	37,8	22	29,7	8	10,8
		Ž	13	6	—	4	—	2	—	1	—
C16	Želodec Stomach	M	289	51	17,6	122	42,2	98	33,9	18	6,2
		Ž	179	40	22,3	73	40,8	53	29,6	13	7,3
C17	Tanko črevo Small intestine	M	20	10	50,0	6	30,0	2	10,0	2	10,0
		Ž	10	3	—	3	—	4	—	0	—
C18	Debelo črevo Colon	M	519	86	16,6	291	56,1	132	25,4	10	1,9
		Ž	388	58	14,9	228	58,8	97	25,0	5	1,3
C19	Rektosigmoidna zveza Rectosigmoid junction	M	89	19	21,3	41	46,1	25	28,1	4	4,5
		Ž	52	9	17,3	32	61,5	9	17,3	2	3,8
C20	Rektum Rectum	M	323	43	13,3	210	65,0	61	18,9	9	2,8
		Ž	194	34	17,5	118	60,8	37	19,1	5	2,6
C21	Anus in analni kanal Anus and anal canal	M	4	3	—	0	—	1	—	0	—
		Ž	9	3	—	5	—	1	—	0	—
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	92	47	51,1	14	15,2	22	23,9	9	9,8
		Ž	46	14	30,4	13	28,3	17	37,0	2	4,3
C23	Žolčnik Gallbladder	M	15	3	20,0	4	26,7	7	46,7	1	6,7
		Ž	57	5	8,8	16	28,1	30	52,6	6	10,5
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	54	10	18,5	23	42,6	14	25,9	7	13,0
		Ž	53	7	13,2	23	43,4	14	26,4	9	17,0
C25	Trebušna slinavka Pancreas	M	154	8	5,2	51	33,1	84	54,5	11	7,1
		Ž	170	15	8,8	51	30,0	87	51,2	17	10,0
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	2	0	—	1	—	1	—	0	—
		Ž	6	0	—	1	—	5	—	0	—

Nadaljevanje →
Continued →

Tabela 9: Nadaljevanje.

Table 9: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	3	2	—	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C31	Obnosni sinusi Accessory sinuses	M	4	1	—	3	—	0	—	0	—
		Ž	5	1	—	4	—	0	—	0	—
C32	Grlo Larynx	M	86	45	52,3	40	46,5	0	0	1	1,2
		Ž	16	7	43,8	8	50,0	1	6,3	0	0
C33	Sapnik Trachea	M	4	0	—	1	—	3	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C34	Sapnica in pljuča Bronchus and lung	M	827	132	16,0	269	32,5	400	48,4	26	3,1
		Ž	351	52	14,8	97	27,6	195	55,6	7	2,0
C37	Timus Thymus	M	0	0	—	0	—	0	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	1	0	—	0	—	1	—	0	—
		Ž	1	0	—	0	—	0	—	1	—
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	4	2	—	2	—	0	—	0	—
		Ž	4	1	—	2	—	1	—	0	—
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	2	2	—	0	—	0	—	0	—
		Ž	2	1	—	1	—	0	—	0	—
C43	Maligni melanom kože Malignant melanoma of skin	M	208	155	74,5	40	19,2	7	3,4	6	2,9
		Ž	242	185	76,4	48	19,8	7	2,9	2	0,8
C44	Druge maligne neoplazme kože Skin, other malignomas	M	924	907	98,2	16	1,7	1	0,1	0	0
		Ž	1012	998	98,6	14	1,4	0	0	0	0
C45	Mezoteliom Mesothelioma	M	23	9	39,1	10	43,5	4	17,4	0	0
		Ž	6	3	—	3	—	0	—	0	—
C46	Kaposijev sarkom Kaposi's sarcoma	M	1	1	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C47	Periferni živci in avtonomno živčevje Peripheral nerves and autonomic nervous system	M	0	0	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	6	1	—	4	—	1	—	0	—
		Ž	18	6	33,3	5	27,8	7	38,9	0	0
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	30	6	20,0	21	70,0	3	10,0	0	0
		Ž	14	6	—	4	—	3	—	1	—
C50	Dojka Breast	M	9	5	—	3	—	0	—	1	—
		Ž	1118	552	49,4	452	40,4	98	8,8	16	1,4
C51	Žensko zunanje spolovilo Vulva	M	—	—	—	—	—	—	—	—	—
		Ž	47	22	46,8	24	51,1	1	2,1	0	0
C52	Nožnica Vagina	M	—	—	—	—	—	—	—	—	—
		Ž	12	2	—	6	—	3	—	1	—
C53	Maternični vrat Cervix uteri	M	—	—	—	—	—	—	—	—	—
		Ž	130	71	54,6	46	35,4	12	9,2	1	0,8
C54	Maternično telo Corpus uteri	M	—	—	—	—	—	—	—	—	—
		Ž	288	204	70,8	51	17,7	22	7,6	11	3,8
C55	Maternica, neopredeljeno Uterus, unspecified	M	—	—	—	—	—	—	—	—	—
		Ž	11	5	—	2	—	3	—	1	—
C56	Jajčnik Ovary	M	—	—	—	—	—	—	—	—	—
		Ž	145	20	13,8	18	12,4	102	70,3	5	3,4
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	—	—	—	—	—	—	—	—	—
		Ž	9	5	—	3	—	1	—	0	—
C58	Posteljica Placenta	M	—	—	—	—	—	—	—	—	—
		Ž	0	0	—	0	—	0	—	0	—
C60	Penis Penis	M	15	12	80,0	3	20,0	0	0	0	0
		Ž	—	—	—	—	—	—	—	—	—
C61	Prostata Prostate	M	1308	837	64,0	316	24,2	91	7,0	64	4,9
		Ž	—	—	—	—	—	—	—	—	—

Tabela 9: Nadaljevanje.

Table 9: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij							
				Omejen		Razširjen		Razsejan		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage							
				Localized		Regional		Distant		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C62	Modo Testis	M	91	64	70,3	20	22,0	6	6,6	1	1,1
		Ž	—	—	—	—	—	—	—	—	—
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	2	2	—	0	—	0	—	0	—
		Ž	—	—	—	—	—	—	—	—	—
C64	Ledvica razen meha Kidney, except renal pelvis	M	210	133	63,3	32	15,2	39	18,6	6	2,9
		Ž	91	53	58,2	14	15,4	23	25,3	1	1,1
C65	Ledvični meh Renal pelvis	M	12	3	—	7	—	2	—	0	—
		Ž	12	3	—	7	—	2	—	0	—
C66	Sečevod Ureter	M	8	2	—	6	—	0	—	0	—
		Ž	5	3	—	2	—	0	—	0	—
C67	Sečni mehur Bladder	M	196	141	71,9	37	18,9	18	9,2	0	0
		Ž	85	54	63,5	16	18,8	11	12,9	4	4,7
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	0	—	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C69	Oklo in očesni adneksi Eye and adnexa	M	16	14	87,5	1	6,3	0	0	1	6,3
		Ž	12	11	—	1	—	0	—	0	—
C70	Meninge Meninges	M	4	4	—	0	—	0	—	0	—
		Ž	1	1	—	0	—	0	—	0	—
C71	Možgani Brain	M	79	76	96,2	1	1,3	2	2,5	0	0
		Ž	59	57	96,6	1	1,7	1	1,7	0	0
C72	Hrbtni mozeg, možganski živci in drugi deli ČZS Spinal cord, cranial nerves and other parts of CNS	M	1	1	—	0	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C73	Ščitnica Thyroid gland	M	27	18	66,7	7	25,9	2	7,4	0	0
		Ž	122	99	81,1	19	15,6	4	3,3	0	0
C74	Nadledvična žleza Adrenal gland	M	1	0	—	0	—	1	—	0	—
		Ž	3	1	—	0	—	2	—	0	—
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	—	1	—	0	—	0	—
		Ž	0	0	—	0	—	0	—	0	—
C76	Druga in slabo opredeljena mesta Other and ill-defined sites	M	5	0	—	3	—	1	—	1	—
		Ž	25	1	4,0	8	32,0	15	60,0	1	4,0
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	15	0	0	0	0	0	0	15	100
		Ž	6	0	—	0	—	0	—	6	—
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	49	0	0	0	0	49	100	0	0
		Ž	42	0	0	0	0	42	100	0	0
C79	Metastaze, drugje Metastases of other sites	M	14	0	—	0	—	14	—	0	—
		Ž	15	0	0	0	0	15	100	0	0
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	56	0	0	0	0	56	100	0	0
		Ž	44	0	0	0	0	44	100	0	0

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Število novih primerov Number of new cases	Stadij (Ann–Arbor)							
				I		II		III+IV		Neznan	
				Število	%*	Število	%*	Število	%*	Število	%*
				Stage (Ann–Arbor)							
				I		II		III+IV		Unknown	
Number	%*	Number	%*	Number	%*	Number	%*				
C81	Hodgkinova bolezen Hodgkin's disease	M	30	5	16,7	12	40,0	13	43,3	0	0
		Ž	32	3	9,4	12	37,5	14	43,8	3	9,4
C82– C85	Ne-Hodgkinov limfom Non-Hodgkin's lymphoma	M	147	37	25,2	24	16,3	69	46,9	17	11,6
		Ž	137	37	27,0	21	15,3	64	46,7	15	10,9

* Odstotki niso računani, če je število novih primerov manjše od 15

* Percentages are not calculated when number of new cases is less than 15

Tabela 10a: Število in deleži bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so bili v okviru prvega zdravljenja operirani, zdravljeni s sistemsko terapijo ali obsevani.

Table 10a: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by surgery, systemic therapy or radiotherapy during their first treatment.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery		Število zdravljenih s sistemsko terapijo Number of treated systemic therapy		Število obsevanih Number of treated by radiotherapy	
			Število Number	%*	Število Number	%*	Število Number	%*
C00–C96	Vse lokacije All sites	12172	7428	61,0	3665	30,1	2771	22,8
C00–C14	Usta in žrelo Mouth and pharynx	353	191	54,1	48	13,6	230	65,2
C15	Požiralnik Oesophagus	87	14	16,1	27	31,0	33	37,9
C16	Želodec Stomach	468	239	51,1	106	22,6	73	15,6
C18	Debelo črevo Colon	907	756	83,4	200	22,1	4	–
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	658	516	78,4	268	40,7	255	38,8
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	138	18	13,0	17	12,3	2	–
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	179	66	36,9	3	–	0	–
C25	Trebušna slinavka Pancreas	324	52	16,0	54	16,7	7	–
C32	Grlo Larynx	102	36	35,3	3	–	91	89,2
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1182	169	14,3	504	42,6	503	42,6
C43	Maligni melanom kože Malignant melanoma of skin	450	441	98,0	0	–	21	4,7
C44	Druge maligne neoplazme kože Skin, other malignomas	1936	1756	90,7	12	–	86	4,4
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	68	56	82,4	15	22,1	18	26,5
C50	Dojka Breast	1127	948	84,1	963	85,4	610	54,1
C53	Maternični vrat Cervix uteri	130	84	64,6	10	–	66	50,8
C54	Maternično telo Corpus uteri	288	256	88,9	18	6,3	126	43,8
C56	Jajčnik Ovary	145	120	82,8	103	71,0	2	–
C61	Prostata Prostate	1308	643	49,2	556	42,5	132	10,1
C62	Modo Testis	91	87	95,6	40	44,0	1	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	325	250	76,9	25	7,7	9	–
C67	Sečni mehur Bladder	281	249	88,6	43	15,3	25	8,9
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	144	107	74,3	40	27,8	71	49,3
C73	Ščitnica Thyroid gland	149	141	94,6	129	86,6	112	75,2
C81	Hodgkinova bolezen Hodgkin's disease	62	0	–	52	83,9	40	64,5
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	39	13,7	178	62,7	115	40,5
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	123	3	–	64	52,0	30	24,4
C91–C95	Levkemije Leukaemias	253	0	–	78	30,8	7	–

* Odstotki niso računani, če je število zdravljenih manjše od 15

* Percentages are not calculated for less than 15 new cases

Tabela 10b: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so bilo v okviru prvega zdravljenja operirani*, po lokaciji raka in bolnici posega.

Table 10b: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by surgery during their first treatment* by primary sites and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število operiranih Number of treated by surgery	Splošna bolnišnica Celje	Splošna bolnišnica Jesenice	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Ptuj	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12172	7428	458	166	258	2585	965	1032	251	283	359	44	486	444	97
C00–C14	Usta in žrelo Mouth and pharynx	353	191	4	1	1	124	0	54	3	2	2	0	0	0	0
C15	Požiralnik Oesophagus	87	14	0	0	0	11	0	3	0	0	0	0	0	0	0
C16	Želodec Stomach	468	239	23	10	15	101	10	51	5	2	8	1	8	4	1
C18	Debelo črevo Colon	907	756	75	41	53	244	25	124	34	48	29	12	36	17	18
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	658	516	28	25	27	190	50	71	25	16	19	8	32	13	12
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	138	18	1	0	0	12	1	4	0	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	179	66	3	0	5	34	0	17	1	0	3	0	1	2	0
C25	Trebušna slinavka Pancreas	324	52	0	0	6	33	0	11	1	0	1	0	0	0	0
C32	Grlo Larynx	102	36	0	0	1	30	0	5	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1182	169	0	0	0	119	1	33	0	0	0	0	0	5	11
C43	Maligni melanom kože Malignant melanoma of skin	450	441	47	21	21	118	54	29	14	13	23	2	22	71	6
C44	Druge maligne neoplazme kože Skin, other malignomas	1936	1756	93	57	25	617	34	145	122	65	166	1	101	324	6
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	68	56	1	1	3	11	30	4	0	0	2	1	2	0	1
C50	Dojka Breast	1127	948	42	0	29	5	587	187	6	64	0	0	24	0	4
C53	Maternični vrat Cervix uteri	130	84	6	3	1	49	4	6	1	2	2	0	2	0	8
C54	Maternično telo Corpus uteri	288	256	20	4	4	113	35	31	1	3	8	10	14	0	13
C56	Jajčnik Ovary	145	120	11	0	1	55	16	22	2	3	1	6	1	0	2
C61	Prostata Prostate	1308	643	42	0	31	195	0	92	16	26	40	0	198	0	3
C62	Modo Testis	91	87	11	0	3	40	0	16	4	4	6	0	3	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	325	250	13	0	13	121	0	38	8	7	25	0	25	0	0
C67	Sečni mehur Bladder	281	249	25	0	11	118	0	41	5	17	18	0	13	0	1
C70–C72	Centralni in avtonomi živčni sistem Central and autonomic nervous system	144	107	0	0	0	91	0	16	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	149	141	2	0	1	30	92	3	0	1	0	0	0	5	7
C81	Hodgkinova bolezen Hodgkin's disease	62	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	39	1	1	1	20	5	3	2	2	2	1	0	1	0
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	123	3	0	0	0	3	0	0	0	0	0	0	0	0	0
C91–C95	Levkemije Leukaemias	253	0	0	0	0	0	0	0	0	0	0	0	0	0	0

* Bolniki, ki so bili v okviru prvega zdravljenja operirani več kot enkrat, so vključeni le s prvo operacijo

* Patients that undergone multiple surgery procedures in the course of first treatment were included with the first procedure only

** V posamezni ustanovi so operirali manj kot 30 bolnikov

** Less than 30 patients were treated by surgery in individual institution

Tabela 10c: Število bolnikov (brez primerov registriranih samo iz zdravniških poročil o vzroku smrti), v Sloveniji zbolelih leta 2009, ki so v okviru prvega zdravljenja prejeli sistemske terapije*, po lokacijah raka in bolnici posega.

Table 10c: Number of patients (without cases registered from death certificates only) diagnosed in Slovenia in 2009, that were treated by systemic therapy during their first treatment* by primary sites and treatment institution.

Šifra MKB ICD code	Primarna lokacija Primary site	Število novih primerov Number of new cases	Število zdravljenih s sistemske terapije Number of treated systemic therapy	Splošna bolnišnica Celje	Bolnišnica Golnik	Splošna bolnišnica Izola	Univerzitetni klinični center Ljubljana	Onkološki inštitut Ljubljana	Univerzitetni klinični center Maribor	Splošna bolnišnica Murska Sobota	Splošna bolnišnica Nova Gorica	Splošna bolnišnica Novo mesto	Splošna bolnišnica Slovenj Gradec	Zasebne ordinacije Private clinics	Ostale ustanove** Other institutions**
C00–C96	Vse lokacije All sites	12172	3665	120	115	44	316	2398	425	25	68	48	37	51	18
C00–C14	Usta in žrelo Mouth and pharynx	353	48	0	0	0	0	48	0	0	0	0	0	0	0
C15	Požiralnik Oesophagus	87	27	0	0	0	1	26	0	0	0	0	0	0	0
C16	Želodec Stomach	468	106	0	0	0	4	99	1	0	0	0	1	0	1
C18	Debelo črevo Colon	907	200	10	0	0	3	182	0	0	0	0	4	0	1
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	658	268	2	0	0	2	259	0	0	0	0	4	0	1
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	138	17	0	0	0	4	9	4	0	0	0	0	0	0
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	179	3	0	0	0	0	3	0	0	0	0	0	0	0
C25	Trebušna slinavka Pancreas	324	54	0	0	0	17	36	0	0	0	0	0	0	1
C32	Grlo Larynx	102	3	0	0	0	0	3	0	0	0	0	0	0	0
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	1182	504	0	100	0	0	327	72	0	0	1	0	1	3
C43	Maligni melanom kože Malignant melanoma of skin	450	0	0	0	0	0	0	0	0	0	0	0	0	0
C44	Druge maligne neoplazme kože Skin, other malignomas	1936	12	1	0	0	0	1	4	0	0	0	0	6	0
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	68	15	0	0	0	0	14	1	0	0	0	0	0	0
C50	Dojka Breast	1127	963	22	0	11	2	676	197	1	43	0	10	0	1
C53	Maternični vrat Cervix uteri	130	10	0	0	0	0	8	1	0	0	0	0	0	1
C54	Maternično telo Corpus uteri	288	18	0	0	0	0	16	2	0	0	0	0	0	0
C56	Jajčnik Ovary	145	103	0	1	0	0	85	17	0	0	0	0	0	0
C61	Prostata Prostate	1308	556	59	1	31	149	86	90	17	22	42	14	39	6
C62	Modo Testis	91	40	0	0	0	0	40	0	0	0	0	0	0	0
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	325	25	1	0	0	4	19	0	0	0	0	0	0	1
C67	Sečni mehur Bladder	281	43	4	0	0	13	25	1	0	0	0	0	0	0
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	144	40	0	0	0	7	33	0	0	0	0	0	0	0
C73	Ščitnica Thyroid gland	149	129	1	0	0	8	114	1	0	0	0	0	5	0
C81	Hodgkinova bolezen Hodgkin's disease	62	52	0	0	0	5	47	0	0	0	0	0	0	0
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	284	178	4	0	0	11	157	4	0	0	1	1	0	0
C90	Difuzni plazmocitomi in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	123	64	10	0	2	30	0	12	6	1	3	0	0	0
C91–C95	Levkemije Leukaemias	253	78	5	1	0	49	3	14	0	1	1	2	0	2

* Bolniki, ki so v okviru prvega zdravljenja prejeli več kot eno vrsto sistemskega zdravljenja, so vključeni le enkrat

* Patients that undergone multiple systemic treatments in the course of first treatment were included with the first treatment only

** V posamezni ustanovi so zdravili manj kot 10 bolnikov

** Less than 10 patients were treated in individual institution

Tabela 11: Prevalenca po spolu in izbrani primarni lokaciji raka, Slovenija, 31. 12. 2009.

Table 11: Prevalence of cancer patients by sex and by selected primary cancer site, Slovenia, December 31, 2009.

Šifra MKB ICD code	Primarna lokacija* Primary site*	Spol Sex	Leta po diagnozi Years after diagnosis				Celotna prevalenca Lifetime prevalence
			<1	1–4	5–9	10+	
C00	Vse lokacije	M+Ž	9741	26087	19757	25267	76968
C96	All sites	M	5158	12415	8299	8357	32325
		Ž	4583	13672	11458	16910	44643
C00–C14	Usta in žrelo Mouth and pharynx	M	227	477	331	414	1449
		Ž	66	171	133	169	539
C15	Požiralnik Oesophagus	M	41	35	22	17	115
		Ž	4	12	8	3	27
C16	Želodec Stomach	M	181	288	224	298	991
		Ž	118	194	176	284	772
C18	Debelo črevo Colon	M	404	892	627	542	2465
		Ž	305	759	577	657	2298
C19–C20	Rektum in rektosigmoidna zveza Rectum and rectosigmoid junction	M	347	795	523	471	2136
		Ž	207	546	393	512	1658
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	37	61	9	11	118
		Ž	14	14	6	9	43
C23–C24	Žolčnik in žolčevodi Gallbladder and biliary tract	M	36	41	16	20	113
		Ž	48	54	20	25	147
C25	Trebušna slinavka Pancreas	M	67	45	14	9	135
		Ž	71	54	18	6	149
C32	Grlo Larynx	M	81	250	232	279	842
		Ž	15	28	32	39	114
C33–C34	Sapnik, sapnici in pljuča Trachea, bronchus and lung	M	503	568	287	299	1657
		Ž	211	282	114	103	710
C43	Malignni melanom kože Malignant melanoma of skin	M	202	619	428	416	1665
		Ž	235	742	543	818	2338
C44	Druge maligne neoplazme kože Skin, other malignomas	M	906	3041	2227	2217	8391
		Ž	997	3357	2651	2882	9887
C48–C49	Vezivno in mehko tkivo Connective and soft tissue	M	31	69	59	147	306
		Ž	28	92	67	164	351
C50	Dojka Breast	M	9	18	23	22	72
		Ž	1066	3796	3375	4624	12861
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–
		Ž	118	479	692	2240	3529
C54	Maternično telo Corpus uteri	M	–	–	–	–	–
		Ž	272	930	964	1798	3964
C56	Jajčnik Ovary	M	–	–	–	–	–
		Ž	119	379	303	708	1509
C61	Prostata Prostate	M	1227	3125	1630	538	6520
		Ž	–	–	–	–	–
C62	Modo Testis	M	90	373	434	871	1768
		Ž	–	–	–	–	–
C64–C65	Ledvica z ledvičnim mehkom Kidney with renal pelvis	M	170	493	294	353	1310
		Ž	80	260	204	310	854
C67	Sečni mehur Bladder	M	160	428	273	286	1147
		Ž	62	125	91	120	398
C70–C72	Centralni in avtonomni živčni sistem Central and autonomic nervous system	M	58	72	59	147	336
		Ž	35	72	57	107	271
C73	Ščitnica Thyroid gland	M	26	105	95	123	349
		Ž	118	437	329	512	1396
C81	Hodgkinova bolezen Hodgkin's disease	M	30	84	99	265	478
		Ž	29	64	95	238	426
C82–C85	Ne-Hodgkinovi limfomi Non-Hodgkin's lymphoma	M	133	286	224	347	990
		Ž	115	346	271	335	1067
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	47	119	39	19	224
		Ž	45	95	36	25	201
C91–C95	Levkemije Leukaemias	M	101	237	184	226	748
		Ž	70	192	143	239	644

* Pri posameznih lokacijah je pri prikazu prevalenca oseba z več raki vključena pri vsaki lokaciji, pri vseh lokacijah skupaj pa se v prevalenci tudi oseba z več raki šteje le enkrat

* For persons with more than one cancer the person is included as a prevalent cancer in each cancer site, but in the all sites group each person is counted once only

Tabela 12: Umrljivost* za rakom po lokaciji, spolu in starosti, Slovenija 2009.

Table 12: Cancer mortality* by site, by sex and by age, Slovenia 2009.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+		
C00 – C97	Vse lokacije All sites	M+Ž	5787	0	6	1	4	7	11	10	40	64	152	306	502	505	734	870	1008	1567		
		M	3260	0	2	0	3	6	5	5	18	35	81	181	319	328	487	546	586	658		
		Ž	2527	0	4	1	1	1	6	5	22	29	71	125	183	177	247	324	422	909		
C00	Ustnica Lip	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C01	Baza jezika Base of tongue	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C02	Jezik, drugi deli Tongue, other & unspecified parts	M	7	0	0	0	0	0	0	0	0	1	1	0	0	2	0	1	1	1		
		Ž	1	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0		
C03	Dlesen Gum	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C04	Ustno dno Floor of mouth	M	12	0	0	0	0	0	0	0	0	0	1	1	2	3	2	0	1	2		
		Ž	4	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1	1	1		
C05	Nebo Palate	M	3	0	0	0	0	0	0	0	0	0	0	1	0	1	1	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C06	Usta, drugi deli Mouth, other & unspecified parts	M	6	0	0	0	0	0	0	0	0	1	1	0	2	0	1	0	1	0		
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	1		
C07	Parotidna žleza Parotid gland	M	5	0	0	0	0	0	0	0	0	0	0	3	0	0	1	1	0	0		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
C08	Druge in neopredeljene velike žleze slinavke Other & unspecified major salivary glands	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C09	Tonzila Tonsil	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C10	Orofarinks Oropharynx	M	53	0	0	0	0	0	0	0	0	6	9	10	9	8	5	3	3	3		
		Ž	9	0	0	0	0	0	0	0	0	1	1	1	2	0	0	1	3			
C11	Nazofarinks Nasopharynx	M	1	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0	0		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0			
C12	Piriformni sinus Pyriform sinus	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0		
C13	Hipofarinks Hypopharynx	M	33	0	0	0	0	0	0	0	1	1	2	10	4	8	3	4	0	0		
		Ž	6	0	0	0	0	0	0	0	0	0	0	2	1	1	1	0	1			
C14	Druga in slabo opredeljena mesta na ustnici, v ustni votlini in farinksu Other and ill-defined sites in the lip, oral cavity and pharynx	M	9	0	0	0	0	0	0	0	0	0	1	1	2	1	2	1	1			
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
C15	Požiralnik Oesophagus	M	77	0	0	0	0	0	0	0	0	1	5	5	12	12	13	14	13	2		
		Ž	17	0	0	0	0	0	0	0	0	0	0	0	1	3	0	4	9			
C16	Želodec Stomach	M	231	0	0	0	0	0	0	1	2	5	8	12	25	19	35	32	47	45		
		Ž	132	0	0	0	0	0	0	0	4	2	6	6	5	13	17	19	60			
C17	Tanko črevo Small intestine	M	6	0	0	0	0	0	0	0	0	0	0	1	1	0	1	2	1	0		
		Ž	8	0	0	0	0	0	0	0	0	0	0	0	1	2	0	2	0	3		
C18	Debelo črevo Colon	M	288	0	0	0	0	1	0	0	0	2	8	19	28	48	50	59	73	72		
		Ž	188	0	0	0	0	0	0	2	2	3	9	9	15	14	27	35	72			
C19	Rektosigmoidna zveza Rectosigmoid junction	M	36	0	0	0	0	0	0	0	0	0	3	3	3	7	6	7	7			
		Ž	24	0	0	0	0	0	0	0	1	0	0	1	1	0	7	5	9			
C20	Rektum Rectum	M	151	0	0	0	0	0	0	0	2	3	7	14	17	17	32	23	36			
		Ž	103	0	0	0	0	0	0	0	1	0	3	8	7	6	7	20	51			
C21	Anus in analni kanal Anus and anal canal	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0		
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	0	2	1	2			
C22	Jetra in intrahepatični vodi Liver and intrahepatic bile ducts	M	132	0	0	0	0	0	0	0	0	2	10	11	26	26	20	20	17			
		Ž	51	0	0	0	0	0	0	0	0	0	5	2	3	10	9	6	16			
C23	Žolčnik Gallbladder	M	14	0	0	0	0	0	0	0	0	0	1	1	1	0	4	4	3			
		Ž	41	0	0	0	0	0	0	0	0	3	1	0	2	1	6	9	19			
C24	Drugi in neopredeljeni deli biliarnega trakta Biliary tract, other and unspecified parts	M	24	0	0	0	0	0	0	0	0	1	1	2	2	2	5	5	6			
		Ž	29	0	0	0	0	0	0	0	0	0	0	0	2	0	4	5	14			
C25	Trebušna slinavka Pancreas	M	170	0	0	0	0	0	0	0	3	0	9	21	18	35	31	21	32			
		Ž	167	0	0	0	0	0	0	0	1	2	4	17	10	17	19	31	66			
C26	Druga in slabo opredeljena mesta v prebavnih organih Other and ill-defined digestive organs	M	12	0	0	0	0	0	0	0	0	1	0	1	0	2	1	2	5			
		Ž	17	0	0	0	0	0	0	0	0	0	1	1	1	0	2	3	9			
C30	Nosna votlina in srednje uho Nasal cavity and middle ear	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
C31	Obnosni sinusi Accessory sinuses	M	4	0	0	0	0	0	0	0	0	1	0	0	0	0	0	2	0	1		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0			
C32	Grlo Larynx	M	47	0	0	0	0	0	0	0	0	3	3	7	6	3	9	7	9			
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	1	2	0	1	1			
C33	Sapnik Trachea	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1	1			
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			

Tabela 12: Nadaljevanje.

Table 12: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+		
C34	Sapnica in pljuča Bronchus and lung	M	738	0	0	0	0	0	0	0	0	3	7	22	49	100	80	126	136	126	89	
		Ž	297	0	0	0	0	0	0	0	0	2	2	13	31	30	22	36	37	55	69	
C37	Timus Thymus	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C38	Srce, mediastinum, plevra Heart, mediastinum, pleura	M	5	0	0	0	0	0	1	0	0	0	0	1	0	0	0	0	1	1	1	1
		Ž	7	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0	0	1	4
C39	Druga in slabo opredeljena mesta v dihalih in prsnih organih Other and ill-defined sites in the respiratory system and intrathoracic organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C40	Kosti, sklepi hrustanec udov Bone and articular cartilage of limbs	M	1	0	0	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C41	Kosti, sklepi hrustanec, drugje Bone and articular cartilage of other and unspecified parts	M	5	0	0	0	0	0	0	0	0	1	0	1	0	1	1	1	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0
C43	Malignni melanom kože Malignant melanoma of skin	M	57	0	0	0	0	1	0	1	3	3	2	5	6	10	5	7	6	8	8	8
		Ž	67	0	0	1	0	0	0	2	0	4	5	7	9	4	10	9	16	16	16	16
C44	Druge maligne neoplazme kože Skin, other malignomas	M	12	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	2	7	7	7
		Ž	16	0	0	0	0	0	0	0	0	0	0	0	0	1	3	2	10	10	10	10
C45	Mezoteliom Mesothelioma	M	23	0	0	0	0	0	0	0	0	0	2	1	1	5	2	5	4	3	3	3
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	2	0	1	0	2	2	2
C46	Kaposijev sarkom Kaposi's sarcoma	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C47	Periferni živci in avtonomno živčevje Peripheral and autonomic nervous system	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C48	Peritonej in retroperitonej Retroperitoneum and peritoneum	M	6	0	0	0	0	0	0	1	1	0	0	0	2	0	1	0	1	0	1	0
		Ž	16	0	0	0	0	0	0	0	0	0	0	0	0	1	6	1	3	5	5	5
C49	Drugo vezivno in mehko tkivo Other connective and soft tissue	M	13	0	0	0	0	0	0	0	0	0	0	3	2	2	1	0	1	4	4	4
		Ž	10	0	0	0	1	0	0	0	0	1	2	0	0	0	1	0	2	3	3	3
C50	Dojka Breast	M	4	0	0	0	0	0	0	0	0	0	0	0	1	0	1	2	0	0	0	0
		Ž	434	0	0	0	0	0	0	2	6	8	21	23	30	30	41	49	60	164	164	164
C51	Žensko zunanje spolovilo Vulva	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	22	0	0	0	0	0	0	0	0	0	0	1	0	2	0	2	2	15	15	15
C52	Nožnica Vagina	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2
C53	Maternični vrat Cervix uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	50	0	0	0	0	0	0	0	5	2	4	8	5	4	7	3	4	8	8	8
C54	Maternično telo Corpus uteri	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	43	0	0	0	0	0	0	0	0	1	1	1	4	3	5	5	8	15	15	15
C55	Maternica, neopredeljeno Uterus, unspecified	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	40	0	0	0	0	0	0	0	1	0	1	0	4	2	2	6	7	17	17	17
C56	Jajčnik Ovary	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	167	0	0	0	0	0	2	1	2	4	6	9	21	21	23	25	26	27	27	27
C57	Drugi in neopredeljeni ženski spolni organi Other and unspecified parts of female genital organs	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	6	0	0	0	0	0	0	0	0	0	0	0	0	1	2	1	1	1	1	1
C58	Posteljica Placenta	M	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
C60	Penis Penis	M	5	0	0	0	0	0	0	0	0	0	0	0	0	1	3	0	0	1	1	1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C61	Prostata Prostate	M	370	0	0	0	0	0	0	0	0	0	0	2	10	15	37	62	91	153	153	153
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C62	Modo Testis	M	6	0	0	0	0	0	0	0	1	0	1	1	1	0	0	0	1	1	1	1
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C63	Drugi in neopredeljeni moški spolni organi Other and unspecified male genital organs	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
C64	Ledvica razen meha Kidney, except renal pelvis	M	104	0	0	0	0	0	0	0	1	4	5	12	13	13	10	19	15	12	12	12
		Ž	48	0	0	0	0	0	0	0	0	0	1	2	3	5	3	10	6	18	18	18
C65	Ledvični meh Renal pelvis	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1
C66	Sečevod Ureter	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0	0
C67	Sečni mehur Bladder	M	134	0	0	0	0	0	0	0	0	1	2	5	8	23	18	30	42	42	42	42
		Ž	55	0	0	0	0	0	0	1	0	1	2	5	1	2	8	10	25	25	25	25
C68	Drugi in neopredeljeni sečni organi Other and unspecified urinary organs	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0	0
		Ž	2	0	0	0	0	0	0	0	0	1	0	1	0	0	0	0	0	0	0	0
C69	Oko in očesni adneksi Eye and adnexa	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	0
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1

Nadaljevanje →
Continued →

Tabela 12: Nadaljevanje.

Table 12: Continued.

Šifra MKB ICD code	Primarna lokacija Primary site	Spol Sex	Vse starosti All ages	Starost Age																		
				0–	5–	10–	15–	20–	25–	30–	35–	40–	45–	50–	55–	60–	65–	70–	75–	80+		
C70	Meninge Meninges	M	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	1	1	0	
		Ž	9	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	2	2	3	
C71	Možgani Brain	M	78	0	2	0	0	3	1	2	6	4	3	12	6	7	11	8	6	7		
		Ž	54	0	2	0	0	0	0	0	1	0	2	1	6	5	13	10	6	8		
C72	Hrbtni mozeg, možganski živci in drugi deli ČŽS Spinal cord, cranial nerves and other parts of CNS	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	0	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C73	Ščitnica Thyroid gland	M	7	0	0	0	0	0	0	0	0	0	1	0	0	1	1	3	1	0		
		Ž	10	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	7		
C74	Nadledvična žleza Adrenal gland	M	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1	1		
		Ž	5	0	0	0	0	1	1	0	0	0	0	0	0	0	1	0	2	0		
C75	Druge endokrine žleze in sorodne strukture Other endocrine glands and related structures	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
C76	Druge in slabo opredeljena mesta Other and ill-defined sites	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3		
C77	Metastaza in neopredeljena maligna neoplazma bezgavk Metastasis and unspecified malignant neoplasm of lymph nodes	M	3	0	0	0	0	0	0	0	0	0	0	1	1	0	0	1	0	0		
		Ž	2	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1		
C78	Metastaze dihal in prebavil Metastases of respiratory and digestive organs	M	43	0	0	0	0	0	0	0	0	0	1	0	3	2	8	6	8	15		
		Ž	32	0	0	0	0	0	0	0	0	0	0	1	0	2	4	4	5	16		
C79	Metastaze, drugje Metastases of other sites	M	7	0	0	0	0	0	0	0	0	0	0	0	0	1	0	2	2	2		
		Ž	13	0	0	0	0	0	0	0	0	0	0	0	1	0	0	4	3	5		
C80	Maligna neoplazma brez opredeljenega mesta Malignant neoplasm without specification of site	M	30	0	0	0	0	0	0	0	0	1	0	2	5	4	8	4	6			
		Ž	38	0	0	0	0	0	0	1	0	0	2	2	3	1	5	22				
C81	Hodgkinova bolezen Hodgkin's disease	M	4	0	0	0	0	1	0	0	0	0	0	0	1	0	0	2	0			
		Ž	5	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	3			
C82	Folikularni ne-Hodgkinov limfom Follicular non-Hodgkin's lymphoma	M	2	0	0	0	0	0	0	0	0	0	0	1	0	0	0	0	1			
		Ž	7	0	0	0	0	0	0	0	0	0	1	1	0	0	2	0	1	2		
C83	Difuzni ne-Hodgkinov limfom Diffuse non-Hodgkin's lymphoma	M	6	0	0	0	0	1	0	1	0	0	0	0	0	1	1	1	1			
		Ž	11	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3	5	3		
C84	Limfomi celic T in kožni limfom celic T Peripheral and cutaneous T-cell lymphomas	M	2	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1			
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	1	0	1	1			
C85	Druge in neopredeljene vrste ne-Hodgkinovega limfoma Other and unspecified types of non-Hodgkin's lymphoma	M	45	0	0	0	0	1	0	0	0	1	5	1	7	4	5	7	14			
		Ž	51	0	0	0	0	1	0	0	0	0	0	3	3	4	9	11	20			
C88	Maligne imunoproliferativne bolezni Malignant immunoproliferative diseases	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
		Ž	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
C90	Difuzni plazmocitom in maligne neoplazme plazmocitov Multiple myeloma and malignant plasma cell neoplasms	M	45	0	0	0	0	0	0	0	0	1	2	2	4	8	8	12	8			
		Ž	48	0	0	0	0	0	0	1	0	0	0	2	1	5	9	14	16			
C91	Limfatična levkemija Lymphoid leukaemia	M	49	0	0	0	2	1	0	0	0	0	1	2	4	3	9	14	13			
		Ž	43	0	0	0	0	1	0	0	1	0	3	3	0	3	4	9	19			
C92	Mieločna levkemija Myeloid leukaemia	M	44	0	0	0	0	0	0	0	0	1	2	8	3	7	7	9	7			
		Ž	24	0	0	0	0	1	0	0	0	2	2	0	0	2	5	5	7			
C93	Monocitna levkemija Monocytic leukaemia	M	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0			
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1			
C94	Druge opredeljene levkemije Other leukaemias of specified cells	M	2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	2	0		
		Ž	3	0	0	0	0	0	0	0	0	0	0	1	0	0	0	1	1			
C95	Levkemija z neopredeljenim celičnim tipom Leukaemia, unspecified cell type	M	7	0	0	0	0	0	0	0	0	0	0	2	1	2	1	0	1			
		Ž	7	0	1	0	0	0	0	0	0	0	0	1	1	0	0	0	4			
C96	Druge in neopredeljene maligne neoplazme limfatičnega, krvotvornega in sorodnega tkiva Other & unspecified malignant neoplasms of lymphoid, haemopoetic & related tissues	M	19	0	0	0	0	0	0	0	0	0	0	3	1	0	4	3	8			
		Ž	20	0	0	0	0	0	0	0	0	0	0	0	1	1	2	5	11			
C97	Maligne neoplazme na več neodvisnih (primarnih) mestih Malignant neoplasms of independent (primary) multiple sites	M	38	0	0	0	0	0	0	0	0	1	2	2	1	6	8	13	5			
		Ž	31	0	0	0	0	0	0	0	0	0	1	2	2	3	4	4	15			
Zgoraj neupoštevani Not included above																						
D32	Meninge, benigna neoplazma Benign neoplasm of meninges	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1		
D33	ČŽS, benigna neoplazma Benign neoplasm of brain and other parts of CNS	M	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0			
		Ž	1	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0	0			
D43	ČŽS, neopredeljeno CNS, uncertain or unknown	M	1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	1	0	0		
		Ž	3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	3		

IZBOR PUBLIKACIJ, ki so jih sodelavci Epidemiologije in Registra raka objavili v zadnjih petih letih (tudi v sodelovanju z drugimi raziskovalci)

SELECTED PUBLICATIONS, published by the members of Epidemiology and Cancer Registry in the last five years (also in cooperation with other researchers)

2007

- Arbyn M, Primic-Žakelj M, Raifu AO, Grce M, Paraskevaidis E, Diakomanolis E, et al. The burden of cervical cancer in South-East Europe at the beginning of the 21st century. *Coll Antropol* 2008; 31 Suppl 2: 7–10.
- Bidoli E, Zadnik V, De Dottori M, Zanier L, Serraino D. Prostate cancer pattern in the bordering areas of Friuli-Venezia Giulia, Italy, and Slovenia, 1995–2003. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. *At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts*. Ljubljana: Institute of Oncology, 2008.
- Bizjak-Ogrinc U, Čufer T, Pompe-Kirn V. Survival of patients with invasive urinary bladder cancer in Slovenia regarding to stage of disease and treatment in years 1987–1997. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. *At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts*. Ljubljana: Institute of Oncology, 2008.
- Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, Tracey E, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood leukemia and lymphoma: an international study. *J Natl Cancer Inst* 2008; 10: 790–800.
- Primic-Žakelj M. Epidemiologija raka pri moških in ženskah. In: Mlakar-Mastnak D, Lokar K, eds. *Ženske, moški in rak*. Ljubljana: Sekcija medicinskih sester in zdravstvenih tehnikov v onkologiji pri Zbornici zdravstvene in babiške nege Slovenije - Zvezi društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije; 2008.
- Primic-Žakelj M. Obvladovanje raka v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. *4. Slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2008. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvlečkov*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2008.
- Primic-Žakelj M. Rak materničnega vratu v Sloveniji in program ZORA. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. *4. slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2008. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvlečkov*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2008.
- Primic-Žakelj M, Zadnik V, Žagar T. Rak v Sloveniji. *Zdrav Vest* 2008; 76: 775–80.
- Primic-Žakelj M, Žagar T. Breast cancer epidemiology in Slovenia. *Senologie* 2008; 4: 205.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija malignega melanoma. *Radiol Oncol* 2008; 41 Suppl 1: S1–S12.
- Primic-Žakelj M, Žagar T, Zadnik V. Epidemiologija pljučnega raka. In: Rott T, Luzar B, eds. *Pljučni rak - današnje stanje in perspektive*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta, 2008.
- Ravnik M, Arko D, Žagar T, Primic-Žakelj M, Čufer T. Breast cancer and second malignancies. *Senologie* 2008; 4: 209.
- Richiardi L, Scelo G, Boffetta P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V, et al. Second malignancies among survivors of germ-cell testicular cancer: a pooled analysis between 13 cancer registries. *Int J Cancer* 2008; 120: 623–31.
- Riska A, Pukkala E, Scelo G, Møller M, Hemminki K, Weiderpass E, Pompe-Kirn V, et al. Second primary malignancies in females with primary fallopian tube cancer. *Int J Cancer* 2008; 120: 2047–51.
- Scelo G, Boffetta P, Autier P, Hemminki K, Pukkala E, Olsen JH, Pompe-Kirn V. Associations between ocular melanoma and other primary cancers: an international population-based study. *Int J Cancer* 2008; 120: 152–9.

- Scelo G, Boffetta P, Corbex M, Chia KS, Hemminki K, Friis S, Pompe-Kirn V, et al. Second primary cancers in patients with nasopharyngeal carcinoma: a pooled analysis of 13 cancer registries. *Cancer Causes Control* 2008; 18: 269–78.
- Tuohimaa P, Pukkala E, Scelo G, Olsen JH, Brewster DH, Hemminki K, Pompe-Kirn V, et al. Does solar exposure, as indicated by the non-melanoma skin cancers, protect from solid cancers: vitamin D as a possible explanation. *Eur J Cancer* 2008; 43: 1701–12.
- Zadnik V, Pompe-Kirn V. Effects of 500-year mercury mining and milling on cancer incidence in the region of Idrija, Slovenia. *Coll Antropol* 2008; 31: 897–903.
- Zver S, Zadnik V, Bunc M, Rogel P, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplantation. *Int J Hematol* 2008; 85: 408–14.
- Žagar T, Droljc A. Connection of Cancer Registry of Slovenia to other state databases. In: Primic-Žakelj M, Žagar T, Zadnik V, eds. *At the crossroad of tradition and new technologies in cancer registration. The role of cancer registries in cancer control: programme and book of abstracts*. Ljubljana: Institute of Oncology, 2008.
- Žagar T, Zadnik V, Primic-Žakelj M. Različne možnosti prikazovanja geografskega razporejanja incidence raka na materničnem vratu v Sloveniji. In: Kraigher A, Berger T, Piškur-Kosmač D, eds. *4. Slovenski kongres preventivne medicine, Portorož, 17. do 19. maj 2008. Izzivi javnega zdravja v tretjem tisočletju: knjiga izvlečkov*. Ljubljana: Sekcija za preventivno medicino Slovenskega zdravniškega društva; 2008.

2008

- Baili P, Micheli A, De Angelis R, Weir HK, Primic-Žakelj M, Pompe-Kirn V, et al. Life tables for world-wide comparison of relative survival for cancer (CONCORD study). *Tumori* 94: 658–68.
- Bešič N, Černivc B, de Greve J, Lokar K, Krajc M, Novaković S, et al. BRCA2 gene mutations in Slovenian male breast cancer patients. *Genet Test* 2008; 12: 203–9.
- Chuang S, Hashibe M, Scelo G, Brewster DH, Pukkala E, Pompe-Kirn V, et al. Risk of second primary cancer among esophageal cancer patients: a pooled analysis of 13 cancer registries. *Cancer Epidemiol Biomarkers Prev* 2008; 17: 1543–9.
- Chuang S, Scelo G, Tonita JM, Tamaro S, Jonasson JG, Pompe-Kirn V, et al. Risk of second primary cancer among patients with head and neck cancers: A pooled analysis of 13 cancer registries. *Int J Cancer* 2008; 123: 2390–6.
- Glumac N, Hočevar M, Zadnik V, Snoj M. Sentinel lymph node micrometastasis may predict nonsentinel involvement in cutaneous melanoma patients. *J Surg Oncol* 2008; 98: 46–8.
- Gondos A, Bray F, Brewster DH, Coebergh JWW, Hakulinen T, Primic-Žakelj M, et al. Recent trends in cancer survival across Europe between 2000 and 2004: a model-based period analysis from 12 cancer registries. *Eur J Cancer* 2008; 44: 1463–75.
- Gouveia J, Coleman MP, Haward R, Zanetti R, Hakama M, Primic-Žakelj M, et al. Improving cancer control in the European Union: conclusions from the Lisbon round-table under the Portuguese EU Presidency, 2008. *Eur J Cancer* 2008; 44: 1457–62.
- Krajc M. Screening. In: Kovačič L, Zaletel-Kragelj L, eds. *Management in health care practice: a handbook for teachers, researchers and health professionals*. Lage: Hans Jacobs Publishing Company; 2008. p. 286–307.
- Krajc M, Teugels E, Žgajnar J, Goelen G, Bešič N, Novaković S, et al. Five recurrent BRCA1/2 mutations are responsible for cancer predisposition in the majority of Slovenian breast cancer families. *BMC Med Genet* 2008; 9: 83–91.
- Maule M, Scelo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Risk of second malignant neoplasms after childhood central nervous system malignant tumours: an international study. *Eur J Cancer* 2008; 44: 830–9.
- Primic-Žakelj M. Cancer epidemiology. In: Schrijvers D, Zakotnik B, eds. *ESMO handbook of cancer prevention*. London: Informa Healthcare; 2008. p. 1–9.
- Primic-Žakelj M, Zadnik V. Rak pri starejših. In: Bilban M, ed. *Zbornik prispevkov Cvahtetovih dnevov*. Ljubljana: Katedra za javno zdravje; 2008.
- Primic-Žakelj M, Zadnik V, Žagar T. Karcinom debelega črevesa in danke v Sloveniji in v Evropi (Colorectal cancer in Slovenia and in Europe). In: Luzar B, Cerar A, Štabuc B, eds. *Tumorji debelega črevesa in danke*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2008.

- Primic-Žakelj M, Žagar T. Cancer control in Slovenia: achievements, shortcomings and opportunities. In: Coleman MP, ed. Responding to the challenge of cancer in Europe. Ljubljana: Institute of Public Health of the Republic of Slovenia; 2008.
- Primic-Žakelj M, Žagar T, Zadnik V. Lung cancer in Slovenia (Pljučni rak v Sloveniji). *Endosk rev* 2008; 13: 5–13.
- Repše-Fokter A, Primic-Žakelj M. Auditing screening laboratories in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 20.
- Repše-Fokter A, Primic-Žakelj M. Cervical cancer screening in Slovenia. *Cytopathology* 2008; 19 Suppl 1: 3.
- Robins G, Crabtree JE, Bailey A, Forman D, Pompe-Kirn V, et al. International variation in *Helicobacter pylori* infection and rates of oesophageal cancer. *Eur J Cancer*. 2008; 44: 726–32.
- Rojnik K, Naveršnik K, Mateović-Rojnik T, Primic-Žakelj M. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia. *Value Health* 11: 139–48.
- Sant M, Allemani C, De Angelis R, Carbone A, de Sanjose S, Pompe-Kirn V, et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. *Eur J Cancer* 2008; 44: 579–87.
- Terčelj M, Aleš A, Rott T, Sever N, Prodrik L, Primic-Žakelj M, et al. DNA-based sputum cell image analysis for lung cancer in a clinical setting. *Acta Cytol* 2008; 52: 584–90.
- Virgili G, Gatta G, Ciccolallo L, Capocaccia R, Primic-Žakelj M, Pompe-Kirn V, et al. Survival in patients with uveal melanoma in Europe. *Arch Ophthalmol* 2008; 126: 1413–8.
- Zadnik V, Ivanuš U, Florjančič M, Primic-Žakelj M. Vloga registra ZORA pri obvladovanju bremena raka materničnega vratu v Sloveniji (The role of ZORA registry in cervical cancer burden control in Slovenia). *Bilt-ekon organ inform zdrav* 2008; 24:179–83.
- Zadnik V, Primic-Žakelj M. Rak pri ženskah. In: Štabuc B, Primic-Žakelj M, Klemenčič M, Piškur J, eds. *Rak rodil*. Ljubljana: Zveza slovenskih društev za boj proti raku; 2008.
- Zadnik V, Žagar T, Drobne S, Primic-Žakelj M. Estimation of cancer burden in Brežice municipality, a community neighboring Krško nuclear power plant in Slovenia. *Croat Med J* 2008; 49: 257–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Ginekološki raki v Sloveniji (Gynecological cancers in Slovenia). In: Takač I, ed. *80 let hospitalne ginekologije in porodništva v Maribor: mednarodni znanstveni simpozij*. Maribor: Univerzitetni klinični center Maribor; 2008.
- Zver S, Zadnik V, Černelč P, Koželj M. Cardiac toxicity of high-dose cyclophosphamide and melphalan in patients with multiple myeloma treated with tandem autologous hematopoietic stem cell transplantation. *Int J Hematol*. 2008; 88: 227–36.
- Zwitter M, Primic-Žakelj M. Lung cancer in Europe. In: Parikh PM, ed. *Lung cancer*. Mumbai: Green Room Media & Event Management Services; 2008. p. 350–7.

2009

- Anttila A, Ronco G, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Zadnik V, et al. Description of the national situation of cervical cancer screening in the member states of the European Union. *Eur J Cancer* 2009; 45: 2685–708.
- Berrino F, Verdecchia A, Lutz JM, Lombardo C, Micheli A, Primic-Žakelj M, et al. Comparative cancer survival information in Europe. *Eur J Cancer* 2009; 45: 901–8.
- Ciccolallo L, Licitra L, Cantu G, Gatta G, Pompe-Kirn V, Primic-Žakelj M, et al. Survival from salivary glands adenoid cystic carcinoma in European populations. *Oral Oncol* 2009; 45: 669–74.
- De Angelis R, Francisci S, Baili P, Marchesi F, Roazzi P, Primic-Žakelj M, et al. The EURO-CARE-4 database on cancer survival in Europe: data standardisation, quality control and methods of statistical analysis. *Eur J Cancer* 2009; 45: 909–30.
- Francisci S, Capocaccia R, Grande E, Santaquilani M, Simonetti A, Primic-Žakelj M, et al. The cure of cancer: a European perspective. *Eur J Cancer* 2009; 45: 1067–79.
- Gatta G, Zigon G, Capocaccia R, Coebergh JW, Desandes E, Primic-Žakelj M, et al. Survival of European children and young adults with cancer diagnosed 1995–2002. *Eur J Cancer* 2009; 45: 992–1005.
- Gondos A, Bray F, Hakulinen T, Brenner H, Usel M, Primic-Žakelj M, et al. Trends in cancer survival in 11 European populations from 1990 to 2009: a model-based analysis. *Ann Oncol* 2009; 20: 564–73.
- Lepage C, Ciccolallo L, De Angelis R, Bouvier AM, Pompe-Kirn V, Primic-Žakelj M, et al. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2009; available from: <http://www.ncbi.nlm.nih.gov/pubmed/19569047>.

- Nicula FA, Anttila A, Neamtiiu L, Primic-Žakelj M, Tachezy R, Chil A, et al. Challenges in starting organised screening programmes for cervical cancer in the new member states of the European Union. *Eur J Cancer* 2009; 45: 2679–84.
- Pasanisi P, Hedelin G, Berrino J, Chang-Claude J, Primic-Žakelj M, Zadnik V, et al. Oral contraceptive use and BRCA penetrance: a case-only study. *Cancer Epidemiol Biomarkers Prev* 2009; 18: 2107–13.
- Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Ivanuš U. Presejalni program ZORA po petih letih delovanja že kaže pomembne javnozdravstvene rezultate. *Onkologija* 2009; 13: 4–6.
- Primic-Žakelj M, Zadnik V, Žagar T. Epidemiologija kožnega raka (Epidemiology of skin cancer). In: Luzar B, Jurčič V, Pižem J, Calonje E, eds. XL. memorialni sestanek profesorja Janeza Plečnika z mednarodnim simpozijem, 3.–4. december 2009, Ljubljana. *Novosti v dermatopatologiji*. Ljubljana: Inštitut za patologijo, Medicinska fakulteta; 2009.
- Primic-Žakelj M, Zadnik V, Žagar T, Zakotnik B. Preživetje bolnikov z rakom, zbolelih v letih 1991–2005 v Sloveniji (Survival of cancer patients, diagnosed in 1991–2005 in Slovenia). Ljubljana: Onkološki inštitut; 2009.
- Primic-Žakelj M, Krajc M, Zadnik V. Državni presejalni programi za raka (National cancer screening programs). *Farm vestn* 2009; 60: 90–4.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka prostate (Epidemiology of prostate cancer). In: Kramer F, ed. *Rak prostate: zbornik predavanj*. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec; 2009.
- Primic-Žakelj M, Žgajnar J. Cervical and breast cancer screening in Slovenia. Public service review, European Union. 2009; 18: 272.
- Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M, Primic-Žakelj M, et al. The cancer survival gap between elderly and middle-aged patients in Europe is widening. *Eur J Cancer* 2009; 45: 1006–16.
- Repše-Fokter A, Fležar M, Pogačnik A, Snoj V. Review of negative or low grade smears in women with invasive cervical cancer in Slovenia. *Virchows Arch* 2009; 455 Suppl,1: S6–S7.
- Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Primic-Žakelj M, et al. Process performance of cervical screening programmes in Europe. *Eur J Cancer* 2009; 45: 2659–70.
- Rosso S, De Angelis R, Ciccolallo L, Carrani E, Soerjomataram I, Primic-Žakelj M, et al. Multiple tumours in survival estimates. *Eur J Cancer* 2009; 45: 1080–94.
- Sant M, Allemani C, Santaquilani M, Knijn A, Marchesi F, Primic-Žakelj M, et al. EURO-CARE-4. Survival of cancer patients diagnosed in 1995–1999. Results and commentary. *Eur J Cancer* 2009 Apr; 45(6): 931–91.
- Snoj Z, Primic-Žakelj M, Ličina M, Pregelj P. Psychosocial correlates of progesterone receptors in breast cancer. *Depress Anxiety* 2009; 26: 544–9.
- Trapido EJ, Primic-Žakelj M, Pogačnik A, Uršič-Vrščaj M, Krajc M, Lešničar H, et al. Critical factors influencing the establishment, maintenance and sustainability of population-based cancer control programs. *Tumori* 2009; 95: 637–45.
- Verdecchia A, Guzzinati S, Francisci S, De Angelis R, Bray F, Primic-Žakelj M, et al. Survival trends in European cancer patients diagnosed from 1988 to 1999. *Eur J Cancer* 2009; 45: 1042–66.
- Zadnik V, Žagar T, Primic-Žakelj M. Pridobivanje in uporaba georeferenciranih podatkov v registru raka Republike Slovenije (Georeferenced data acquisition and usage in the cancer registry of Republic of Slovenia). *Bilt-ekon organ inform zdrav* 2009; 25 (izr. št.): 14.
- Zwitter M, Kovač V, Smrdel U, Vrankar M, Zadnik V. Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. *J Thorac Oncol* 2009; 4: 1148–55.
- Žagar T, Zadnik V, Primic-Žakelj M. Register raka Republike Slovenije in pridobivanje informacij o bolnikih iz drugih državnih podatkovnih zbirk po elektronski poti (Cancer Registry of Slovenia obtains patient information from other state databases via electronic mediums). In: Orel M, ed. *Nova vizija tehnologij prihodnosti*. Ljubljana: Evropska hiša; 2009.

2010

- Bouvier A, Pompe-Kirn V. What reasons lie behind long-term survival differences for gastric cancer within Europe? *Eur J Cancer* 2010; 46: 1086–92.
- Chuang S, Pompe-Kirn V. Risks of second primary cancer among patients with major histological types of lung cancers in both men and women. *Br J Cancer* 2010; 102: 1190–5.

- EurocareWorking Group, Lepage C, Pompe-Kirn V, Primic-Žakelj M. European disparities in malignant digestive endocrine tumours survival. *Int J Cancer* 2010; 126: 2928–34.
- Kofol-Bric T, Zadnik V et al. Zdravje moških med 20. in 64. letom. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 80–6.
- Krajc M, Kadivec M, Hertl K, Primic-Žakelj M. V državnem presejalnem programu za raka dojk Dora do sedaj odkritih 86 rakov dojk. *Onkologija* 2010; 14: 104–10.
- Mihevc Ponikvar B, Zadnik V et al. Zdravje žensk med 20. in 64. letom. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010, 71–9.
- Primic-Žakelj M. Country-specific description: Slovenia. In: Obergainer W, Vittadello F eds. *Cancer mapping in Alpine regions: Austria, Italy, Slovenia, Switzerland: 2001–2005*. Innsbruck: Department of Clinical Epidemiology of TILAK; 2010, 47–9.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA danes. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. *Prvi izobraževalni dan programa ZORA z mednarodno udeležbo*. Zbornik. Ljubljana: Onkološki inštitut; 2010, 9-15.
- Primic-Žakelj M, Zadnik V. Rak. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 96–100.
- Primic-Žakelj M, Zadnik V, Žagar T. Breme raka v Sloveniji. *Naša lekarna* 2010; 41: 22–8.
- Primic-Žakelj M, Zadnik V, Žagar T. Razširjenost raka v Sloveniji in Evropi. In: Rotar-Pavlič D. *Obravnavna bolnika z rakom v osnovnem zdravstvenem varstvu: zbornik predavanj*, Bled, 24. april 2010. Ljubljana: Zavod za razvoj družinske medicine; 2010, 5–8.
- Rebolj M, Ivanuš U, Lynge E. Indicators of quality assurance in cancer screening - the case of cervical cancer = Kazalniki kakovosti presejalnih programov - primer presejalnega programa za raka na materničnem vratu. *Bilt.-ekon. organ. inform. zdrav* 2010; 26(2): 44-51.
- Repše-Fokter A, Pogačnik A, Snoj V, Primic-Žakelj M, Strojjan Fležar M. Review of negative and lowgrade cervical smears in women with invasive cervical cancer after the first 3 years of the national cervical screening programme in Slovenia. *Cytopathology* 2010; 22: 1–7.
- Rosso S, Gondos A, Zanetti R, Bray F, Primic-Žakelj M, Žagar T, Smalley G, Ponti A, Brewster DH, Voogd AC, Crocetti E, Brenner H; EUNICE SurvivalWorking Group. Up-to-date estimates of breast cancer survival for the years 2000–2004 in 11 European countries : the role of screening and a comparison with data from the United States. *Eur J Cancer* 2010; 46: 3351–7.
- Strojjan Fležar M, Snoj V, Ivanuš U, Primic-Žakelj M. Standardizacija izvidov patologije materničnega vratu. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Škulj P eds. *Prvi izobraževalni dan programa ZORA z mednarodno udeležbo*. Zbornik. Ljubljana: Onkološki inštitut; 2010; 21-23, 61–72.
- Šelb-Šemerl J, Mihevc Ponikvar B, Primic-Žakelj M, Rok Simon M, Tomšič S, Zadnik V. Zdravje starejših. In: *Zdravje v Sloveniji*. Ljubljana: Inštitut za varovanje zdravja RS; 2010: 87–91.

2011

- Anttila A, Bielska-Lasota M, Davidson T, Van Delden JJ, Von Karsa L, Primic-Žakelj M, et al. Determinants for a successful implementation of population-based cancer screening programmes. Brussels: European Science Advisory Network for Health, 2011.
- Bosetti C, Scelo G, Chuang SC, Tonita JM, Tamaro S, Pompe-Kirn V, et al. High constant incidence rates of second primary cancers of the head and neck: a pooled analysis of 13 cancer registries. *Int J Cancer* 2011; 129(1):173–9.
- Buzeti T, Djomba JK, Tomšič S, Gabrijelčič Blenkuš M, Ivanuša M, Zadnik V, et al. Neenakosti v zdravju v Sloveniji. *Health inequalities in Slovenia*. Ljubljana: Inštitut za varovanje zdravja, 2011.
- Gatta G, Van der Zwan JM, Casali PG, Siesling S, Dei Tos AP, Primic-Žakelj M, et al. Rare cancers are not so rare: the rare cancer burden in Europe. *Eur J Cancer* 2011; 47(17): 2493–511.
- Ivanuš U, Primic-Žakelj M, Uršič-Vrščaj M. Pomen triažnega testa HPV. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 26–39.
- Kadivec M, Krajc M. Rezultati in kazalniki uspešnosti programa DORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 40–8.

- Krajc M. Prednosti in omejitve mamografskega presejanja. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 49–58.
- Krajc M. Epidemiologija raka dojk. In: Mamografska šola, 9. in 10. junij 2011. Ljubljana: Onkološki inštitut, SZD, Združenje radiologov Slovenije, 2011: 1–6.
- Krajc M. Kazalci kakovosti presejalnega programa za raka dojk. In: Farkaš-Lainščak J, ed. Z dokazi podprto javno zdravje: zbornik prispevkov. Ljubljana: Medicinska fakulteta, Katedra za javno zdravje, 2011: str 128.
- Maule M, Scélo G, Pastore G, Brennan P, Hemminki K, Pompe-Kirn V, et al. Second malignancies after childhood noncentral nervous system solid cancer: Results from 13 cancer registries. *Int J Cancer* 2011;129(8):1940–52.
- Primic-Žakelj M. Presejanje za raka kot javnozdravstveni ukrep. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 7–12.
- Primic-Žakelj M. Epidemiologija raka in stopnja preživetja v Sloveniji v populaciji do 39 let. In: Ribič-Pucelj M, ed. Ohranjanje plodne sposobnosti pri onkoloških bolnicah in bolnikih: zbornik. Ljubljana: Slovensko društvo za reproduktivno medicino, 2011: 1–4.
- Primic-Žakelj M, Ivanuš U. Presejanje za raka pri ženskah. In: Čeh A, ed. Presejalni testi pri ženskah in otrocih: zbornik predavanj z recenzijo. Ljubljana: Zbornica zdravstvene in babiške nege Slovenije - Zveza strokovnih društev medicinskih sester, babic in zdravstvenih tehnikov Slovenije, Sekcija medicinskih sester – babic, 2011: 7–15.
- Primic-Žakelj M, Ivanuš U. Rezultati in kazalniki uspešnosti programa ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 13–7.
- Primic-Žakelj M, Ivanuš U. Državni program ZORA v letih 2005-2009. In: Ivanuš U, Primic-Žakelj M, Florjančič M, Kuster M, eds. 2. izobraževalni dan programa ZORA, Brdo pri Kranju, 8. april 2011. Zbornik. Ljubljana: Onkološki inštitut Ljubljana, 2011: 9–12.
- Primic-Žakelj M, Zadnik V. Epidemiologija raka sečnega mehurja = Epidemiology of bladder cancer. In: Zupančič M, ed. Rak sečnega mehurja: zbornik predavanj. Slovenj Gradec: Oddelek za urologijo, Splošna bolnišnica Slovenj Gradec, 2009: 7–12.
- Rotovnik Kozjek N, Kompan L, Soeters P, Oblak I, Mlakar Mastnak D, Zadnik V, et al. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Clin Nutr* 2011; 30(5): 567–70.
- Uršič-Vrščaj M, Primic-Žakelj M, Ivanuš U. Novosti v programu ZORA. In: Primic-Žakelj M, ed. XIX. seminar In memoriam dr. Dušana Reje. Državni presejalni programi za raka. Ljubljana: Zveza slovenskih društev za boj proti raku, 2011: 18–25.
- Velenik V, Štrbac D, Maučec Zakotnik J, Zadnik V. Oral glutamine supplementation during preoperative radiochemotherapy in patients with rectal cancer: a randomised double blinded, placebo controlled pilot study. *Eur J Cancer* 2011; 47(Supp1): S267.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Geografska analiza incidence raka v Beli krajini in okolici: ugotavljanje morebitnega presežka incidence raka zaradi izpostavljenosti PCB-jem: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Ivanuš U, Primic-Žakelj M. Pojavljanje raka v upravnih enotah Celje in Šentjur pri Celju: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Kovše K, Tomšič S, Primic-Žakelj M. Breme raka v občini Dolenjske Toplice: zaključno poročilo. Ljubljana: Onkološki inštitut, 2011.
- Zadnik V, Primic-Žakelj M. SLORA - spletna stran z epidemiološkimi podatki o raku. *Onkologija* 2011; 15(1): 61–3.
- Zadnik V, Primic-Žakelj M. Breme raka uroloških in reproduktivnih organov v Sloveniji. *Slov 2000 in rak* 2011; 8–12.
- Žagar T, Zadnik V, Primic-Žakelj M. Local standardized incidence ratio estimates and comparison with other mapping methods for small geographical areas using Slovenian breast cancer data. *Journal of Applied Statistics* 2011; 38(12): 2751–61.

